
<html lang="en"     class="pb-page"  data-request-id="ffc0efed-36d1-49b0-a128-82d51971f6cc"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.9b02083;issue:issue:10.1021/jmcmar.2020.63.issue-8;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Selective Small Molecule Degraders of BRAF-V600E" /></meta><meta name="dc.Creator" content="Xiao-Ran  Han" /></meta><meta name="dc.Creator" content="Liqun  Chen" /></meta><meta name="dc.Creator" content="Yuanqi  Wei" /></meta><meta name="dc.Creator" content="Weihua  Yu" /></meta><meta name="dc.Creator" content="Yanke  Chen" /></meta><meta name="dc.Creator" content="Chunyan  Zhang" /></meta><meta name="dc.Creator" content="Bingyang  Jiao" /></meta><meta name="dc.Creator" content="Tingting  Shi" /></meta><meta name="dc.Creator" content="Lei  Sun" /></meta><meta name="dc.Creator" content="Chao  Zhang" /></meta><meta name="dc.Creator" content="Yang  Xu" /></meta><meta name="dc.Creator" content="Matthew R.  Lee" /></meta><meta name="dc.Creator" content="Ying  Luo" /></meta><meta name="dc.Creator" content="Michael B.  Plewe" /></meta><meta name="dc.Creator" content="Jialiang  Wang" /></meta><meta name="dc.Description" content="BRAF is among the most frequently mutated oncogenes in human cancers. Multiple small molecule BRAF kinase inhibitors have been approved for treating melanoma carrying BRAF-V600 mutations. However, ..." /></meta><meta name="Description" content="BRAF is among the most frequently mutated oncogenes in human cancers. Multiple small molecule BRAF kinase inhibitors have been approved for treating melanoma carrying BRAF-V600 mutations. However, ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 30, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b02083" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright Â© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02083" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b02083" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b02083" /></link>
        
    
    

<title>Discovery of Selective Small Molecule Degraders of BRAF-V600E | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b02083" /></meta><meta property="og:title" content="Discovery of Selective Small Molecule Degraders of BRAF-V600E" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0008.jpeg" /></meta><meta property="og:description" content="BRAF is among the most frequently mutated oncogenes in human cancers. Multiple small molecule BRAF kinase inhibitors have been approved for treating melanoma carrying BRAF-V600 mutations. However, the benefits of BRAF kinase inhibitors are generally short-lived. Small molecule-mediated targeted protein degradation has recently emerged as a novel pharmaceutical strategy to remove disease proteins through hijacking the cellular ubiquitin proteasome system (UPS). In this study, we developed thalidomide-based heterobifunctional compounds that induced selective degradation of BRAF-V600E, but not the wild-type BRAF. Downregulation of BRAF-V600E suppressed the MEK/ERK kinase cascade in melanoma cells and impaired cell growth in culture. Abolishing the interaction between degraders and cereblon or blocking the UPS significantly impaired the activities of these degraders, validating a mechanistic role of UPS in mediating targeted degradation of BRAF-V600E. These findings highlight a new approach to modulate the functions of oncogenic BRAF mutants and provide a framework to treat BRAF-dependent human cancers." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b02083"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02083">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b02083&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b02083&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b02083&amp;href=/doi/10.1021/acs.jmedchem.9b02083" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 4069-4080</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b02076" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b02025" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Selective Small Molecule Degraders of BRAF-V600E</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xiao-Ran Han</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiao-Ran Han</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cullgen Inc., 12671 High Bluff Drive, Suite 130, San Diego, California 92130, United States</div><div class="loa-info-affiliations-info">Cullgen (Shanghai) Inc., Building 6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiao-Ran++Han">Xiao-Ran Han</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Liqun Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liqun Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cullgen (Shanghai) Inc., Building 6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liqun++Chen">Liqun Chen</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Yuanqi Wei</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuanqi Wei</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cullgen (Shanghai) Inc., Building 6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuanqi++Wei">Yuanqi Wei</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Weihua Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Weihua Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cullgen (Shanghai) Inc., Building 6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Weihua++Yu">Weihua Yu</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Yanke Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yanke Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cullgen (Shanghai) Inc., Building 6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yanke++Chen">Yanke Chen</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Chunyan Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chunyan Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cullgen (Shanghai) Inc., Building 6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chunyan++Zhang">Chunyan Zhang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Bingyang Jiao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bingyang Jiao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cullgen (Shanghai) Inc., Building 6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bingyang++Jiao">Bingyang Jiao</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Tingting Shi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tingting Shi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cullgen (Shanghai) Inc., Building 6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tingting++Shi">Tingting Shi</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Lei Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lei Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cullgen (Shanghai) Inc., Building 6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Sun">Lei Sun</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Chao Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chao Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cullgen (Shanghai) Inc., Building 6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chao++Zhang">Chao Zhang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Yang Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yang Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cullgen (Shanghai) Inc., Building 6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs Republic of China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yang++Xu">Yang Xu</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Matthew R. Lee</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew R. Lee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cullgen Inc., 12671 High Bluff Drive, Suite 130, San Diego, California 92130, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+R.++Lee">Matthew R. Lee</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Ying Luo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ying Luo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cullgen Inc., 12671 High Bluff Drive, Suite 130, San Diego, California 92130, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ying++Luo">Ying Luo</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Michael B. Plewe</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael B. Plewe</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cullgen Inc., 12671 High Bluff Drive, Suite 130, San Diego, California 92130, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#593429353c2e3c193a2c35353e3c37773a3634"><span class="__cf_email__" data-cfemail="86ebf6eae3f1e3c6e5f3eaeae1e3e8a8e5e9eb">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+B.++Plewe">Michael B. Plewe</a></span></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Jialiang Wang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jialiang Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cullgen Inc., 12671 High Bluff Drive, Suite 130, San Diego, California 92130, United States</div><div class="loa-info-affiliations-info">Cullgen (Shanghai) Inc., Building 6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs Republic of China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#a2c8cbc3cecbc3ccc58cd5c3ccc5e2c1d7cecec5c7cc8cc1cdcf"><span class="__cf_email__" data-cfemail="02686b636e6b636c652c75636c654261776e6e65676c2c616d6f">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jialiang++Wang">Jialiang Wang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7677-449X" title="Orcid link">http://orcid.org/0000-0001-7677-449X</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02083&amp;href=/doi/10.1021%2Facs.jmedchem.9b02083" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 4069â4080</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 30, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 December 2019</li><li><span class="item_label"><b>Published</b> online</span>30 March 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 April 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b02083" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02083</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4069%26pageCount%3D12%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXiao-Ran%2BHan%252C%2BLiqun%2BChen%252C%2BYuanqi%2BWei%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D8%26contentID%3Dacs.jmedchem.9b02083%26title%3DDiscovery%2Bof%2BSelective%2BSmall%2BMolecule%2BDegraders%2Bof%2BBRAF-V600E%26numPages%3D12%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4080%26publicationDate%3DApril%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b02083"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2637</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">13</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b02083" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Selective Small Molecule Degraders of BRAF-V600E&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xiao-Ran&quot;,&quot;last_name&quot;:&quot;Han&quot;},{&quot;first_name&quot;:&quot;Liqun&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Yuanqi&quot;,&quot;last_name&quot;:&quot;Wei&quot;},{&quot;first_name&quot;:&quot;Weihua&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Yanke&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Chunyan&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Bingyang&quot;,&quot;last_name&quot;:&quot;Jiao&quot;},{&quot;first_name&quot;:&quot;Tingting&quot;,&quot;last_name&quot;:&quot;Shi&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Chao&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Yang&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;R. Lee&quot;},{&quot;first_name&quot;:&quot;Ying&quot;,&quot;last_name&quot;:&quot;Luo&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;B. Plewe&quot;},{&quot;first_name&quot;:&quot;Jialiang&quot;,&quot;last_name&quot;:&quot;Wang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;30&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;4069-4080&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b02083&quot;},&quot;abstract&quot;:&quot;BRAF is among the most frequently mutated oncogenes in human cancers. Multiple small molecule BRAF kinase inhibitors have been approved for treating melanoma carrying BRAF-V600 mutations. However, the benefits of BRAF kinase inhibitors are generally short-lived. Small molecule-mediated targeted protein degradation has recently emerged as a novel pharmaceutical strategy to remove disease proteins through hijacking the cellular ubiquitin proteasome system (UPS). In this study, we developed thalidomide-based heterobifunctional compounds that induced selective degradation of BRAF-V600E, but not the wild-type BRAF. Downregulation of BRAF-V600E suppressed the MEK/ERK kinase cascade in melanoma cells and impaired cell growth in culture. Abolishing the interaction between degraders and cereblon or blocking the UPS significantly impaired the activities of these degraders, validating a mechanistic role of UPS in mediating targeted degradation of BRAF-V600E. These findings highlight a new approach to modulate the functi&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02083&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02083" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02083&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02083" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b02083&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02083" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b02083&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b02083&amp;href=/doi/10.1021/acs.jmedchem.9b02083" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b02083" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b02083" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b02083%26sid%3Dliteratum%253Aachs%26pmid%3D32223235%26genre%3Darticle%26aulast%3DHan%26date%3D2020%26atitle%3DDiscovery%2Bof%2BSelective%2BSmall%2BMolecule%2BDegraders%2Bof%2BBRAF-V600E%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D8%26spage%3D4069%26epage%3D4080%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291781" title="Degradation">Degradation</a>,</li><li><a href="/action/doSearch?ConceptID=291264" title="Kinase inhibitors">Kinase inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/8" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/jmcmar.2020.63.issue-8/20200423/jmcmar.2020.63.issue-8.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/medium/jm9b02083_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02083&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">BRAF is among the most frequently mutated oncogenes in human cancers. Multiple small molecule BRAF kinase inhibitors have been approved for treating melanoma carrying BRAF-V600 mutations. However, the benefits of BRAF kinase inhibitors are generally short-lived. Small molecule-mediated targeted protein degradation has recently emerged as a novel pharmaceutical strategy to remove disease proteins through hijacking the cellular ubiquitin proteasome system (UPS). In this study, we developed thalidomide-based heterobifunctional compounds that induced selective degradation of BRAF-V600E, but not the wild-type BRAF. Downregulation of BRAF-V600E suppressed the MEK/ERK kinase cascade in melanoma cells and impaired cell growth in culture. Abolishing the interaction between degraders and cereblon or blocking the UPS significantly impaired the activities of these degraders, validating a mechanistic role of UPS in mediating targeted degradation of BRAF-V600E. These findings highlight a new approach to modulate the functions of oncogenic BRAF mutants and provide a framework to treat BRAF-dependent human cancers.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88465" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88465" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The rapidly accelerated fibrosarcoma (RAF) family of serine/threonine kinases, including ARAF, BRAF, and CRAF, transduce signals downstream of RAS to the mitogen-activated protein kinase (MAPK) cascade. They are the core components of a signal transduction network that supports proliferation and survival in mammalian cells.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Aberrations of BRAF are widely documented in human cancer, accounting for 6â8% of all cases.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> In particular, almost half of melanoma and virtually all hairy cell leukemia are driven by BRAF mutations. While many forms of BRAF mutations have been identified, approximately 90% of these mutations convert the valine residue at codon 600 into a glutamic acid residue (i.e., V600E), which renders BRAF acting as a constitutively active monomer.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> BRAF-V600E and other oncogenic BRAF mutants result in aberrant activation of the downstream MEK/ERK kinase cascade and other signaling pathways, thereby promoting oncogenesis.</div><div class="NLM_p">To date, three BRAF kinase inhibitors, vemurafenib,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> dabrafenib,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and encorafenib,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> have been approved for treating melanoma patients carrying BRAF-V600 mutations. These inhibitors belong to the second generation of BRAF inhibitors that selectively target BRAF-V600 mutants and block activity of these proteins in monomeric forms. These BRAF kinase inhibitors have wide therapeutic windows because they spare dimeric wild-type BRAF in normal tissues.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> In addition, they are not active against other classes of BRAF mutants, such as BRAF fusions and splice variants.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Furthermore, the second-generation BRAF inhibitors are known to enhance formation of BRAF homodimer or heterodimers between BRAF and other RAF proteins.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> This unique mechanism is thought to compromise clinical efficacy of these drugs, promote acquired resistance, and induce adverse effects, particularly induction of secondary skin cancer.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Nevertheless, vemurafenib and other approved BRAF kinase inhibitors have produced marked responses in melanoma patients with BRAF-V600 mutations.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The clinical benefits of currently approved BRAF kinase inhibitors are greatly restrained by rapid emergence of acquired resistance.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Combination with MEK inhibitors neutralizes the paradoxical activation of wild-type BRAF induced by BRAF inhibitors, modestly improves response rate, and extends tumor control.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> However, resistance and tumor recurrence remain inevitable. Approaches leading to more potent, selective, and durable suppression of oncogenic BRAF mutants are expected to produce better tumor response and provide additional clinical benefits to patients.</div><div class="NLM_p">Hijacking the ubiquitin proteasome system via heterobifunctional small molecule compounds is an emerging pharmaceutical strategy aiming to selectively remove disease-causing proteins in affected cells.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> These small molecule degraders are also known as proteolysis-targeting chimeras (PROTACs), as these compounds comprise two recruiting ligands connected by a linker. One of the ligands binds to an E3 ubiquitin complex, and the other recruits the protein of interest (POI) to the E3 ligase complex. Once brought to close proximity of E3 ligases, the POI is polyubiquitinated and subsequently degraded by the proteasome. Targeted degradation of POIs not only compromises the catalytic activities of these proteins but also removes their scaffolding and other noncatalytic functions, providing unique advantages over inhibitors.</div><div class="NLM_p last">A growing list of disease-relevant proteins, mostly implicated in oncology, has been targeted by PROTAC molecules, such as BRD4, BRD9, ALK, and CDK4/6.<a onclick="showRef(event, 'ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20">(13â20)</a> In the current study, we report two BRAF-V600E degraders generated from the E3 ligase ligand thalidomide and two BRAF kinase inhibitors, vemurafenib and BI882370.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> These degraders selectively induced downregulation of BRAF-V600E in melanoma cells at nanomolar concentrations but not wild-type BRAF, leading to growth arrest and apoptosis in target cells. Degradation of BRAF-V600E was verified to be dependent on the ubiquitin proteasome system. Thereby we demonstrated a novel therapeutic approach modulating oncogenic BRAF mutants at protein levels.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17420" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17420" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Design and Synthesis of BRAF Degraders</h3><div class="NLM_p">From multiple reported BRAF kinase inhibitors,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> we selected vemurafenib and BI882370 as the BRAF binding moiety (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Vemurafenib is the first approved BRAF kinase inhibitor for the treatment of late stage melanoma with 3-fold selectivity for BRAF-V600E over wild-type BRAF,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> while BI882370 is a more potent pan-RAF kinase inhibitor.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Co-crystal structures of BRAF in complex with vemurafenib (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3OG7">3OG7</a>) and with <b>5</b> (Vem-bisamide-2) (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JT2">5JT2</a>)<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> show that part of the phenyl ring is solvent exposed allowing attachment of the linker. We connected the linker through an amide bond, with molecular modeling suggesting that the amide carbonyl group is capable of forming a hydrogen bond with the imidazole ring of His539 in BRAF-V600E (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02083/suppl_file/jm9b02083_si_001.pdf" class="ext-link">Supporting Figure S1</a>). In the co-crystal structure of BRAF with BI882370 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CSX">5CSX</a>), the ethylpiperidinyl group is exposed to solvent and was exploited for attachment of the linker. Besides the correct site of attachment, the choice of linker and E3-ligase ligand is critical for the development of effective PROTACs. In this study, a set of degraders varying in linkers and E3-ligase ligands was screened against BRAF-V600E (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02083/suppl_file/jm9b02083_si_001.pdf" class="ext-link">Supporting Figures S2â5</a>), leading to the identification of two degraders of BRAF-V600E, namely <b>12</b> and <b>23</b>. In <b>12</b>, vemurafenib is attached to the E3 ligase ligand thalidomide at the meta-position through a pentanoyl linker. In <b>23</b>, using BI882370 as a warhead, an 11-atom PEG linker was found to be the better choice (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). We prepared <b>13</b> and <b>24</b> as the corresponding negative control compounds by N-methylation of the thalidomide moiety which disabled binding to cereblon.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> We developed a convergent synthetic route for the synthesis of the designed BRAF degraders and their negative control compounds (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Suzuki coupling of <b>6</b> and <b>7</b>, followed by Boc deprotection afforded the vemurafenib analog <b>8</b> as the BRAF binding warhead. The thalidomide derivatives <b>11a</b> and <b>11b</b> were synthesized by nucleophilic aromatic substitution of the meta-fluoro-substituted thalidomide derivatives <b>9a</b> and <b>9b</b> with amino ester <b>10</b>, followed by <i>tert</i>-butyl ester deprotection. Amide coupling of <b>8</b> with <b>11a</b> and <b>11b</b> afforded <b>12</b> and its negative control <b>13</b> as the desired product. Ullman type CâN coupling of <b>14</b> and <b>15</b> gave intermediate <b>16</b>, which was converted to <b>17</b> by iodination. Warhead <b>19</b> was made by Suzuki coupling of <b>17</b> with 5-pyrimidinylboronic acid <b>18</b>, followed by Boc deprotection. The linker attached pomalidomide analogs <b>22a</b> and <b>22b</b> were synthesized following similar procedures as for <b>11a</b>. Amide coupling of <b>22a</b> and <b>22b</b> with warhead <b>19</b> afforded the desired compound <b>23</b> and its negative control <b>24</b>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/medium/jm9b02083_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of <b>1</b> (vemurafenib), <b>2</b> (dabrafenib), <b>3</b> (encorafenib), <b>4</b> (BI882370), and <b>5</b> (Vem-bisamide-2).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02083&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/medium/jm9b02083_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>12</b> and <b>23</b> and Their Cereblon Binding-Deficient Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02083&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd(dppf)Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 80 Â°C, 6 h; (b) HCl/EtOAc, rt, overnight; (c) DIEA, NMP, microwave, 85 Â°C, 30 min; (d) TFA, rt, 2 h; (e) EDCI, HOAt, NMM, DMSO, rt, overnight; (f) CuI, (<i>R</i>,<i>R</i>)-<i>N</i>,<i>N</i>â²-dimethyl-1,2-diaminocyclohexane, Cs<sub>2</sub>CO<sub>3</sub>, toluene, 120 Â°C, 48 h; (g) NIS, DMF/THF, rt, 1 h; and (h) Pd(dppf)Cl<sub>2</sub>, LiCl, Na<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 100 Â°C, 1 h.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Compounds <b>12</b> and <b>23</b> Bind BRAF and BRAF-V600E with High Affinity</h3><div class="NLM_p">Using the DiscoverX KINOMEscan platform, the binding affinities of the two degraders to wild-type BRAF or BRAF-V600E mutant were compared with their corresponding warheads. Our results demonstrated that the affinities of <b>23</b> were approximately 6-fold lower than those of BI882370 for both BRAF and BRAF-V600E mutant (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). In contrast, the affinities of <b>12</b> were 4- to 5-fold higher compared to vemurafenib (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), most likely due to the formation of an additional hydrogen bond between the amide carbonyl of <b>12</b> and the imidazole ring of His539 in BRAF as predicted by molecular modeling (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02083/suppl_file/jm9b02083_si_001.pdf" class="ext-link">Supporting Figure S1</a>). Modifications to the thalidomide moiety by N-methylation (<b>13</b>, <b>24</b>) did not significantly affect affinities to either wild-type BRAF or BRAF-V600E (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/medium/jm9b02083_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding affinities of vemurafenib, BI882370, degraders (<b>12</b>, <b>23</b>), and negative controls (<b>13</b>, <b>24</b>) to BRAF or BRAF-V600E. Binding affinities of individual compounds were determined using the KINOMEscan assay (DiscoveryX). The lowest concentration points represent data for the DMSO samples. Data are shown as mean Â± SEM derived from duplicated independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02083&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Compounds <b>12</b> and <b>23</b> Induce Degradation of BRAF-V600E</h3><div class="NLM_p">The ability of <b>12</b> and <b>23</b> to degrade BRAF-V600E protein was first examined in A375 cells, a melanoma cell line homogeneously expressing BRAF-V600E. Cells were incubated with the degraders at various concentrations for 16 h. For both degraders, reductions of BRAF-V600E protein levels were detected at 12 nM and intensified at higher concentrations, with the downstream ERK phosphorylation inhibited accordingly (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A,B). Moderate hook effects were observed at 1000 nM for both <b>12</b> and <b>23</b>, probably as excessive compounds undermined formation of the ternary complex of E3-degrader-BRAF-V600E. To determine the kinetics of BRAF-V600E degradation, we showed that significant depletion was not detected until 16 h after degrader treatment (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C). However, reduction in the phosphorylation of ERK induced by <b>23</b> was detected as early as 2 h after incubation with cells, suggesting that degradation of BRAF-V600E was substantially delayed after binding of the degraders and the target protein.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/medium/jm9b02083_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. <b>12</b> and <b>23</b> induce degradation of BRAF-V600E. (A, B) A375 cells were treated with DMSO or serial dilutions of indicated compounds for 16 h. (C) A375 cells were treated with DMSO, 500 nM BI882370 or <b>23</b> for the indicated length of time.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02083&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition to BRAF-V600E, both vemurafenib and BI882370 are known to bind to the active form of wild-type BRAF.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The KINOMEscan data also suggested that the degraders bound to wild-type BRAF and BRAF-V600E with comparable affinities (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Hence, we explored whether these degraders also degraded wild-type BRAF using a lung cancer cell line, A549, in which BRAF is constantly activated by signals transduced from the oncogenic KRAS mutant. Our results demonstrated that neither <b>12</b> nor <b>23</b> resulted in significant degradation of wild-type BRAF (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A,B), suggesting that binding to the targeted protein is insufficient to induce degradation in the case of BRAF. To exclude influences from variations in cellular context, we introduced expression of the kinase domain (residues: 448â723) of BRAF-V600E or wild-type BRAF into A375 cells. In line with the observations with full-length proteins, <b>12</b> and <b>23</b> selectively degraded the kinase domain of BRAF-V600E but not the wild-type one (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C,D). These results collectively demonstrate that compounds <b>12</b> and <b>23</b> are potent and selective degraders for BRAF-V600E. However, there is a latency of degradation following binding of the degraders and the target protein, which appeared to be longer than those for some of the reported degraders, such as BRD4,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> ALK,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> CDK4/6,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and BRD7/9.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> It is possible that our degraders require further optimization to facilitate the formation of productive ternary complexes comprising of E3 ligase, the degrader, and BRAF-V600E.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/medium/jm9b02083_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <b>12</b> and <b>23</b> do not degrade wild-type BRAF. (A, B) A549 cells were treated with DMSO or indicated compounds following a 3-fold serial dilution for 16 h. (C, D) A375 cells stably expressing the kinase domain of BRAF or BRAF-V600E were treated with DMSO or indicated compounds for 16 h following a 3-fold serial dilution. Levels of indicated proteins were shown using immunoblotting.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02083&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Degradation of BRAF-V600E Is Mediated by the Ubiquitin-Proteasome System</h3><div class="NLM_p">To confirm that the activities of our degraders were mediated via the cullin family E3 ligases and the ubiquitin-proteasome system (UPS), we employed multiple approaches to validate the mechanisms of BRAF-V600E targeted degradation. We generated derivatives of <b>12</b> and <b>23</b> that were deficient in binding to cereblon (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). These negative control compounds, <b>13</b> and <b>24</b>, respectively, were incapable of inducing degradation of BRAF-V600E in A375 cells (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A,B). However, their abilities of suppressing the downstream ERK phosphorylation were impaired but not blocked (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A,B), suggesting that the impact on downstream signaling for the degraders could result from both kinase inhibitory and protein degrading activities. We further demonstrated that degradation of BRAF-V600E induced by <b>12</b> and <b>23</b> could be rescued by pretreatment with proteasome inhibitors MG-132 or bortezomib (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C,D). Additionally, an excessive amount of pomalidomide also counteracted the degrading activities of <b>12</b> and <b>23</b>, likely through competitive interaction with cereblon (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C,D). Similarly, pretreatment with MLN4924, an inhibitor of the NEDD8-activating enzyme (NAE) that activates the cullin family E3 ligases, also restored BRAF-V600E levels in the presence of <b>12</b> and <b>23</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C,D). These results collectively validate a cullin-UPS-mediated mechanism for targeted degradation of BRAF-V600E.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/medium/jm9b02083_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Degradation of BRAF-V600E is mediated by the UPS. (A, B) A375 cells were treated with serial dilutions of compound <b>12</b>, <b>23</b>, or their respective negative controls <b>13</b> or <b>24</b> for 16 h prior to immunoblotting. (C, D) A375 cells were pretreated for 1 h with DMSO, pomalidomide (POM, 10 Î¼M), MG-132 (20 Î¼M), bortezomib (200 nM), or MLN4924 (1 Î¼M) and subsequently incubated with 500 nM <b>12</b> or <b>23</b> for 6 h prior to immunoblotting.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02083&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Degradation of BRAF-V600E Impairs Melanoma Cell Growth</h3><div class="NLM_p">We next assessed the cellular activities of BRAF-V600E degraders. In line with previous publications, BRAF kinase inhibitors vemurafenib and BI882370 reduced viability of A375 cells (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A,B). The IC<sub>50</sub> value of <b>23</b> was approximately 10 times higher than its warhead, BI882370, while the IC<sub>50</sub> of <b>24</b>, the cereblon binding-deficient derivative, was 4 times higher than <b>23</b>, suggesting that target degradation contributed substantially to the cellular activity of <b>23</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). In contrast, the IC<sub>50</sub> values of <b>12</b> and its nondegrading control <b>13</b> were similar (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A), suggesting that target degradation and kinase inhibition are implicated in the cellular activity of <b>12</b> to comparable extents. In the BRAF-V600E-dependent colon cancer cell line HT-29, these degraders and their negative controls induced similar patterns of growth inhibition, although the IC<sub>50</sub> value of <b>12</b> appeared to be slightly lower in this line (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C,D). These compounds as well as their warheads also impaired colony formation by A375 cells in a fashion resembling the observations in cell viability assays (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>E,F). On the contrary, the degraders and their warheads did not induce significant loss of cell viability at physiologically concentrations in three non-neoplastic human cell lines (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02083/suppl_file/jm9b02083_si_001.pdf" class="ext-link">Supporting Figure S6</a>). Taken together, our data suggest that selective degradation of BRAF-V600E by small molecule compounds impairs cell growth and viability in BRAF-V600E-driven melanoma and colon cancer cells.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/medium/jm9b02083_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Degradation of BRAF-V600E impairs cell viability and colony formation. (AâD) Compounds <b>12</b> and <b>23</b> reduced viability of A375 and HT-29 cells in a dose-dependent manner. (E, F) Compounds <b>12</b> and <b>23</b> inhibited colony formation of A375 cells. Data are shown as mean Â± SD *: <i>p</i> < 0.05 by Studentâs <i>t</i> test compared with the corresponding control groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02083&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Discussion and Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42216" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42216" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">BRAF-V600E expression has been reported in a wide variety of human cancers. Mutations of BRAF are particularly common in melanoma, colon cancer, and thyroid cancer.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Additional aberrations that activate BRAF, such as alternative splicing and chromosomal translocation, have been increasingly recognized.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Multiple approved BRAF-V600E kinase inhibitors provide significant yet short-lived benefits to melanoma patients. In the current study, we report development of small molecule BRAF degraders. Degraders generated using VHL-1 as the E3 ligand were modestly active at best. In contrast, both thalidomide and pomalidomide yielded potent BRAF degraders with either vemurafenib or BI882370 as the warhead. Linker length had significant yet contrasting impact on the efficacy of degraders. Shorter linker length was associated with higher potency for degraders with vemurafenib as the warhead, while BI882370-based degraders required a longer linker length in order to induce significant degradation. The development efforts were culminated in the discovery of two low-nanomolar degraders, <b>12</b> and <b>23</b>. These compounds selectively induced degradation of BRAF-V600E but not wild-type BRAF, despite binding to both proteins with similar affinities. Mounting evidence shows that PROTAC compounds differentially degrade closely related target proteins,<a onclick="showRef(event, 'ref28 ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30 ref31">(28â31)</a> suggesting that forming the ternary complex is necessary but insufficient to induce effective degradation of the target proteins. It has been well documented that BRAF kinase inhibitors bind to wild-type BRAF and BRAF-V600E in distinct modes.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Hence, our results suggest that <b>12</b> and <b>23</b> may bind to BRAF-V600E in a conformation that favors the formation of cooperative ternary complex with the E3 complex, whereas they may form a disruptive ternary complex with wild-type BRAF. Following rapid binding to BRAF-V600E and blockade of the downstream MAPK kinase cascade, there were several hours of delay before significant degradation of BRAF-V600E could be detected. Therefore, the rate-limiting step of small molecule-induced proteolysis of BRAF-V600E is likely not the formation of the degrader-BRAF-V600E binary complex. Additional data, particularly crystal structures, will be required to fully address how <b>12</b> and <b>23</b> differentially target wild-type BRAF and BRAF-V600E mutant.</div><div class="NLM_p last">In BRAF-V600E-dependent melanoma cells and colon cancer cells, <b>12</b> and <b>23</b> provoked <i>in vitro</i> antineoplastic activities comparable to clinical stage BRAF kinase inhibitors, but not in non-neoplastic human cells. Further studies are required to optimize the physiochemical properties of these novel degraders for preclinical and clinical development. Their activities should also be characterized in a wider range of BRAF-V600E-expressing cells. While the kinase activity has been well documented to be essential for the oncogenic potential of BRAF-V600E, kinase-independent activities of wild-type BRAF and BRAF mutants have been described in various diseases.<a onclick="showRef(event, 'ref33 ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35 ref36">(33â36)</a> Thus, the development of BRAF-V600E selective degraders provides a platform to systemically investigate the impact of depleting oncogenic BRAF mutants in human cancers.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80742" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80742" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> General Chemistry Methods</h3><div class="NLM_p last">All chemicals and reagents were purchased from commercial suppliers and used without further purification. LCMS spectra for all compounds were acquired using a Shimadzu LC-MS 2020 system comprising a pump (LC-20AD) with degasser (DGU-20A3), an autosampler (SIL-20AHT), a column oven (CTO-20A) (set at 40 Â°C, unless otherwise indicated), a photodiode array (PDA) (SPD-M20A) detector, an evaporative light-scattering (ELSD) (Alltech 3300ELSD) detector. Chromatography was performed on a Shimadzu SunFire C18 (5 Î¼m, 50 Ã 4.6 mm) with water containing 0.1% formic acid as solvent A and acetonitrile containing 0.1% formic acid as solvent B at a flow rate of 2.0 mL/min. Flow from the column was split to a MS spectrometer. The MS detector was configured with an electrospray ionization source. Nitrogen was used as the nebulizer gas. Data acquisition was performed with a Labsolution data system. Proton nuclear magnetic resonance (<sup>1</sup>H NMR) spectra were recorded on a Bruker Avance III400 spectrometer. Chemical shifts are expressed in parts per million (ppm) and reported as Î´ value (chemical shift Î´). Coupling constants are reported in units of Hertz (<i>J</i> value, Hz; integration and splitting patterns: where s = singlet, d = double, t = triplet, q = quartet, brs = broad singlet, m = multiple). Preparative HPLC was performed on Agilent Prep 1260 series with UV detector set to 254 or 220 nm. Samples were injected onto a Phenomenex Luna 75 Ã 30 mm, 5 Î¼m, C18 column at room temperature (rt). The flow rate was 40 mL/min. A linear gradient was used with 10% (or 50%) of MeOH (A) in H<sub>2</sub>O (with 0.1% TFA) (B) to 100% of MeOH (A). All compounds showed >95% purity using the LCMS methods described above. Purities of final compounds were confirmed by UPLC-MS.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Synthesis of <b>12</b>, <b>13</b>, <b>23</b>, and <b>24</b></h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> <i>N</i>-(3-(5-(4-(Aminomethyl)phenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide hydrochloride (<b>8</b>)</h4><div class="NLM_p">To a solution of <i>N</i>-(3-(5-bromo-1<i>H</i>-pyrrolo[2,3-<i>b</i>] pyridine-3-carbonyl)-2,4-difluorophenyl) propane-1-sulfonamide (2 g, 4.36 mmol) in 1,4-dixoane (100 mL) were added <i>tert</i>-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzylcarbamate (1.45 g, 4.36 mmol), K<sub>3</sub>PO<sub>4</sub> (2.32 g, 10.91 mmol) in water (30 mL), and [1,1â²-bis(diphenylphosphino)ferrocene] dichloropalladium(II) (200 mg, 10 wt %). After the reaction mixture was heated to 80 Â°C for 6 h, it was diluted with EtOAc (50 mL), washed with 5% lithium chloride aqueous solution (3 Ã 20 mL), and brine (20 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (petroleum ether:EtOAc = 1:4) to afford <i>tert</i>-butyl 4-(3-(2,6-difluoro-3-(propylsulfonamido) benzoyl)-1<i>H</i>-pyrrolo [2,3-<i>b</i>]pyridin-5-yl)benzylcarbamate (1.3 g, yield: 51%) as an off-white solid. MS (ESI) <i>m</i>/<i>z</i>: 585 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 12.98 (s, 1H), 9.76 (s, 1H), 8.70 (d, <i>J</i> = 2.4 Hz, 1H), 8.61 (s, 1H), 8.28 (s, 1H), 7.71 (d, <i>J</i> = 8.0 Hz, 2H), 7.62â7.56 (m, 1H), 7.45 (t, <i>J</i> = 6.0 Hz, 1H), 7.39 (d, <i>J</i> = 8.0 Hz, 2H), 7.31â7.26 (m, 1H), 4.20 (d, <i>J</i> = 6.0 Hz, 2H), 3.14â3.11 (m, 2H), 1.77 (dd, <i>J</i> = 8.0 Hz, 13.2, 2H), 1.42 (s, 9H), 0.97 (t, <i>J</i> = 7.2 Hz, 3H).</div><div class="NLM_p last">A mixture of <i>tert</i>-butyl 4-(3-(2,6-difluoro-3-(propylsulfonamido)benzoyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin- 5-yl)benzylcarbamate (1.25 g, 2.14 mmol) and HC1 acid in EtOAc (3 M, 10 mL) was stirred at rt overnight. The reaction mixture was filtered to give the crude product, which was washed with EtOAc and dried in vacuum to afford the title compound (1.06 g, yield: 95%) as an off-white solid. MS (ESI) <i>m</i>/<i>z</i>: 485 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 13.10 (s, 1H), 9.80 (s, 1H), 8.74 (d, <i>J</i> = 2.4 Hz, 1H), 8.67 (s, 1H), 8.54 (br, 3H), 8.23 (s, 1H), 7.83 (d, <i>J</i> = 8.4 Hz, 2H), 7.66 (d, <i>J</i> = 8.0 Hz, 2H), 7.61â7.57 (m, 1H), 7.31â7.27 (m, 1H), 4.10 (q, <i>J</i> = 5.6 Hz, 2H), 3.16â3.20 (m, 2H), 1.78â1.72 (m, 2H), 0.97 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> 5-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)pentanoic acid (<b>11a</b>)</h4><div class="NLM_p last">A mixture of 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (6.6 g, 24.0 mmol), <i>tert</i>-butyl 5-aminopentanoate (5.0 g, 26.4 mmol), and DIEA (9.3 g, 72 mmol) in NMP (60 mL) was stirred at 140 Â°C in a microwave reactor for 30 min. After cooling down to rt, the mixture was poured into EtOAc (200 mL), washed with water (2 Ã 200 mL) and brine (200 mL). The organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The resulting crude product was purified by silica gel chromatography (petroleum ether:EtOAc = 1:1) to give <i>tert</i>-butyl 5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)pentanoate (1.5 g, yield: 13%) as a yellow solid. MS (ESI) <i>m</i>/<i>z</i>: 374.1 [M + H]<sup>+</sup>. A solution of <i>tert</i>-butyl 5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)pentanoate (1.5 g, 3.5 mmol) in TFA (15 mL) was stirred at rt for 1 h. The reaction mixture was concentrated, and the residue was purified by silica gel chromatography (DCM:MeOH = 20:1) to give the title compound (660 mg, yield: 51%) as a yellow solid. MS (ESI) <i>m</i>/<i>z</i>: 374.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 12.03 (br, 1H), 11.05 (s, 1H), 7.55 (d, <i>J</i> = 8.4 Hz, 1H), 7.10 (t, <i>J</i> = 5.2 Hz, 1H), 6.94 (s, 1H), 6.83 (dd, <i>J</i> = 1.6 Hz, 8.4 Hz, 1H), 5.02 (dd, <i>J</i> = 5.6 Hz, 12.8 Hz, 1H), 3.17â3.16 (m, 2H), 2.92â2.83 (m, 1H), 2.60â2.53 (m, 2H), 2.26â2.25 (m, 2H), 2.01â1.98 (m, 1H), 1.60â1.59 (m, 4H).</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> 5-((2-(1-Methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)pentanoic acid (<b>11b</b>)</h4><div class="NLM_p last">The title compound (41% yield over 2 steps) was synthesized according to procedures for the preparation of <b>11a</b> from 5-fluoro-2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione and <i>tert</i>-butyl 5-aminopentanoate, followed by <i>tert</i>-butyl ester deprotection. MS (ESI) <i>m</i>/<i>z</i>: 388.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> <i>N</i>-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzyl)-5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)pentanamide (<b>12</b>)</h4><div class="NLM_p last">A solution of <i>N</i>-(3-(5-(4-(aminomethyl)phenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1- sulfonamide hydrochloride (10 mg, 0.019 mmol), 5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin- 5-yl)amino)pentanoic acid (8.6 mg, 0.023 mmol), EDCI (5.94 mg, 0.031 mmol), HOAt (4.18 mg, 0.031 mmol), and NMM (12.53 mg, 0.12 mmol) in DMSO (3 mL) was stirred at rt overnight. The reaction solution was diluted with EtOAc (100 mL) and washed with water (100 mL). The aqueous layer was extracted with EtOAc (50 mL). The combined organic layer was washed with brine twice, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The resulting residue was purified by Prep-TLC (DCM:MeOH = 10:1) to give the title compound (10 mg, 63% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.71 (s, 1H), 8.60 (d, <i>J</i> = 2.0 Hz, 1H), 7.98 (s, 1H), 7.63â7.71 (m, 3H), 7.51 (d, <i>J</i> = 8.4 Hz, 1H), 7.43 (d, <i>J</i> = 8.4 Hz, 2H), 7.16 (t, <i>J</i> = 8.4 Hz, 1H), 6.95 (d, <i>J</i> = 1.6 Hz, 1H), 6.81â6.84 (m, 1H), 4.98â5.03 (m, 1H), 4.44 (s, 2H), 3.23 (t, <i>J</i> = 7.2 Hz, 2H), 3.11 (t, <i>J</i> = 8.0 Hz, 2H), 2.60â2.87 (m, 3H), 2.34 (t, <i>J</i> = 7.2 Hz, 2H), 2.01â2.08 (m, 1H), 1.74â1.90 (m, 4H), 1.66â1.73 (m, 2H), 1.03 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 181.7, 174.4, 173.3, 170.4, 168.3, 167.9, 154.7, 148.5, 143.8, 138.3, 137.9, 137.3, 134.5, 132.3, 129.5, 128.1, 127.1, 124.8, 118.2, 116.6, 116.5, 115.4, 112.0, 111.7, 105.2, 53.8, 48.9, 42.4, 35.2, 35.1, 31.7, 30.8, 30.4, 29.4, 29.3, 29.2, 29.1, 28.9, 27.9, 26.7, 25.5, 23.0, 22.4, 16.9, 11.8. HRMS calcd for C<sub>42</sub>H<sub>40</sub>F<sub>2</sub>N<sub>7</sub>O<sub>8</sub>S [M + H<sup>+</sup>] 840.2622, found 840.2628.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> <i>N</i>-(4-(3-(2,6-Difluoro-3-(propylsulfonamido)benzoyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-5-yl)benzyl)-5-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)pentanamide (<b>13</b>)</h4><div class="NLM_p last">The title compound (28% yield) was synthesized according to the procedures for the preparation of <b>12</b> from <i>N</i>-(3-(5-(4-(aminomethyl)phenyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide hydrochloride and 5-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino) pentanoic acid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 8.71 (s, 1H), 8.60 (s, 1H), 7.97 (s, 1H), 7.63â7.73 (m, 3H), 7.52 (d, <i>J</i> = 8.4 Hz, 1H), 7.42 (d, <i>J</i> = 8.0 Hz, 2H), 7.16 (t, <i>J</i> = 8.4 Hz, 1H), 6.95 (d, <i>J</i> = 1.6 Hz, 1H), 6.83 (d, <i>J</i> = 9.2 Hz, 1H), 5.01â5.05 (m, 1H), 4.44 (s, 2H), 3.24 (t, <i>J</i> = 6.8 Hz, 2H), 3.09â3.13 (m, 5H), 2.80â2.86 (m, 2H), 2.59â2.68 (m, 1H), 2.34 (t, <i>J</i> = 7.2 Hz, 2H), 2.00â2.05 (m, 1H), 1.76â1.90 (m, 4H), 1.68â1.73 (m, 2H), 1.03 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 181.7, 174.4, 172.3, 170.1, 168.3, 167.9, 154.7, 148.3, 143.6, 138.4, 137.9, 137.3, 134.6, 129.5, 128.2, 128.1, 127.2, 124.8, 118.3, 116.6, 116.5, 115.4, 112.0, 111.8, 105.2, 105.1, 53.8, 49.5, 42.4, 35.2, 31.7, 31.1, 30.4, 29.4, 29.3, 29.2, 29.1, 28.9, 27.9, 26.7, 25.9, 23.0, 22.3, 21.7, 16.9, 13.0, 11.7. HRMS calcd for C<sub>43</sub>H<sub>42</sub>F<sub>2</sub>N<sub>7</sub>O<sub>8</sub>S [M + H<sup>+</sup>] 854.2778, found 854.2778.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> <i>tert</i>-Butyl 4-((1-(2,6-Difluoro-3-(propylsulfonamido)phenyl)-1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridin-5-yl)(methyl) amino)piperidine-1-carboxylate (<b>16</b>)</h4><div class="NLM_p last">A mixture of <i>tert</i>-butyl 4-(methyl-(1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridin-5-yl) amino)piperidine-1-carboxylate (7.0 g, 21.21 mmol), <i>N</i>-(2,4-difluoro-3-iodophenyl) propane-1-sulfonamide (11.5 g, 31.82 mmol), cuprous iodide (806 mg, 4.24 mmol), (<i>R</i>,<i>R</i>)-<i>N</i>,<i>N</i>â²-dimethyl-1,2-diaminocyclohexane (1.34 mL, 8.48 mmol), and cesium carbonate (20.8 g, 63.64 mmol) in dry toluene (30 mL) was stirred at 120 Â°C for 16 h. After addition of cuprous iodide (806 mg, 4.24 mmol), (<i>R</i>,<i>R</i>)-<i>N</i>,<i>N</i>â²-dimethyl-1,2-diaminocyclohexane (1.34 mL, 8.48 mmol), and cesium carbonate (20.8 g, 63.64 mmol), the reaction mixture was stirred further for 24 h. Upon removal of solvent in vacuo, the residue was diluted with DCM and washed with sodium bicarbonate solution. The organic layer was dried over anhydrous sodium sulfate and filtered. The solvent was removed in vacuo, and the residue was purified by silica gel column chromatography (petroleum ether:EtOAc = 2:1) to afford the title compound (5.5 g, yield: 46%) as a yellow solid. MS (ESI) <i>m</i>/<i>z</i>: 564 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.64â7.58 (m, 1H), 7.26â7.25 (m, 2H), 7.16â7.11 (m, 1H), 6.70 (d, <i>J</i> = 3.2 Hz, 1H), 6.53 (d, <i>J</i> = 9.2 Hz, 1H), 4.82â4.74 (m, 1H), 4.35â4.17 (m, 2H), 3.14â3.10 (m, 2H), 2.96â2.83 (m, 5H), 1.96â1.86 (m, 2H), 1.75â1.66 (m, 4H), 1.49 (s, 9H), 1.07 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>tert</i>-Butyl 4-((1-(2,6-Difluoro-3-(propylsulfonamido)phenyl)-3-iodo-1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridin-5-yl) (methyl)amino)piperidine-1-carboxylate (<b>17</b>)</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl 4-((1-(2,6-difluoro-3-(propylsulfonamido)phenyl)-1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridin-5-yl)(methyl)amino)piperidine-1-carboxylate (5.5 g, 9.75 mmol) in DMF (50 mL) and THF (1 mL) was added <i>N</i>-iodosuccinimide (2.4 g, 10.73 mmol). After the mixture was stirred at rt for 1 h, the reaction was diluted with DCM (30 mL) and washed with aqueous saturated NaHCO<sub>3</sub>. The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (petroleum ether:EtOAc = 2:1) to afford the title compound (5.1 g, yield: 76%) as a yellow solid. MS (ESI) <i>m</i>/<i>z</i>: 690 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.66â7.60 (m, 1H), 7.33 (s, 1H), 7.21 (d, <i>J</i> = 9.2 Hz, 1H), 7.14 (t, <i>J</i> = 8.8 Hz, 1H), 6.55 (d, <i>J</i> = 8.8 Hz, 1H), 6.49 (s, 1H), 4.85â4.78 (m, 1H), 4.37â4.25 (m, 2H), 3.15â3.11 (m, 2H), 2.99â2.86 (m, 5H), 1.96â1.86 (m, 2H), 1.80â1.65 (m, 4H), 1.49 (s, 9H), 1.07 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> <i>N</i>-(2,4-Difluoro-3-(5-(methyl(piperidin-4-yl)amino)-3-(pyrimidin-5-yl)-1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridin-1-yl)phenyl)propane-1-sulfonamide hydrochloride (<b>19</b>)</h4><div class="NLM_p">To a solution of <i>tert</i>-butyl 4-((1-(2,6-difluoro-3-(propylsulfonamido)phenyl)-3-iodo-1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridin-5-yl)(methyl)amino)piperidine-1-carboxylate (5.7 g, 8.26 mmol) in 1,4-dioxane and water (2:1 mixture, 60 mL) were added pyrimidin-5-yl-boronic acid (3.07g, 24.78 mmol), [1,1â²-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (604 mg, 0.83 mmol), lithium chloride (1.7 g, 41.3 mmol), and sodium carbonate (2.6 g, 24.78 mmol). After the resulting mixture was stirred at 100 Â°C for 1 h, it was diluted with DCM and washed with sodium bicarbonate solution. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by column chromatography (petroleum ether:EtOAc = 1:9) to afford <i>tert</i>-butyl 4-((1-(2,6-difluoro-3-(propylsulfonamido)phenyl)-3-(pyrimidin-5-yl)-1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridin-5-yl)(methyl)amino)piperidine-1-carboxylate (2.2 g, yield: 41%) as a yellow solid. MS (ESI) <i>m</i>/<i>z</i>: 642 [M + 1]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.93 (s, 1H), 9.66 (s, 2H), 9.03 (s, 1H), 8.42 (s, 1H), 7.64â7.58 (m, 1H), 7.49â7.44 (m, 2H), 6.81 (d, <i>J</i> = 9.6 Hz, 1H), 4.59â4.53 (m, 1H), 4.16â4.13 (m, 2H), 3.19â3.15 (m, 2H), 2.94â2.83 (m, 5H), 1.80â1.59 (m, 6H), 1.43 (s, 9H), 0.85 (t, <i>J</i> = 7.2 Hz, 3H).</div><div class="NLM_p last">To a solution of <i>tert</i>-butyl 4-((1-(2,6-difluoro-3-(propylsulfonamido)phenyl)-3-(pyrimidin-5-yl)-1<i>H</i>- pyrrolo[3,2-<i>b</i>]pyridin-5-yl)(methyl)amino)piperidine-1-carboxylate (2.2 g, 3.43 mmol) in DCM/MeOH (5:1, 30 mL) was added HCl (3 M in EtOAc, 20 mL), and the mixture was stirred at rt for 3 h. After evaporation, the residue was diluted with EtOAc. The precipitate was collected by filtration and dried to give <i>N</i>-(2,4-difluoro-3-(5-(methyl(piperidin-4-yl)amino)-3-(pyrimidin-5-yl)-1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridin-1-yl)phenyl) propane-1-sulfonamide hydrochloride (1.9 g, yield: 96%) as a yellow solid. MS (ESI) <i>m</i>/<i>z</i>: 542 [M + 1]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 10.00 (s, 1H), 9.74 (s, 2H), 9.27â9.18 (m, 3H), 8.53 (s, 1H), 7.68â7.62 (m, 1H), 7.58 (d, <i>J</i> = 9.2 Hz, 1H), 7.51â7.46 (m, 1H), 6.94 (d, <i>J</i> = 9.2 Hz, 1H), 4.72â4.66 (m, 1H), 3.42â3.39 (m, 2H), 3.32â3.08 (m, 4H), 3.00 (s, 3H), 2.17â2.08 (m, 2H), 1.92â1.87 (m, 2H), 1.83â1.74 (m, 2H), 1.00 (t, <i>J</i> = 7.6 Hz, 3H).</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 3-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy) ethoxy) propanoic acid (<b>22a</b>)</h4><div class="NLM_p last">The title compound (8% yield over 2 steps) was synthesized by coupling of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione and <i>tert</i>-butyl 3-(2-(2-(2-aminoethoxy)ethoxy) ethoxy)propanoate, followed by TFA-mediated <i>tert</i>-butyl ester deprotection according to the procedures for the preparation of compound <b>11a</b>. MS (ESI) <i>m</i>/<i>z</i>: 478.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 7.59 (d, <i>J</i> = 11.2 Hz, 1H), 7.23 (t, <i>J</i> = 6.8 Hz, 1H), 7.04 (d, <i>J</i> = 1.6 Hz, 1H), 7.04 (dd, <i>J</i> = 2.4 Hz, 11.2 Hz, 1H), 5.06 (dd, <i>J</i> = 7.2 Hz, 16.8 Hz, 1H), 3.64â3.57 (m, 8H), 3.54â3.48 (m, 4H), 3.40â3.38 (m, 2H), 2.92â2.89 (m, 1H), 2.64â2.54 (m, 2H), 2.42â2.38 (m, 2H), 2.05â2.01 (m, 1H).</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 3-(2-(2-(2-((2-(1-Methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)propanoic acid (<b>22b</b>)</h4><div class="NLM_p last">The title compound (60% yield over 2 steps) was synthesized by coupling of 4-fluoro-2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione and <i>tert</i>-butyl 3-(2-(2-(2-aminoethoxy) ethoxy)ethoxy)propanoate, followed by <i>tert</i>-butyl ester deprotection according to the procedures for the preparationof <b>11a</b>. MS (ESI) <i>m</i>/<i>z</i>: 492.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>N</i>-(3-(5-((1-(3-(2-(2-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)propanoyl)piperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide (<b>23</b>)</h4><div class="NLM_p last">The title compound (72% yield) was synthesized according to the procedures for the preparation of <b>12</b> from <i>N</i>-(2,4-difluoro-3-(5-(methyl(piperidin-4-yl)amino)- 3-(pyrimidin-5-yl)-1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridin-1-yl)phenyl)propane-1-sulfonamide hydrochloride and 3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy) ethoxy) propanoic acid. <sup>1</sup>H NMR (400 MHz, MeOD) Î´ 9.55 (s, 2H), 9.08 (s, 1H), 8.19 (s, 1H), 7.68â7.74 (m, 1H), 7.58â7.60 (m, 1H), 7.45 (t, <i>J</i> = 8.4 Hz, 1H), 7.31â7.36 (m, 1H), 6.92â7.00 (m, 3H), 4.96â5.03 (m, 1H), 4.60â4.80 (m, 2H), 4.18 (d, <i>J</i> = 14.0 Hz, 1H), 3.72â3.82 (m, 2H), 3.59â3.67 (m, 12H), 3.40â3.42 (m, 2H), 3.16â3.20 (m, 2H), 3.05 (s, 3H), 2.57â2.86 (m, 6H), 2.03â2.07 (m, 1H), 1.82â1.94 (m, 5H), 1.70â1.78 (m, 1H), 1.06 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 173.3, 170.5, 169.4, 169.2, 167.8, 156.5, 154.5, 154.0, 153.7, 153.3, 150.8, 146.9, 141.2, 136.7, 132.5, 131.1, 128.8, 128.2, 128.1, 125.7, 123.4, 123.3, 122.4, 117.9, 115.7, 115.5, 113.1, 112.9, 111.1, 109.7, 109.6, 70.3, 70.1, 69.3, 67.3, 54.2, 49.0, 45.0, 42.2, 41.1, 33.2, 32.6, 31.4, 29.3, 28.6, 22.6, 17.3, 13.1. HRMS calcd for C<sub>48</sub>H<sub>55</sub>F<sub>2</sub>N<sub>10</sub>O<sub>10</sub>S [M + H<sup>+</sup>] 1001.3786, found 1001.3812.</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>N</i>-(2,4-Difluoro-3-(5-(methyl(1-(3-(2-(2-(2-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)propanoyl)piperidin-4-yl)amino)-3-(pyrimidin-5-yl)-1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridin-1-yl)phenyl)propane-1-sulfonamide (<b>24</b>)</h4><div class="NLM_p last">The title compound (50% yield) was synthesized according to the procedures for the preparation of <b>12</b> from <i>N</i>-(2,4-difluoro-3-(5-(methyl (piperidin-4-yl)amino)-3-(pyrimidin-5-yl)-1<i>H</i>-pyrrolo[3,2-<i>b</i>]pyridin-1-yl)phenyl)propane-1-sulfonamide hydrochloride and 3-(2-(2-(2-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy) ethoxy)ethoxy)propanoic acid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.92 (s, 1H), 9.65 (s, 2H), 9.03 (s, 1H), 8.42 (s, 1H), 7.55â7.64 (m, 2H), 7.45â7.49 (m, 2H), 7.13 (d, <i>J</i> = 8.4 Hz, 1H), 7.03 (d, <i>J</i> = 6.8 Hz, 1H), 6.81 (d, <i>J</i> = 9.2 Hz, 1H), 6.60 (s, 1H), 5.10â5.14 (m, 1H), 4.59 (d, <i>J</i> = 10.8 Hz, 1H), 4.05 (d, <i>J</i> = 12.0 Hz, 1H), 3.40â3.66 (m, 17H), 3.10â3.20 (m, 3H), 3.01 (s, 3H), 2.93 (s, 3H), 2.54â2.77 (m, 4H), 2.01â2.05 (m, 1H), 1.73â1.80 (m, 5H), 1.52â1.62 (m, 1H), 1.00 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 172.3, 170.3, 169.4, 169.1, 167.7, 159.0, 158.6, 156.0, 155.8, 154.0, 153.7, 146.9, 141.7, 136.7, 132.6, 129.6, 128.8, 127.7, 127.6, 124.4, 123.3, 123.2, 121.7, 117.9, 117.1, 116.1, 114.2, 113.0, 112.8, 111.1, 109.9, 109.7, 104.8, 70.3, 70.2, 69.3, 67.4, 54.2, 49.6, 45.4, 42.2, 41.4, 33.3, 31.6, 30.7, 29.6, 28.9, 27.0, 21.8, 17.3, 13.1. HRMS calcd for C<sub>49</sub>H<sub>57</sub>F<sub>2</sub>N<sub>10</sub>O<sub>10</sub>S [M + H<sup>+</sup>] 1015.3942, found 1015.3944.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Binding Affinity Assays</h3><div class="NLM_p last">BRAF binding affinities were determined by DiscoverX (San Diego, USA) using the KINOMEscan platform. KINOMEscan is based on a competition binding assay that quantitatively measures the ability of a compound to compete with an immobilized, active-site directed ligand. The assay is performed by combining three components: DNA-tagged BRAF, immobilized ligand, and a test compound. The ability of the test compound to compete with the immobilized ligand is measured via quantitative PCR of the DNA tag. <i>K</i><sub>d</sub>s were determined using an 11-point 3-fold compound dilution series (top concentration = 10 Î¼M in this case) with three DMSO control points in duplicates. Some outlier data points were subtracted.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Cell Culture and Transfection</h3><div class="NLM_p last">A375, HT-29, A549, HaCaT, WI-38, and IMR-90 cells were purchased from the Cell Line Bank of Chinese Academy of Sciences. All cells were cultured at 37 Â°C with 5% CO<sub>2</sub> in Dulbeccoâs modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (Gibco, Thermo Fisher). Cells were authenticated using the short tandem repeat (STR) assays by BioWing Applied Biotechnology, Shanghai. Mycoplasma contamination was excluded following a PCR-based method. Cell transfection was performed using Lipofectamine 2000 (Invitrogen) following the manufacturerâs instructions. Stable cell lines were established by lentivirus transduction, selected, and maintained in medium containing 1 Î¼g/mL puromycin (Beyotime Biotechnology).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Antibodies and Reagents</h3><div class="NLM_p last">Mouse anti-BRAF antibody (sc-5284) was purchased from Santa Cruz Biotechnology. Mouse anti-<i>p</i>-ERK1/2 antibody (4696S) was purchase from Cell Signaling Technology. HRP-conjugated anti-Î±-tubulin antibody was produced in house. The CellTiter-Lumi Assay kit was purchased from Beyotime Biotechnology, Beijing. Vemurafenib was purchased from MedKoo Biosciences, Morrisville, NC, USA. BI882370 was prepared following published procedures (WO2012/104388).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Immunoblotting</h3><div class="NLM_p last">Cultured cells were washed with cold PBS once and lysed in cold RIPA buffer supplemented with protease inhibitors and phosphatase inhibitors (Beyotime Biotechnology). The solutions were then incubated at 4 Â°C for 30 min with gentle agitation to fully lyse cells. Cell lysates were centrifuged at 13,000 rpm for 10 min at 4 Â°C, and pellets were discarded. Total protein concentrations in the lysates were determined following BCA assays (Beyotime Biotechnology). Cell lysates were mixed with Laemmli loading buffer to 1Ã and heated at 99 Â°C for 5 min. Proteins were resolved on SDS-PAGE and visualized using Western ECL Substrate kits on a ChemiDoc MP Imaging system (Bio-Rad). Protein bands were quantitated using the Image Lab software provided by Bio-Rad.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Cell Viability Assay</h3><div class="NLM_p last">Cells were seeded at a density of 2000 cells per well in 96-well assay plates and treated with test compounds following a 12-point serial dilution. Three days later, cell viability was determined using the CellTiter-Lumi assay kit according to the manufacturerâs instructions. The doseâresponse curves and IC<sub>50</sub> values were calculated using the GraphPad Prism software following a nonlinear regression (least-squares fit) method.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Colony Formation Assay</h3><div class="NLM_p last">A375 cells were plated at 200 cells per well in 6-well plates and treated the next day as indicated in figure legends. Seven days after incubated with DMSO or indicated compounds, cells were fixed and visualized using 0.5% crystal violet. Colonies were counted using the ImageJ software.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Statistical Analyses</h3><div class="NLM_p last">Data presented were mean Â± standard deviation unless otherwise indicated. Statistical significance was determined using the GraphPad Prism 5.0 software. <i>P</i> values of <0.05 were considered significant.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33"><a href="/doi/suppl/10.1021/acs.jmedchem.9b02083" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71307" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71307" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b02083?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02083</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Figures S1âS6 compound information (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02083/suppl_file/jm9b02083_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular string data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b02083/suppl_file/jm9b02083_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02083/suppl_file/jm9b02083_si_001.pdf">jm9b02083_si_001.pdf (6.18 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02083/suppl_file/jm9b02083_si_002.csv">jm9b02083_si_002.csv (4.9 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b02083" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75585" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75585" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael B. Plewe</span> - <span class="hlFld-Affiliation affiliation">Cullgen
Inc., 12671 High Bluff
Drive, Suite 130, San Diego, California 92130, United States</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#234e534f4654466340564f4f44464d0d404c4e"><span class="__cf_email__" data-cfemail="016c716d6476644162746d6d66646f2f626e6c">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jialiang Wang</span> - <span class="hlFld-Affiliation affiliation">Cullgen
Inc., 12671 High Bluff
Drive, Suite 130, San Diego, California 92130, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Cullgen
(Shanghai) Inc., Building
6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs
Republic of China</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7677-449X" title="Orcid link">http://orcid.org/0000-0001-7677-449X</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b4deddd5d8ddd5dad39ac3d5dad3f4d7c1d8d8d3d1da9ad7dbd9"><span class="__cf_email__" data-cfemail="d2b8bbb3bebbb3bcb5fca5b3bcb592b1a7bebeb5b7bcfcb1bdbf">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiao-Ran Han</span> - <span class="hlFld-Affiliation affiliation">Cullgen
Inc., 12671 High Bluff
Drive, Suite 130, San Diego, California 92130, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Cullgen
(Shanghai) Inc., Building
6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liqun Chen</span> - <span class="hlFld-Affiliation affiliation">Cullgen
(Shanghai) Inc., Building
6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuanqi Wei</span> - <span class="hlFld-Affiliation affiliation">Cullgen
(Shanghai) Inc., Building
6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Weihua Yu</span> - <span class="hlFld-Affiliation affiliation">Cullgen
(Shanghai) Inc., Building
6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanke Chen</span> - <span class="hlFld-Affiliation affiliation">Cullgen
(Shanghai) Inc., Building
6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chunyan Zhang</span> - <span class="hlFld-Affiliation affiliation">Cullgen
(Shanghai) Inc., Building
6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bingyang Jiao</span> - <span class="hlFld-Affiliation affiliation">Cullgen
(Shanghai) Inc., Building
6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tingting Shi</span> - <span class="hlFld-Affiliation affiliation">Cullgen
(Shanghai) Inc., Building
6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Sun</span> - <span class="hlFld-Affiliation affiliation">Cullgen
(Shanghai) Inc., Building
6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chao Zhang</span> - <span class="hlFld-Affiliation affiliation">Cullgen
(Shanghai) Inc., Building
6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yang Xu</span> - <span class="hlFld-Affiliation affiliation">Cullgen
(Shanghai) Inc., Building
6, 230 ChuanHong Road, Chuansha, Pudong New Area, Shanghai 201202, Peopleâs
Republic of China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew R. Lee</span> - <span class="hlFld-Affiliation affiliation">Cullgen
Inc., 12671 High Bluff
Drive, Suite 130, San Diego, California 92130, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ying Luo</span> - <span class="hlFld-Affiliation affiliation">Cullgen
Inc., 12671 High Bluff
Drive, Suite 130, San Diego, California 92130, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): All authors are employees of Cullgen.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e2066-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33715" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33715" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The design, study, and financial support for the research were provided by Cullgen.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbeccoâs modified Eagle medium</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last"><i>N</i>-(3-(dimethylamino)propyl)-<i>N</i>â²-ethylcarbodiimide</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal regulated kinase</p></td></tr><tr><td class="NLM_term">HOAt</td><td class="NLM_def"><p class="first last">1-hydroxy-7-azabenzotrizaole</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">NIS</td><td class="NLM_def"><p class="first last"><i>N</i>-iodosuccinimide</p></td></tr><tr><td class="NLM_term">NMM</td><td class="NLM_def"><p class="first last"><i>N</i>-methylmorpholine</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last"><i>N</i>-methylpyrrolidone</p></td></tr><tr><td class="NLM_term">PROTAC</td><td class="NLM_def"><p class="first last">proteolysis-targeting chimera</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">RAF</td><td class="NLM_def"><p class="first last">rapidly accelerated fibrosarcoma</p></td></tr><tr><td class="NLM_term">UPS</td><td class="NLM_def"><p class="first last">ubiquitin proteasome system</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70262" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70262" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 36 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durrant, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. K.</span></span> <span> </span><span class="NLM_article-title">Targeting the Raf kinases in human cancer: the Raf dimer dilemma</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">3</span>â <span class="NLM_lpage">8</span>, <span class="refDoi">Â DOI: 10.1038/bjc.2017.399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1038%2Fbjc.2017.399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=29235562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFKhu7vL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=3-8&author=D.+E.+Durrantauthor=D.+K.+Morrison&title=Targeting+the+Raf+kinases+in+human+cancer%3A+the+Raf+dimer+dilemma&doi=10.1038%2Fbjc.2017.399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Raf kinases in human cancer: the Raf dimer dilemma</span></div><div class="casAuthors">Durrant, David E.; Morrison, Deborah K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-8</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The Raf protein kinases are key intermediates in cellular signal transduction, functioning as direct effectors of the Ras GTPases and as the initiating kinases in the ERK cascade.  In human cancer, Raf activity is frequently dysregulated due to mutations in the Raf family member B-Raf or to alterations in upstream Raf regulators, including Ras and receptor tyrosine kinases.  First-generation Raf inhibitors, such as vemurafenib and dabrafenib, have yielded dramatic responses in malignant melanomas contg. B-Raf mutations; however, their overall usefulness has been limited by both intrinsic and acquired drug resistance.  In particular, issues related to the dimerization of the Raf kinases can impact the efficacy of these compds. and are a primary cause of drug resistance.  Here, we will review the importance of Raf dimerization in cell signalling as well as its effects on Raf inhibitor therapy, and we will present the new strategies that are being pursued to overcome the 'Raf Dimer Dilemma'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHTShTLpMLiLVg90H21EOLACvtfcHk0lhZupiCUlkjtg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFKhu7vL&md5=186dbe3ee9006a384d9b50831000e144</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2017.399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2017.399%26sid%3Dliteratum%253Aachs%26aulast%3DDurrant%26aufirst%3DD.%2BE.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DTargeting%2520the%2520Raf%2520kinases%2520in%2520human%2520cancer%253A%2520the%2520Raf%2520dimer%2520dilemma%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2018%26volume%3D118%26spage%3D3%26epage%3D8%26doi%3D10.1038%2Fbjc.2017.399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignell, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clegg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teague, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woffendin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottomley, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicks, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmidou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mould, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayatilake, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gusterson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard-Jones, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitland, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenevix-Trench, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggins, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigner, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seigler, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wooster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futreal, P. A.</span></span> <span> </span><span class="NLM_article-title">Mutations of the BRAF gene in human cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>417</i></span>,  <span class="NLM_fpage">949</span>â <span class="NLM_lpage">954</span>, <span class="refDoi">Â DOI: 10.1038/nature00766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1038%2Fnature00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=12068308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=949-954&author=H.+Daviesauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S.+Edkinsauthor=S.+Cleggauthor=J.+Teagueauthor=H.+Woffendinauthor=M.+J.+Garnettauthor=W.+Bottomleyauthor=N.+Davisauthor=E.+Dicksauthor=R.+Ewingauthor=Y.+Floydauthor=K.+Grayauthor=S.+Hallauthor=R.+Hawesauthor=J.+Hughesauthor=V.+Kosmidouauthor=A.+Menziesauthor=C.+Mouldauthor=A.+Parkerauthor=C.+Stevensauthor=S.+Wattauthor=S.+Hooperauthor=R.+Wilsonauthor=H.+Jayatilakeauthor=B.+A.+Gustersonauthor=C.+Cooperauthor=J.+Shipleyauthor=D.+Hargraveauthor=K.+Pritchard-Jonesauthor=N.+Maitlandauthor=G.+Chenevix-Trenchauthor=G.+J.+Rigginsauthor=D.+D.+Bignerauthor=G.+Palmieriauthor=A.+Cossuauthor=A.+Flanaganauthor=A.+Nicholsonauthor=J.+W.+Hoauthor=S.+Y.+Leungauthor=S.+T.+Yuenauthor=B.+L.+Weberauthor=H.+F.+Seiglerauthor=T.+L.+Darrowauthor=H.+Patersonauthor=R.+Maraisauthor=C.+J.+Marshallauthor=R.+Woosterauthor=M.+R.+Strattonauthor=P.+A.+Futreal&title=Mutations+of+the+BRAF+gene+in+human+cancer&doi=10.1038%2Fnature00766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the BRAF gene in human cancer</span></div><div class="casAuthors">Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian; Hall, Sarah; Hawes, Rachel; Hughes, Jaime; Kosmidou, Vivian; Menzies, Andrew; Mould, Catherine; Parker, Adrian; Stevens, Claire; Watt, Stephen; Hooper, Steven; Wilson, Rebecca; Jayatilake, Hiran; Gusterson, Barry A.; Cooper, Colin; Shipley, Janet; Hargrave, Darren; Pritchard-Jones, Katherine; Maitland, Norman; Chenevix-Trench, Georgia; Riggins, Gregory J.; Bigner, Darell D.; Palmieri, Giuseppe; Cossu, Antonio; Flanagan, Adrienne; Nicholson, Andrew; Ho, Judy W. C.; Leung, Suet Y.; Yuen, Siu T.; Weber, Barbara L.; Seigler, Hilliard F.; Darrow, Timothy L.; Paterson, Hugh; Marais, Richard; Marshall, Christopher J.; Wooster, Richard; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6892</span>),
    <span class="NLM_cas:pages">949-954</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancers arise owing to the accumulation of mutations in crit. genes that alter normal programs of cell proliferation, differentiation and death.  As the first stage of a systematic genome-wide screen for these genes, we have prioritized for anal. signalling pathways in which at least one gene is mutated in human cancer.  The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular responses to growth signals.  RAS is mutated to an oncogenic form in about 15% of human cancer.  The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS.  Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers.  All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%.  Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.  Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.  As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBmhJC0GAjrVg90H21EOLACvtfcHk0lgA2rWPxbbnog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D&md5=4625be53ad9a382d51b6ee753d0c17e8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnature00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature00766%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DClegg%26aufirst%3DS.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWoffendin%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DBottomley%26aufirst%3DW.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DDicks%26aufirst%3DE.%26aulast%3DEwing%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DHawes%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DKosmidou%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DA.%26aulast%3DMould%26aufirst%3DC.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DJayatilake%26aufirst%3DH.%26aulast%3DGusterson%26aufirst%3DB.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DPritchard-Jones%26aufirst%3DK.%26aulast%3DMaitland%26aufirst%3DN.%26aulast%3DChenevix-Trench%26aufirst%3DG.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DJ.%2BW.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSeigler%26aufirst%3DH.%2BF.%26aulast%3DDarrow%26aufirst%3DT.%2BL.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520of%2520the%2520BRAF%2520gene%2520in%2520human%2520cancer%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D949%26epage%3D954%26doi%3D10.1038%2Fnature00766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lavoie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, M.</span></span> <span> </span><span class="NLM_article-title">Regulation of RAF protein kinases in ERK signalling</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">281</span>â <span class="NLM_lpage">298</span>, <span class="refDoi">Â DOI: 10.1038/nrm3979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1038%2Fnrm3979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=25907612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFCitbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=281-298&author=H.+Lavoieauthor=M.+Therrien&title=Regulation+of+RAF+protein+kinases+in+ERK+signalling&doi=10.1038%2Fnrm3979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of RAF protein kinases in ERK signalling</span></div><div class="casAuthors">Lavoie, Hugo; Therrien, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">281-298</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">RAF family kinases were among the first oncoproteins to be described more than 30 years ago.  They primarily act as signalling relays downstream of RAS, and their close ties to cancer have fuelled a large no. of studies.  However, we still lack a systems-level understanding of their regulation and mode of action.  The recent discovery that the catalytic activity of RAF depends on an allosteric mechanism driven by kinase domain dimerization is providing a vital new piece of information towards a comprehensive model of RAF function.  The fact that current RAF inhibitors unexpectedly induce ERK signalling by stimulating RAF dimerization also calls for a deeper structural characterization of this family of kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwzK227mPD3rVg90H21EOLACvtfcHk0ligdECu8CVK7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFCitbk%253D&md5=1f4c4fbbacb1e3d790b81dbb027520b9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrm3979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3979%26sid%3Dliteratum%253Aachs%26aulast%3DLavoie%26aufirst%3DH.%26aulast%3DTherrien%26aufirst%3DM.%26atitle%3DRegulation%2520of%2520RAF%2520protein%2520kinases%2520in%2520ERK%2520signalling%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2015%26volume%3D16%26spage%3D281%26epage%3D298%26doi%3D10.1038%2Fnrm3979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAndrea, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grippo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathanson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span> <span> </span><span class="NLM_article-title">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>467</i></span>,  <span class="NLM_fpage">596</span>â <span class="NLM_lpage">599</span>, <span class="refDoi">Â DOI: 10.1038/nature09454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1038%2Fnature09454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=20823850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=596-599&author=G.+Bollagauthor=P.+Hirthauthor=J.+Tsaiauthor=J.+Zhangauthor=P.+N.+Ibrahimauthor=H.+Choauthor=W.+Spevakauthor=C.+Zhangauthor=Y.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=G.+Tsangauthor=B.+L.+Westauthor=B.+Powellauthor=R.+Shellooeauthor=A.+Marimuthuauthor=H.+Nguyenauthor=K.+Y.+Zhangauthor=D.+R.+Artisauthor=J.+Schlessingerauthor=F.+Suauthor=B.+Higginsauthor=R.+Iyerauthor=K.+D%E2%80%99Andreaauthor=A.+Koehlerauthor=M.+Stummauthor=P.+S.+Linauthor=R.+J.+Leeauthor=J.+Grippoauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+B.+Chapmanauthor=K.+T.+Flahertyauthor=X.+Xuauthor=K.+L.+Nathansonauthor=K.+Nolop&title=Clinical+efficacy+of+a+RAF+inhibitor+needs+broad+target+blockade+in+BRAF-mutant+melanoma&doi=10.1038%2Fnature09454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span></div><div class="casAuthors">Bollag, Gideon; Hirth, Peter; Tsai, James; Zhang, Jiazhong; Ibrahim, Prabha N.; Cho, Hanna; Spevak, Wayne; Zhang, Chao; Zhang, Ying; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Tsang, Garson; West, Brian L.; Powell, Ben; Shellooe, Rafe; Marimuthu, Adhirai; Nguyen, Hoa; Zhang, Kam Y. J.; Artis, Dean R.; Schlessinger, Joseph; Su, Fei; Higgins, Brian; Iyer, Raman; D'Andrea, Kurt; Koehler, Astrid; Stumm, Michael; Lin, Paul S.; Lee, Richard J.; Grippo, Joseph; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; Chapman, Paul B.; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.; Nolop, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">596-599</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B-RAF is the most frequently mutated protein kinase in human cancers.  The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway, offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients.  Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity.  Preclin. expts. demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts.  Toxicol. studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clin. trials using a cryst. formulation of PLX4032 (ref. 5).  In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following 2 wk of treatment.  This anal. revealed substantial inhibition of ERK phosphorylation, yet clin. evaluation did not show tumor regressions.  At higher drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK phosphorylation in the tumors of patients correlated with clin. response.  Indeed, the Phase 1 clin. data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily.  These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYwlns1EfcLVg90H21EOLACvtfcHk0lgg7ZJzjWDk1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK&md5=8a26d0ab41970f39a109ddafff2f17b4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnature09454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09454%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DKoehler%26aufirst%3DA.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DNolop%26aufirst%3DK.%26atitle%3DClinical%2520efficacy%2520of%2520a%2520RAF%2520inhibitor%2520needs%2520broad%2520target%2520blockade%2520in%2520BRAF-mutant%2520melanoma%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D596%26epage%3D599%26doi%3D10.1038%2Fnature09454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouary, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutzmer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaempgen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Algarra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaszewska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haney, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirakhur, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guckert, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span> <span> </span><span class="NLM_article-title">Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">358</span>â <span class="NLM_lpage">365</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(12)60868-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2FS0140-6736%2812%2960868-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=22735384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt1SgtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2012&pages=358-365&author=A.+Hauschildauthor=J.+J.+Grobauthor=L.+V.+Demidovauthor=T.+Jouaryauthor=R.+Gutzmerauthor=M.+Millwardauthor=P.+Rutkowskiauthor=C.+U.+Blankauthor=W.+H.+Millerauthor=E.+Kaempgenauthor=S.+Martin-Algarraauthor=B.+Karaszewskaauthor=C.+Mauchauthor=V.+Chiarion-Sileniauthor=A.+M.+Martinauthor=S.+Swannauthor=P.+Haneyauthor=B.+Mirakhurauthor=M.+E.+Guckertauthor=V.+Goodmanauthor=P.+B.+Chapman&title=Dabrafenib+in+BRAF-mutated+metastatic+melanoma%3A+a+multicentre%2C+open-label%2C+phase+3+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2812%2960868-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</span></div><div class="casAuthors">Hauschild, Axel; Grob, Jean-Jacques; Demidov, Lev V.; Jouary, Thomas; Gutzmer, Ralf; Millward, Michael; Rutkowski, Piotr; Blank, Christian U.; Miller, Wilson H.; Kaempgen, Eckhart; Martin-Algarra, Salvador; Karaszewska, Boguslawa; Mauch, Cornelia; Chiarion-Sileni, Vanna; Martin, Anne-Marie; Swann, Suzanne; Haney, Patricia; Mirakhur, Beloo; Guckert, Mary E.; Goodman, Vicki; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">9839</span>),
    <span class="NLM_cas:pages">358-365</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dabrafenib, an inhibitor of mutated BRAF, has clin. activity with a manageable safety profile in studies of phase 1 and 2 in patients with BRAFV600-mutated metastatic melanoma.  We studied the efficacy of dabrafenib in patients with BRAFV600E-mutated metastatic melanoma.We enrolled patients in this open-label phase 3 trial between Dec 23, 2010, and Sept 1, 2011.  This report is based on a data cutoff date of Dec 19, 2011.  Patients aged 18 years or older with previously untreated, stage IV or unresectable stage III BRAFV600E mutation-pos. melanoma were randomly assigned (3:1) to receive dabrafenib (150 mg twice daily, orally) or dacarbazine (1000 mg/m2 i.v. every 3 wk).  Patients were stratified according to American Joint Committee on Cancer stage (unresectable III+IVM1a+IVM1b vs IVM1c).  The primary endpoint was investigator-assessed progression-free survival and was analyzed by intention to treat; safety was assessed per protocol.  This study is registered with ClinicalTrials.gov, no. NCT01227889.Of the 733 patients screened, 250 were randomly assigned to receive either dabrafenib (187 patients) or dacarbazine (63 patients).  Median progression-free survival was 5Â·1 mo for dabrafenib and 2Â·7 mo for dacarbazine, with a hazard ratio (HR) of 0Â·30 (95% CI 0Â·18-0Â·51; p<0Â·0001).  At data cutoff, 107 (57%) patients in the dabrafenib group and 14 (22%) in the dacarbazine group remained on randomized treatment.  Treatment-related adverse events (grade 2 or higher) occurred in 100 (53%) of the 187 patients who received dabrafenib and in 26 (44%) of the 59 patients who received dacarbazine.  The most common adverse events with dabrafenib were skin-related toxic effects, fever, fatigue, arthralgia, and headache.  The most common adverse events with dacarbazine were nausea, vomiting, neutropenia, fatigue, and asthenia.  Grade 3-4 adverse events were uncommon in both groups.Dabrafenib significantly improved progression-free survival compared with dacarbazine.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEDYPJULE5c7Vg90H21EOLACvtfcHk0liPXb-fC_H7YA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt1SgtLg%253D&md5=5e8699780f47bd37e075d39636e0d809</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2960868-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252960868-X%26sid%3Dliteratum%253Aachs%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DDemidov%26aufirst%3DL.%2BV.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DGutzmer%26aufirst%3DR.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DBlank%26aufirst%3DC.%2BU.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DKaempgen%26aufirst%3DE.%26aulast%3DMartin-Algarra%26aufirst%3DS.%26aulast%3DKaraszewska%26aufirst%3DB.%26aulast%3DMauch%26aufirst%3DC.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DSwann%26aufirst%3DS.%26aulast%3DHaney%26aufirst%3DP.%26aulast%3DMirakhur%26aufirst%3DB.%26aulast%3DGuckert%26aufirst%3DM.%2BE.%26aulast%3DGoodman%26aufirst%3DV.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DDabrafenib%2520in%2520BRAF-mutated%2520metastatic%2520melanoma%253A%2520a%2520multicentre%252C%2520open-label%252C%2520phase%25203%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D380%26spage%3D358%26epage%3D365%26doi%3D10.1016%2FS0140-6736%2812%2960868-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koelblinger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuerigen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span> <span> </span><span class="NLM_article-title">Development of encorafenib for BRAF-mutated advanced melanoma</span>. <i>Curr. Opin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">125</span>â <span class="NLM_lpage">133</span>, <span class="refDoi">Â DOI: 10.1097/CCO.0000000000000426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1097%2FCCO.0000000000000426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=29356698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ymtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2018&pages=125-133&author=P.+Koelblingerauthor=O.+Thuerigenauthor=R.+Dummer&title=Development+of+encorafenib+for+BRAF-mutated+advanced+melanoma&doi=10.1097%2FCCO.0000000000000426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Development of encorafenib for BRAF-mutated advanced melanoma</span></div><div class="casAuthors">Koelblinger, Peter; Thuerigen, Olaf; Dummer, Reinhard</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-133</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: To describe the pharmacol. properties, preclin. and clin. data of the novel V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF)-inhibitor encorafenib (LGX818) and to compare these with established BRAF-inhibitors in the treatment of locally advanced or metastatic melanoma.  Recent findings: Encorafenib has shown improved efficacy in the treatment of metastatic melanoma in comparison with vemurafenib.  Combination with the MEK inhibitor (MEKi) binimetinib allows for higher dose intensities of encorafenib further improving response rates (RRs).  Summary: Combination therapy with BRAF and MEKi has evolved as a std. of care in the treatment of locally advanced or metastatic BRAF-mutated melanoma.  Despite compelling initial RRs, development of treatment resistance eventually leads to tumor progression in the majority of BRAF/MEK-inhibitor treated patients.  Moreover, treatment-related adverse events are frequent, resulting in a substantial proportion of dose modifications and/or treatment discontinuations.  The second-generation BRAF inhibitor encorafenib has been developed aiming at improved efficacy and tolerability through modifications in pharmacol. properties.  Clin. phase 3 data show improved progression-free survival both for encorafenib monotherapy and combination therapy with binimetinib compared with vemurafenib.  Overall survival data and regulatory approval of this novel substance are eagerly awaited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomkirq-JaxiLVg90H21EOLACvtfcHk0liPXb-fC_H7YA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ymtLg%253D&md5=1c1a53766823737b3039bbd96bb8910f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1097%2FCCO.0000000000000426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0000000000000426%26sid%3Dliteratum%253Aachs%26aulast%3DKoelblinger%26aufirst%3DP.%26aulast%3DThuerigen%26aufirst%3DO.%26aulast%3DDummer%26aufirst%3DR.%26atitle%3DDevelopment%2520of%2520encorafenib%2520for%2520BRAF-mutated%2520advanced%2520melanoma%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2018%26volume%3D30%26spage%3D125%26epage%3D133%26doi%3D10.1097%2FCCO.0000000000000426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span>,  <span class="NLM_fpage">427</span>â <span class="NLM_lpage">430</span>, <span class="refDoi">Â DOI: 10.1038/nature08902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1038%2Fnature08902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=20179705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFWjsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=427-430&author=P.+I.+Poulikakosauthor=C.+Zhangauthor=G.+Bollagauthor=K.+M.+Shokatauthor=N.+Rosen&title=RAF+inhibitors+transactivate+RAF+dimers+and+ERK+signalling+in+cells+with+wild-type+BRAF&doi=10.1038%2Fnature08902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</span></div><div class="casAuthors">Poulikakos, Poulikos I.; Zhang, Chao; Bollag, Gideon; Shokat, Kevan M.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">427-430</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tumors with mutant BRAF are dependent on the RAF-MEK-ERK signaling pathway for their growth.  We found that ATP-competitive RAF inhibitors inhibit ERK signaling in cells with mutant BRAF, but unexpectedly enhance signaling in cells with wild-type BRAF.  Here we demonstrate the mechanistic basis for these findings.  We used chem. genetic methods to show that drug-mediated transactivation of RAF dimers is responsible for paradoxical activation of the enzyme by inhibitors.  Induction of ERK signaling requires direct binding of the drug to the ATP-binding site of one kinase of the dimer and is dependent on RAS activity.  Drug binding to one member of RAF homodimers (CRAF-CRAF) or heterodimers (CRAF-BRAF) inhibits one protomer, but results in transactivation of the drug-free protomer.  In BRAF(V600E) tumors, RAS is not activated, thus transactivation is minimal and ERK signaling is inhibited in cells exposed to RAF inhibitors.  These results indicate that RAF inhibitors will be effective in tumors in which BRAF is mutated.  Furthermore, because RAF inhibitors do not inhibit ERK signaling in other cells, the model predicts that they would have a higher therapeutic index and greater antitumor activity than mitogen-activated protein kinase (MEK) inhibitors, but could also cause toxicity due to MEK/ERK activation.  These predictions have been borne out in a recent clin. trial of the RAF inhibitor PLX4032 (refs 4, 5).  The model indicates that promotion of RAF dimerization by elevation of wild-type RAF expression or RAS activity could lead to drug resistance in mutant BRAF tumors.  In agreement with this prediction, RAF inhibitors do not inhibit ERK signaling in cells that coexpress BRAF(V600E) and mutant RAS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMlm9feupyNrVg90H21EOLACvtfcHk0lh96ib6AD2yfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFWjsrs%253D&md5=8323a558886ccbb8f7d85b22b9bfbc15</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature08902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08902%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DRAF%2520inhibitors%2520transactivate%2520RAF%2520dimers%2520and%2520ERK%2520signalling%2520in%2520cells%2520with%2520wild-type%2520BRAF%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D427%26epage%3D430%26doi%3D10.1038%2Fnature08902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fedorenko, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paraiso, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S.</span></span> <span> </span><span class="NLM_article-title">Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">201</span>â <span class="NLM_lpage">209</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2011.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2Fj.bcp.2011.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=21635872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVegsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2011&pages=201-209&author=I.+V.+Fedorenkoauthor=K.+H.+Paraisoauthor=K.+S.+Smalley&title=Acquired+and+intrinsic+BRAF+inhibitor+resistance+in+BRAF+V600E+mutant+melanoma&doi=10.1016%2Fj.bcp.2011.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma</span></div><div class="casAuthors">Fedorenko, Inna V.; Paraiso, Kim H. T.; Smalley, Keiran S. M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">201-209</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The discovery of activating BRAF V600E mutations in 50% of all cutaneous melanomas has revolutionized the understanding of melanoma biol. and provided new strategies for the therapeutic management of this deadly disease.  Highly potent small mol. inhibitors of BRAF are now showing great promise as a novel therapeutic strategy for melanomas harboring activating BRAF V600E mutations and are assocd. with high levels of response.  This commentary article discusses the latest data on the role of mutated BRAF in the development and progression of melanoma as the basis for understanding the mechanism of action of BRAF inhibitors in the preclin. and clin. settings.  We further address the issue of BRAF inhibitor resistance and outline the latest insights into the mechanisms of therapeutic escape as well as describing approaches to prevent and abrogate the onset of both intrinsic and acquired drug resistance.  It is likely that our evolving understanding of melanoma genetics and signaling will allow for the further personalization of melanoma therapy with the goal of improving clin. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqup86oCotLPrVg90H21EOLACvtfcHk0lh96ib6AD2yfg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVegsro%253D&md5=2afe517b5af24ff622263777057b4ef1</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2011.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2011.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DFedorenko%26aufirst%3DI.%2BV.%26aulast%3DParaiso%26aufirst%3DK.%2BH.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%26atitle%3DAcquired%2520and%2520intrinsic%2520BRAF%2520inhibitor%2520resistance%2520in%2520BRAF%2520V600E%2520mutant%2520melanoma%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2011%26volume%3D82%26spage%3D201%26epage%3D209%26doi%3D10.1016%2Fj.bcp.2011.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milagre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trunzer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spleiss, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koya, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilton, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhomen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preece, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kockx, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lestini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joe, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">207</span>â <span class="NLM_lpage">215</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1105358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1056%2FNEJMoa1105358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=22256804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yltr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=207-215&author=F.+Suauthor=A.+Virosauthor=C.+Milagreauthor=K.+Trunzerauthor=G.+Bollagauthor=O.+Spleissauthor=J.+S.+Reis-Filhoauthor=X.+Kongauthor=R.+C.+Koyaauthor=K.+T.+Flahertyauthor=P.+B.+Chapmanauthor=M.+J.+Kimauthor=R.+Haywardauthor=M.+Martinauthor=H.+Yangauthor=Q.+Wangauthor=H.+Hiltonauthor=J.+S.+Hangauthor=J.+Noeauthor=M.+Lambrosauthor=F.+Geyerauthor=N.+Dhomenauthor=I.+Niculescu-Duvazauthor=A.+Zambonauthor=D.+Niculescu-Duvazauthor=N.+Preeceauthor=L.+Robertauthor=N.+J.+Otteauthor=S.+Mokauthor=D.+Keeauthor=Y.+Maauthor=C.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=H.+Nguyenauthor=M.+Kockxauthor=L.+Andriesauthor=B.+Lestiniauthor=K.+B.+Nolopauthor=R.+J.+Leeauthor=A.+K.+Joeauthor=J.+L.+Troyauthor=R.+Gonzalezauthor=T.+E.+Hutsonauthor=I.+Puzanovauthor=B.+Chmielowskiauthor=C.+J.+Springerauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=R.+S.+Loauthor=A.+Ribasauthor=R.+Marais&title=RAS+mutations+in+cutaneous+squamous-cell+carcinomas+in+patients+treated+with+BRAF+inhibitors&doi=10.1056%2FNEJMoa1105358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors</span></div><div class="casAuthors">Su, Fei; Viros, Amaya; Milagre, Carla; Trunzer, Kerstin; Bollag, Gideon; Spleiss, Olivia; Reis-Filho, Jorge S.; Kong, Xiangju; Koya, Richard C.; Flaherty, Keith T.; Chapman, Paul B.; Kim, Min Jung; Hayward, Robert; Martin, Matthew; Yang, Hong; Wang, Qiongqing; Hilton, Holly; Hang, Julie S.; Noe, Johannes; Lambros, Maryou; Geyer, Felipe; Dhomen, Nathalie; Niculescu-Duvaz, Ion; Zambon, Alfonso; Niculescu-Duvaz, Dan; Preece, Natasha; Robert, Lidia; Otte, Nicholas J.; Mok, Stephen; Kee, Damien; Ma, Yan; Zhang, Chao; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Nguyen, Hoa; Kockx, Mark; Andries, Luc; Lestini, Brian; Nolop, Keith B.; Lee, Richard J.; Joe, Andrew K.; Troy, James L.; Gonzalez, Rene; Hutson, Thomas E.; Puzanov, Igor; Chmielowski, Bartosz; Springer, Caroline J.; McArthur, Grant A.; Sosman, Jeffrey A.; Lo, Roger S.; Ribas, Antoni; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">207-215</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Cutaneous squamous-cell carcinomas and keratoacanthomas are common findings in patients treated with BRAF inhibitors.  METHODS: We performed a mol. anal. to identify oncogenic mutations (HRAS, KRAS, NRAS, CDKN2A, and TP53) in the lesions from patients treated with the BRAF inhibitor vemurafenib.  An anal. of an independent validation set and functional studies with BRAF inhibitors in the presence of the prevalent RAS mutation was also performed.  RESULTS: Among 21 tumor samples, 13 had RAS mutations (12 in HRAS).  In a validation set of 14 samples, 8 had RAS mutations (4 in HRAS).  Thus, 60% (21 of 35) of the specimens harbored RAS mutations, the most prevalent being HRAS Q61L.  Increased proliferation of HRAS Q61L-mutant cell lines exposed to vemurafenib was assocd. with mitogen-activated protein kinase (MAPK)-pathway signaling and activation of ERK-mediated transcription.  In a mouse model of HRAS Q61L-mediated skin carcinogenesis, the vemurafenib analog PLX4720 was not an initiator or a.promoter of carcinogenesis but accelerated growth of the lesions harboring HRAS mutations, and this growth was blocked by concomitant treatment with a MEK inhibitor.  CONCLUSIONS: Mutations in RAS, particularly HRAS, are frequent in cutaneous squamous-cell carcinomas and keratoacanthomas that develop in patients treated with vemurafenib.  The mol. mechanism is consistent with the paradoxical activation of MAPK signaling and leads to accelerated growth of these lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplrkvSEAdDG7Vg90H21EOLACvtfcHk0lgmkTgtQERt7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yltr8%253D&md5=6c813dc23344a8eedcc7a289d2326f4f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1105358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1105358%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DF.%26aulast%3DViros%26aufirst%3DA.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DTrunzer%26aufirst%3DK.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DSpleiss%26aufirst%3DO.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DHayward%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHilton%26aufirst%3DH.%26aulast%3DHang%26aufirst%3DJ.%2BS.%26aulast%3DNoe%26aufirst%3DJ.%26aulast%3DLambros%26aufirst%3DM.%26aulast%3DGeyer%26aufirst%3DF.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DNiculescu-Duvaz%26aufirst%3DI.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DPreece%26aufirst%3DN.%26aulast%3DRobert%26aufirst%3DL.%26aulast%3DOtte%26aufirst%3DN.%2BJ.%26aulast%3DMok%26aufirst%3DS.%26aulast%3DKee%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DKockx%26aufirst%3DM.%26aulast%3DAndries%26aufirst%3DL.%26aulast%3DLestini%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%2BB.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DJoe%26aufirst%3DA.%2BK.%26aulast%3DTroy%26aufirst%3DJ.%2BL.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DRAS%2520mutations%2520in%2520cutaneous%2520squamous-cell%2520carcinomas%2520in%2520patients%2520treated%2520with%2520BRAF%2520inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D207%26epage%3D215%26doi%3D10.1056%2FNEJMoa1105358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouary, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDay, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkwood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggermont, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Group, B.-S.</span></span> <span> </span><span class="NLM_article-title">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">2507</span>â <span class="NLM_lpage">2516</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1103782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-2516&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthurauthor=B.-S.+Group&title=Improved+survival+with+vemurafenib+in+melanoma+with+BRAF+V600E+mutation&doi=10.1056%2FNEJMoa1103782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0lgmkTgtQERt7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DGroup%26aufirst%3DB.-S.%26atitle%3DImproved%2520survival%2520with%2520vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2507%26epage%3D2516%26doi%3D10.1056%2FNEJMoa1103782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroyakovskiy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levchenko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Braud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouary, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondarenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utikal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraresi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovalenko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Probachai, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMarini, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irani, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K.</span></span> <span> </span><span class="NLM_article-title">Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">1877</span>â <span class="NLM_lpage">1888</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1406037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1056%2FNEJMoa1406037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=25265492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslGnuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=1877-1888&author=G.+V.+Longauthor=D.+Stroyakovskiyauthor=H.+Gogasauthor=E.+Levchenkoauthor=F.+de+Braudauthor=J.+Larkinauthor=C.+Garbeauthor=T.+Jouaryauthor=A.+Hauschildauthor=J.+J.+Grobauthor=V.+Chiarion+Sileniauthor=C.+Lebbeauthor=M.+Mandalaauthor=M.+Millwardauthor=A.+Aranceauthor=I.+Bondarenkoauthor=J.+B.+Haanenauthor=J.+Hanssonauthor=J.+Utikalauthor=V.+Ferraresiauthor=N.+Kovalenkoauthor=P.+Mohrauthor=V.+Probachaiauthor=D.+Schadendorfauthor=P.+Nathanauthor=C.+Robertauthor=A.+Ribasauthor=D.+J.+DeMariniauthor=J.+G.+Iraniauthor=M.+Caseyauthor=D.+Ouelletauthor=A.+M.+Martinauthor=N.+Leauthor=K.+Patelauthor=K.+Flaherty&title=Combined+BRAF+and+MEK+inhibition+versus+BRAF+inhibition+alone+in+melanoma&doi=10.1056%2FNEJMoa1406037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma</span></div><div class="casAuthors">Long, G. V.; Stroyakovskiy, D.; Gogas, H.; Levchenko, E.; de Braud, F.; Larkin, J.; Garbe, C.; Jouary, T.; Hauschild, A.; Grob, J. J.; Sileni, V. Chiarion; Lebbe, C.; Mandala, M.; Millward, M.; Arance, A.; Bondarenko, I.; Haanen, J. B. A. G.; Hansson, J.; Utikal, J.; Ferraresi, V.; Kovalenko, N.; Mohr, P.; Probachai, V.; Schadendorf, D.; Nathan, P.; Robert, C.; Ribas, A.; De Marini, D. J.; Irani, J. G.; Casey, M.; Ouellet, D.; Martin, A.-M.; Le, N.; Patel, K.; Flaherty, K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1877-1888, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone, delays the emergence of resistance and reduces toxic effects in patients who have melanoma with BRAF V600E or V600K mutations.  Methods: In this phase 3 trial, we randomly assigned 423 previously untreated patients who had unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K mutation to receive a combination of dabrafenib (150 mg orally twice daily) and trametinib (2 mg orally once daily) or dabrafenib and placebo.  The primary end point was progression-free survival.  Secondary end points included overall survival, response rate, response duration, and safety.  A preplanned interim overall survival anal. was conducted. Results: The median progression-free survival was 9.3 mo in the dabrafenib-trametinib group and 8.8 mo in the dabrafenib-only group (hazard ratio for progression or death in the dabrafenib-trametinib group, 0.75; 95% confidence interval [CI], 0.57 to 0.99; P = 0.03).  The overall response rate was 67% in the dabrafenib-trametinib group and 51% in the dabrafenib-only group (P = 0.002).  At 6 mo, the interim overall survival rate was 93% with dabrafenib-trametinib and 85% with dabrafenib alone (hazard ratio for death, 0.63; 95% CI, 0.42 to 0.94; P = 0.02).  However, a specified efficacy-stopping boundary (two-sided P = 0.00028) was not crossed.  Rates of adverse events were similar in the two groups, although more dose modifications occurred in the dabrafenib-trametinib group.  The rate of cutaneous squamous-cell carcinoma was lower in the dabrafenib-trametinib group than in the dabrafenib-only group (2% vs. 9%), whereas pyrexia occurred in more patients (51% vs. 28%) and was more often severe (grade 3, 6% vs. 2%) in the dabrafenib-trametinib group. Conclusions: A combination of dabrafenib and trametinib, as compared with dabrafenib alone, improved the rate of progression-free survival in previously untreated patients who had metastatic melanoma with BRAF V600E or V600K mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV_cVsKKBhY7Vg90H21EOLACvtfcHk0lgfhgQrZbei1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslGnuw%253D%253D&md5=65dbfbb0d9d16017ac58729326835724</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1406037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1406037%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DStroyakovskiy%26aufirst%3DD.%26aulast%3DGogas%26aufirst%3DH.%26aulast%3DLevchenko%26aufirst%3DE.%26aulast%3Dde%2BBraud%26aufirst%3DF.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DChiarion%2BSileni%26aufirst%3DV.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DMandala%26aufirst%3DM.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DHansson%26aufirst%3DJ.%26aulast%3DUtikal%26aufirst%3DJ.%26aulast%3DFerraresi%26aufirst%3DV.%26aulast%3DKovalenko%26aufirst%3DN.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DProbachai%26aufirst%3DV.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DDeMarini%26aufirst%3DD.%2BJ.%26aulast%3DIrani%26aufirst%3DJ.%2BG.%26aulast%3DCasey%26aufirst%3DM.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DLe%26aufirst%3DN.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DFlaherty%26aufirst%3DK.%26atitle%3DCombined%2520BRAF%2520and%2520MEK%2520inhibition%2520versus%2520BRAF%2520inhibition%2520alone%2520in%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D1877%26epage%3D1888%26doi%3D10.1056%2FNEJMoa1406037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Induced protein degradation: an emerging drug discovery paradigm</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">101</span>â <span class="NLM_lpage">114</span>, <span class="refDoi">Â DOI: 10.1038/nrd.2016.211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1038%2Fnrd.2016.211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=27885283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=101-114&author=A.+C.+Laiauthor=C.+M.+Crews&title=Induced+protein+degradation%3A+an+emerging+drug+discovery+paradigm&doi=10.1038%2Fnrd.2016.211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation: an emerging drug discovery paradigm</span></div><div class="casAuthors">Lai, Ashton C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-114</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function, and this approach typically precludes targeting proteins that lack such amenable sites.  Furthermore, high systemic drug exposures may be needed to maintain sufficient target inhibition in vivo, increasing the risk of undesirable off-target effects.  Induced protein degrdn. is an alternative approach that is event-driven: upon drug binding, the target protein is tagged for elimination.  Emerging technologies based on proteolysis-targeting chimaeras (PROTACs) that exploit cellular quality control machinery to selectively degrade target proteins are attracting considerable attention in the pharmaceutical industry owing to the advantages they could offer over traditional small-mol. strategies.  These advantages include the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj-O7zXGOpXLVg90H21EOLACvtfcHk0lhSXFlPlb4jqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP&md5=a01ff43e9b696fe4dc03f0815158a98f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.211%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DInduced%2520protein%2520degradation%253A%2520an%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D101%26epage%3D114%26doi%3D10.1038%2Fnrd.2016.211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Development of dual and selective degraders of cyclin-dependent kinases 4 and 6</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6321</span>â <span class="NLM_lpage">6326</span>, <span class="refDoi">Â DOI: 10.1002/anie.201901336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1002%2Fanie.201901336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlKqsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=6321-6326&author=B.+Jiangauthor=E.+S.+Wangauthor=K.+A.+Donovanauthor=Y.+Liangauthor=E.+S.+Fischerauthor=T.+Zhangauthor=N.+S.+Gray&title=Development+of+dual+and+selective+degraders+of+cyclin-dependent+kinases+4+and+6&doi=10.1002%2Fanie.201901336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6</span></div><div class="casAuthors">Jiang, Baishan; Wang, Eric S.; Donovan, Katherine A.; Liang, Yanke; Fischer, Eric S.; Zhang, Tinghu; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6321-6326</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases 4 and 6 (CDK4/6) are key regulators of the cell cycle, and there are FDA-approved CDK4/6 inhibitors for treating patients with metastatic breast cancer.  However, due to conservation of their ATP-binding sites, development of selective agents has remained elusive.  Here, we report imide-based degrader mols. capable of degrading both CDK4/6, or selectively degrading either CDK4 or CDK6.  We were also able to tune the activity of these mols. against Ikaros (IKZF1) and Aiolos (IKZF3), which are well-established targets of imide-based degraders.  We found that in mantle cell lymphoma cell lines, combined IKZF1/3 degrdn. with dual CDK4/6 degrdn. produced enhanced anti-proliferative effects compared to CDK4/6 inhibition, CDK4/6 degrdn., or IKZF1/3 degrdn.  In summary, we report here the first compds. capable of inducing selective degrdn. of CDK4 and CDK6 as tools to pharmacol. dissect their distinct biol. functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_Vsqs-SM6hrVg90H21EOLACvtfcHk0lhSXFlPlb4jqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlKqsrw%253D&md5=39a6937b24abad0940d359020e2b2f74</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fanie.201901336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201901336%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DE.%2BS.%26aulast%3DDonovan%26aufirst%3DK.%2BA.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520dual%2520and%2520selective%2520degraders%2520of%2520cyclin-dependent%2520kinases%25204%2520and%25206%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2019%26volume%3D58%26spage%3D6321%26epage%3D6326%26doi%3D10.1002%2Fanie.201901336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellerschmied, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salami, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Modular PROTAC design for the degradation of oncogenic BCR-ABL</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">807</span>â <span class="NLM_lpage">810</span>, <span class="refDoi">Â DOI: 10.1002/anie.201507634</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1002%2Fanie.201507634" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOlt7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=807-810&author=A.+C.+Laiauthor=M.+Toureauthor=D.+Hellerschmiedauthor=J.+Salamiauthor=S.+Jaime-Figueroaauthor=E.+Koauthor=J.+Hinesauthor=C.+M.+Crews&title=Modular+PROTAC+design+for+the+degradation+of+oncogenic+BCR-ABL&doi=10.1002%2Fanie.201507634"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL</span></div><div class="casAuthors">Lai, Ashton C.; Toure, Momar; Hellerschmied, Doris; Salami, Jemilat; Jaime-Figueroa, Saul; Ko, Eunhwa; Hines, John; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">807-810</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Proteolysis Targeting Chimera (PROTAC) technol. is a rapidly emerging alternative therapeutic strategy with the potential to address many of the challenges currently faced in modern drug development programs.  PROTAC technol. employs small mols. that recruit target proteins for ubiquitination and removal by the proteasome.  The synthesis of PROTAC compds. that mediate the degrdn. of c-ABL and BCR-ABL by recruiting either Cereblon or Von Hippel Lindau E3 ligases is reported.  During the course of their development, the authors discovered that the capacity of a PROTAC to induce degrdn. involves more than just target binding: the identity of the inhibitor warhead and the recruited E3 ligase largely det. the degrdn. profiles of the compds.; thus, as a starting point for PROTAC development, both the target ligand and the recruited E3 ligase should be varied to rapidly generate a PROTAC with the desired degrdn. profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdcSTHt5WfILVg90H21EOLACvtfcHk0lgKsYVX1DvL1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOlt7rN&md5=58a5d78f32bc8a21fd1a6e0c38b8979c</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fanie.201507634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201507634%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DToure%26aufirst%3DM.%26aulast%3DHellerschmied%26aufirst%3DD.%26aulast%3DSalami%26aufirst%3DJ.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DModular%2520PROTAC%2520design%2520for%2520the%2520degradation%2520of%2520oncogenic%2520BCR-ABL%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D807%26epage%3D810%26doi%3D10.1002%2Fanie.201507634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">755</span>â <span class="NLM_lpage">763</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2015.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2Fj.chembiol.2015.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=26051217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWrtbrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=755-763&author=J.+Luauthor=Y.+Qianauthor=M.+Altieriauthor=H.+Dongauthor=J.+Wangauthor=K.+Rainaauthor=J.+Hinesauthor=J.+D.+Winklerauthor=A.+P.+Crewauthor=K.+Colemanauthor=C.+M.+Crews&title=Hijacking+the+E3+ubiquitin+ligase+cereblon+to+efficiently+target+BRD4&doi=10.1016%2Fj.chembiol.2015.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4</span></div><div class="casAuthors">Lu, Jing; Qian, Yimin; Altieri, Martha; Dong, Hanqing; Wang, Jing; Raina, Kanak; Hines, John; Winkler, James D.; Crew, Andrew P.; Coleman, Kevin; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">755-763</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">BRD4, a bromodomain and extraterminal domain (BET) family member, is an attractive target in multiple pathol. settings, particularly cancer.  While BRD4 inhibitors have shown some promise in MYC-driven malignancies such as Burkitt's lymphoma (BL), we show that BRD4 inhibitors lead to robust BRD4 protein accumulation, which may account for their limited suppression of MYC expression, modest antiproliferative activity, and lack of apoptotic induction.  To address these limitations we designed ARV-825, a hetero-bifunctional PROTAC (Proteolysis Targeting Chimera) that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degrdn. of BRD4 in all BL cell lines tested.  Consequently, ARV-825 more effectively suppresses c-MYC levels and downstream signaling than small-mol. BRD4 inhibitors, resulting in more effective cell proliferation inhibition and apoptosis induction in BL.  Our findings provide strong evidence that cereblon-based PROTACs provide a better and more efficient strategy in targeting BRD4 than traditional small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Ol4grCG2RbVg90H21EOLACvtfcHk0lgKsYVX1DvL1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWrtbrM&md5=a64675e7a0cd006a8737be9730f447e3</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2015.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2015.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DAltieri%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DRaina%26aufirst%3DK.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DColeman%26aufirst%3DK.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DHijacking%2520the%2520E3%2520ubiquitin%2520ligase%2520cereblon%2520to%2520efficiently%2520target%2520BRD4%26jtitle%3DChem.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D755%26epage%3D763%26doi%3D10.1016%2Fj.chembiol.2015.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przybranowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meagher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziazadeh, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of QCA570 as an exceptionally potent and efficacious proteolysis targeting chimera (PROTAC) degrader of the bromodomain and extra-Terminal (BET) proteins capable of inducing complete and durable tumor regression</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6685</span>â <span class="NLM_lpage">6704</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00506</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00506" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlaqsLrE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6685-6704&author=C.+Qinauthor=Y.+Huauthor=B.+Zhouauthor=E.+Fernandez-Salasauthor=C.+Y.+Yangauthor=L.+Liuauthor=D.+McEachernauthor=S.+Przybranowskiauthor=M.+Wangauthor=J.+Stuckeyauthor=J.+Meagherauthor=L.+Baiauthor=Z.+Chenauthor=M.+Linauthor=J.+Yangauthor=D.+N.+Ziazadehauthor=F.+Xuauthor=J.+Huauthor=W.+Xiangauthor=L.+Huangauthor=S.+Liauthor=B.+Wenauthor=D.+Sunauthor=S.+Wang&title=Discovery+of+QCA570+as+an+exceptionally+potent+and+efficacious+proteolysis+targeting+chimera+%28PROTAC%29+degrader+of+the+bromodomain+and+extra-Terminal+%28BET%29+proteins+capable+of+inducing+complete+and+durable+tumor+regression&doi=10.1021%2Facs.jmedchem.8b00506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression</span></div><div class="casAuthors">Qin, Chong; Hu, Yang; Zhou, Bing; Fernandez-Salas, Ester; Yang, Chao-Yie; Liu, Liu; McEachern, Donna; Przybranowski, Sally; Wang, Mi; Stuckey, Jeanne; Meagher, Jennifer; Bai, Longchuan; Chen, Zhuo; Lin, Mei; Yang, Jiuling; Ziazadeh, Danya N.; Xu, Fuming; Hu, Jiantao; Xing, Weiguo; Huang, Liyue; Li, Siwei; Wen, Bo; Sun, Duxin; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6685-6704</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Proteins of the bromodomain and extra-terminal (BET) family are epigenetics "readers" and promising therapeutic targets for cancer and other human diseases.  We describe herein a structure-guided design of [1,4]oxazepines as a new class of BET inhibitors and our subsequent design, synthesis, and evaluation of proteolysis-targeting chimeric (PROTAC) small-mol. BET degraders.  Our efforts have led to the discovery of extremely potent BET degraders, exemplified by QCA570, which effectively induces degrdn. of BET proteins and inhibits cell growth in human acute leukemia cell lines even at low picomolar concns.  QCA570 achieves complete and durable tumor regression in leukemia xenograft models in mice at well-tolerated dose-schedules.  QCA570 is the most potent and efficacious BET degrader reported to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6ZUIsfX3p6LVg90H21EOLACvtfcHk0lhAcr-Oywleng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlaqsLrE&md5=2a731730641372f4526543e03d9ac76f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00506%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DFernandez-Salas%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DPrzybranowski%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DMeagher%26aufirst%3DJ.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZiazadeh%26aufirst%3DD.%2BN.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DXiang%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520QCA570%2520as%2520an%2520exceptionally%2520potent%2520and%2520efficacious%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%2520degrader%2520of%2520the%2520bromodomain%2520and%2520extra-Terminal%2520%2528BET%2529%2520proteins%2520capable%2520of%2520inducing%2520complete%2520and%2520durable%2520tumor%2520regression%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6685%26epage%3D6704%26doi%3D10.1021%2Facs.jmedchem.8b00506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Remillard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brien, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonnett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dastjerdi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuhr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span> <span> </span><span class="NLM_article-title">Degradation of the BAF complex factor BRD9 by heterobifunctional ligands</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5738</span>â <span class="NLM_lpage">5743</span>, <span class="refDoi">Â DOI: 10.1002/anie.201611281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1002%2Fanie.201611281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtFGrurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=5738-5743&author=D.+Remillardauthor=D.+L.+Buckleyauthor=J.+Paulkauthor=G.+L.+Brienauthor=M.+Sonnettauthor=H.+S.+Seoauthor=S.+Dastjerdiauthor=M.+Wuhrauthor=S.+Dhe-Paganonauthor=S.+A.+Armstrongauthor=J.+E.+Bradner&title=Degradation+of+the+BAF+complex+factor+BRD9+by+heterobifunctional+ligands&doi=10.1002%2Fanie.201611281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands</span></div><div class="casAuthors">Remillard, David; Buckley, Dennis L.; Paulk, Joshiawa; Brien, Gerard L.; Sonnett, Matthew; Seo, Hyuk-Soo; Dastierdi, Shiva; Wuehr, Martin; Dhe-Paganon, Sirano; Armstrong, Scott A.; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5738-5743</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The bromodomain-contg. protein BRD9, a subunit of the human BAF (SWI/SNF) nucleosome remodeling complex, has emerged as an attractive therapeutic target in cancer.  Despite the development of chem. probes targeting the BRD9 bromodomain, there is a limited understanding of BRD9 function beyond acetyl-lysine recognition.  We have therefore created the first BRD9-directed chem. degraders, through iterative design and testing of heterobifunctional ligands that bridge the BRD9 bromodomain and the cereblon E3 ubiquitin ligase complex.  Degraders of BRD9 exhibit markedly enhanced potency compared to parental ligands (10- to 100-fold).  Parallel study of degraders with divergent BRD9-binding chemotypes in models of acute myeloid leukemia resolves bromodomain polypharmacol. in this emerging drug class.  Together, these findings reveal the tractability of non-BET bromodomain contg. proteins to chem. degrdn., and highlight lead compd. dBRD9 as a tool for the study of BRD9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ9FU2Ipaq27Vg90H21EOLACvtfcHk0lj78fNRti_l6g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtFGrurk%253D&md5=2eb6562cc9d976c7ae6070c9a419e9ea</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fanie.201611281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201611281%26sid%3Dliteratum%253Aachs%26aulast%3DRemillard%26aufirst%3DD.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DPaulk%26aufirst%3DJ.%26aulast%3DBrien%26aufirst%3DG.%2BL.%26aulast%3DSonnett%26aufirst%3DM.%26aulast%3DSeo%26aufirst%3DH.%2BS.%26aulast%3DDastjerdi%26aufirst%3DS.%26aulast%3DWuhr%26aufirst%3DM.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26aulast%3DArmstrong%26aufirst%3DS.%2BA.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DDegradation%2520of%2520the%2520BAF%2520complex%2520factor%2520BRD9%2520by%2520heterobifunctional%2520ligands%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D5738%26epage%3D5743%26doi%3D10.1002%2Fanie.201611281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Proteolysis targeting chimeras (PROTACs) of naplastic Lymphoma Kinase (ALK)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">304</span>â <span class="NLM_lpage">314</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2018.03.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2Fj.ejmech.2018.03.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=29627725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ejs7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=304-314&author=C.+Zhangauthor=X.+R.+Hanauthor=X.+Yangauthor=B.+Jiangauthor=J.+Liuauthor=Y.+Xiongauthor=J.+Jin&title=Proteolysis+targeting+chimeras+%28PROTACs%29+of+naplastic+Lymphoma+Kinase+%28ALK%29&doi=10.1016%2Fj.ejmech.2018.03.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Zhang, Chengwei; Han, Xiao-Ran; Yang, Xiaobao; Jiang, Biao; Liu, Jing; Xiong, Yue; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">304-314</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) activation has been assocd. with many types of human cancer.  Significant efforts have been devoted to the development of ALK inhibitors to antagonize the kinase activity of ALK.  Four ALK inhibitors have been approved by the FDA to date for treating patients with ALK-pos. nonsmall cell lung cancers (NSCLC).  However, drug resistance has been obsd. in the majority of patients treated with these inhibitors.  New therapeutic strategies (e.g., compds. with novel mechanisms of action) are needed to overcome the drug resistance issue.  The emerging PROTAC (Proteolysis Targeting Chimera) technol. has been successfully applied to selective degrdn. of multiple protein targets, but not ALK.  Since ALK protein levels are not important for viability in mammals, ALK PROTACs could lead to novel therapeutics with minimal toxicity.  Here the authors report the design, synthesis and biol. evaluation of novel PROTACs (degraders) of ALK.  MS4077 (I) and MS4078 (II) potently decreased cellular levels of oncogenic active ALK fusion proteins in a concn.- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells.  The ALK protein degrdn. induced by compds. I and II was cereblon and proteasome dependent.  In addn., compds. I and II potently inhibited proliferation of SU-DHL-1 cells.  Furthermore, compd. II displayed good plasma exposure in a mouse pharmacokinetic study, thus is suitable for in vivo efficacy studies.  The authors also developed MS4748 and MS4740 , very close analogs of I and II resp., which are incapable to degrade the ALK fusion proteins, as neg. controls.  All 4 compds. are valuable chem. tools for investigating effects of ALK pharmacol. degrdn.  The study paved the way for developing the next generation of ALK PROTACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPGM3aAZZ6h7Vg90H21EOLACvtfcHk0lj78fNRti_l6g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ejs7Y%253D&md5=804324b95034f38b46e45f89e18e55be</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.071%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DX.%2BR.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DProteolysis%2520targeting%2520chimeras%2520%2528PROTACs%2529%2520of%2520naplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D304%26epage%3D314%26doi%3D10.1016%2Fj.ejmech.2018.03.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, K.</span></span> <span> </span><span class="NLM_article-title">PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer</span>. <i>Chem. Commun. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2704</span>â <span class="NLM_lpage">2707</span>, <span class="refDoi">Â DOI: 10.1039/C9CC00163H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1039%2FC9CC00163H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=30758029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtFGht7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2019&pages=2704-2707&author=B.+Zhaoauthor=K.+Burgess&title=PROTACs+suppression+of+CDK4%2F6%2C+crucial+kinases+for+cell+cycle+regulation+in+cancer&doi=10.1039%2FC9CC00163H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer</span></div><div class="casAuthors">Zhao, Bosheng; Burgess, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2704-2707</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">PROTACs based on two selective, FDA approved, CDK4/6 inhibitors were formed.  One of them, based on palbociclib, potently initiates degrdn. of these CDK proteins, and suppresses phosphorylation of retinoblastoma protein (Rb) leading to cell cycle arrest.  These PROTACs are active at nanomolar concns., and appear to be the first for CDK4/6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBWDRf65Fl6bVg90H21EOLACvtfcHk0ljuUWOPUntg3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtFGht7c%253D&md5=8798e9aa7ecc0e6504c2717e815b04fc</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1039%2FC9CC00163H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9CC00163H%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DBurgess%26aufirst%3DK.%26atitle%3DPROTACs%2520suppression%2520of%2520CDK4%252F6%252C%2520crucial%2520kinases%2520for%2520cell%2520cycle%2520regulation%2520in%2520cancer%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2019%26volume%3D55%26spage%3D2704%26epage%3D2707%26doi%3D10.1039%2FC9CC00163H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zoppi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maniaci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmaschitz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieshofer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koegl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riching, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spallarossa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span> <span> </span><span class="NLM_article-title">Iterative design and optimization of initially inactive proteolysis targeting chimeras (PROTACs) identify VZ185 as a potent, fast, and selective von Hippel-Lindau (VHL) based dual degrader probe of BRD9 and BRD7</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">699</span>â <span class="NLM_lpage">726</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b01413</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01413" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVyhsLjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=699-726&author=V.+Zoppiauthor=S.+J.+Hughesauthor=C.+Maniaciauthor=A.+Testaauthor=T.+Gmaschitzauthor=C.+Wieshoferauthor=M.+Koeglauthor=K.+M.+Richingauthor=D.+L.+Danielsauthor=A.+Spallarossaauthor=A.+Ciulli&title=Iterative+design+and+optimization+of+initially+inactive+proteolysis+targeting+chimeras+%28PROTACs%29+identify+VZ185+as+a+potent%2C+fast%2C+and+selective+von+Hippel-Lindau+%28VHL%29+based+dual+degrader+probe+of+BRD9+and+BRD7&doi=10.1021%2Facs.jmedchem.8b01413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7</span></div><div class="casAuthors">Zoppi, Vittoria; Hughes, Scott J.; Maniaci, Chiara; Testa, Andrea; Gmaschitz, Teresa; Wieshofer, Corinna; Koegl, Manfred; Riching, Kristin M.; Daniels, Danette L.; Spallarossa, Andrea; Ciulli, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">699-726</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Developing PROTACs to redirect the ubiquitination activity of E3 ligases and potently degrade a target protein within cells can be a lengthy and unpredictable process, and it remains unclear whether any combination of E3 and target might be productive for degrdn.  The authors describe a probe-quality degrader for a ligase-target pair deemed unsuitable: the von Hippel-Lindau (VHL) and BRD9, a bromodomain-contg. subunit of the SWI/SNF chromatin remodeling complex BAF.  VHL-based degraders could be optimized from suboptimal compds. in two rounds by systematically varying conjugation patterns and linkers and monitoring cellular degrdn. activities, kinetic profiles, and ubiquitination, as well as ternary complex formation thermodn.  The emerged structure-activity relations guided the discovery of VZ185, a potent, fast, and selective degrader of BRD9 and of its close homolog BRD7.  The authors' findings qualify a new chem. tool for BRD7/9 knockdown and provide a roadmap for PROTAC development against seemingly incompatible target-ligase combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiPnajotKvqLVg90H21EOLACvtfcHk0ljuUWOPUntg3w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVyhsLjN&md5=be7938c26807a2535b7f9b7de8ebfbb0</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01413%26sid%3Dliteratum%253Aachs%26aulast%3DZoppi%26aufirst%3DV.%26aulast%3DHughes%26aufirst%3DS.%2BJ.%26aulast%3DManiaci%26aufirst%3DC.%26aulast%3DTesta%26aufirst%3DA.%26aulast%3DGmaschitz%26aufirst%3DT.%26aulast%3DWieshofer%26aufirst%3DC.%26aulast%3DKoegl%26aufirst%3DM.%26aulast%3DRiching%26aufirst%3DK.%2BM.%26aulast%3DDaniels%26aufirst%3DD.%2BL.%26aulast%3DSpallarossa%26aufirst%3DA.%26aulast%3DCiulli%26aufirst%3DA.%26atitle%3DIterative%2520design%2520and%2520optimization%2520of%2520initially%2520inactive%2520proteolysis%2520targeting%2520chimeras%2520%2528PROTACs%2529%2520identify%2520VZ185%2520as%2520a%2520potent%252C%2520fast%252C%2520and%2520selective%2520von%2520Hippel-Lindau%2520%2528VHL%2529%2520based%2520dual%2520degrader%2520probe%2520of%2520BRD9%2520and%2520BRD7%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D699%26epage%3D726%26doi%3D10.1021%2Facs.jmedchem.8b01413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agianian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span> <span> </span><span class="NLM_article-title">Current insights of BRAF inhibitors in cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5775</span>â <span class="NLM_lpage">5793</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01306</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01306" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFChu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5775-5793&author=B.+Agianianauthor=E.+Gavathiotis&title=Current+insights+of+BRAF+inhibitors+in+cancer&doi=10.1021%2Facs.jmedchem.7b01306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Current Insights of BRAF Inhibitors in Cancer</span></div><div class="casAuthors">Agianian, Bogos; Gavathiotis, Evripidis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5775-5793</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oncogenic BRAF kinase deregulates the ERK signaling pathway in a large no. of human tumors.  FDA-approved BRAF inhibitors for BRAFV600E/K tumors have provided impressive clin. responses extending survival of melanoma patients.  However, these drugs display paradoxical activation in normal tissue with BRAFWT due to RAF transactivation and priming, acquired drug resistance, and limited clin. effectiveness in non-V600 BRAF-dependent tumors, underscoring the urgent need to develop improved BRAF inhibitors.  This review provides an overview of recent structural and biochem. insights into the mechanisms of BRAF regulation by BRAF inhibitors that are linked to their clin. activity, clin. liabilities, and medicinal chem. properties.  The effectiveness and challenges of structurally diverse next generation RAF inhibitors currently in preclin. and clin. development are discussed, along with mechanistic insights for developing more effective RAF inhibitors targeting different oncogenic BRAF conformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFSsceLmTALVg90H21EOLACvtfcHk0lj0R0tViSD80A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFChu70%253D&md5=7dcd6ce731bb591ecfac244b3b2b9b32</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01306%26sid%3Dliteratum%253Aachs%26aulast%3DAgianian%26aufirst%3DB.%26aulast%3DGavathiotis%26aufirst%3DE.%26atitle%3DCurrent%2520insights%2520of%2520BRAF%2520inhibitors%2520in%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5775%26epage%3D5793%26doi%3D10.1021%2Facs.jmedchem.7b01306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAndrea, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grippo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathanson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span> <span> </span><span class="NLM_article-title">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>467</i></span>,  <span class="NLM_fpage">596</span>â <span class="NLM_lpage">599</span>, <span class="refDoi">Â DOI: 10.1038/nature09454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1038%2Fnature09454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=20823850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=596-599&author=G+H.+P.+Bollagauthor=P.+Hirthauthor=J.+Tsaiauthor=J.+Zhangauthor=P.+N.+Ibrahimauthor=H.+Choauthor=W.+Spevakauthor=C.+Zhangauthor=Y.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=G.+Tsangauthor=B.+L.+Westauthor=B.+Powellauthor=R.+Shellooeauthor=A.+Marimuthuauthor=H.+Nguyenauthor=K.+Y.+Zhangauthor=D.+R.+Artisauthor=J.+Schlessingerauthor=F.+Suauthor=B.+Higginsauthor=R.+Iyerauthor=K.+D%E2%80%99Andreaauthor=A.+Koehlerauthor=M.+Stummauthor=P.+S.+Linauthor=R.+J.+Leeauthor=J.+Grippoauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+B.+Chapmanauthor=K.+T.+Flahertyauthor=X.+Xuauthor=K.+L.+Nathansonauthor=K.+Nolop&title=Clinical+efficacy+of+a+RAF+inhibitor+needs+broad+target+blockade+in+BRAF-mutant+melanoma&doi=10.1038%2Fnature09454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span></div><div class="casAuthors">Bollag, Gideon; Hirth, Peter; Tsai, James; Zhang, Jiazhong; Ibrahim, Prabha N.; Cho, Hanna; Spevak, Wayne; Zhang, Chao; Zhang, Ying; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Tsang, Garson; West, Brian L.; Powell, Ben; Shellooe, Rafe; Marimuthu, Adhirai; Nguyen, Hoa; Zhang, Kam Y. J.; Artis, Dean R.; Schlessinger, Joseph; Su, Fei; Higgins, Brian; Iyer, Raman; D'Andrea, Kurt; Koehler, Astrid; Stumm, Michael; Lin, Paul S.; Lee, Richard J.; Grippo, Joseph; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; Chapman, Paul B.; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.; Nolop, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">596-599</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B-RAF is the most frequently mutated protein kinase in human cancers.  The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway, offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients.  Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity.  Preclin. expts. demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts.  Toxicol. studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clin. trials using a cryst. formulation of PLX4032 (ref. 5).  In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following 2 wk of treatment.  This anal. revealed substantial inhibition of ERK phosphorylation, yet clin. evaluation did not show tumor regressions.  At higher drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK phosphorylation in the tumors of patients correlated with clin. response.  Indeed, the Phase 1 clin. data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily.  These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYwlns1EfcLVg90H21EOLACvtfcHk0lj0R0tViSD80A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK&md5=8a26d0ab41970f39a109ddafff2f17b4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnature09454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09454%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG%2BH.%2BP.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DKoehler%26aufirst%3DA.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DNolop%26aufirst%3DK.%26atitle%3DClinical%2520efficacy%2520of%2520a%2520RAF%2520inhibitor%2520needs%2520broad%2520target%2520blockade%2520in%2520BRAF-mutant%2520melanoma%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D596%26epage%3D599%26doi%3D10.1038%2Fnature09454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waizenegger, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steurer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmuller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaaf, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garin-Chesa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlattl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweifer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haslinger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colbatzky, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalkuhl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraut, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adolf, G. R.</span></span> <span> </span><span class="NLM_article-title">A Novel RAF kinase inhibitor with DFG-out-binding mode: high efficacy in BRAF-mutant tumor xenograft models in the absence of normal tissue hyperproliferation</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">354</span>â <span class="NLM_lpage">365</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-15-0617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1158%2F1535-7163.MCT-15-0617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=26916115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslCms7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=354-365&author=I.+C.+Waizeneggerauthor=A.+Baumauthor=S.+Steurerauthor=H.+Stadtmullerauthor=G.+Baderauthor=O.+Schaafauthor=P.+Garin-Chesaauthor=A.+Schlattlauthor=N.+Schweiferauthor=C.+Haslingerauthor=F.+Colbatzkyauthor=S.+Mousaauthor=A.+Kalkuhlauthor=N.+Krautauthor=G.+R.+Adolf&title=A+Novel+RAF+kinase+inhibitor+with+DFG-out-binding+mode%3A+high+efficacy+in+BRAF-mutant+tumor+xenograft+models+in+the+absence+of+normal+tissue+hyperproliferation&doi=10.1158%2F1535-7163.MCT-15-0617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation</span></div><div class="casAuthors">Waizenegger, Irene C.; Baum, Anke; Steurer, Steffen; Stadtmuller, Heinz; Bader, Gerd; Schaaf, Otmar; Garin-Chesa, Pilar; Schlattl, Andreas; Schweifer, Norbert; Haslinger, Christian; Colbatzky, Florian; Mousa, Sien; Kalkuhl, Arno; Kraut, Norbert; Adolf, Gunther R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">354-365</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">BI 882370 is a highly potent and selective RAF inhibitor that binds to the DFG-out (inactive) conformation of the BRAF kinase.  The compd. inhibited proliferation of human BRAF-mutant melanoma cells with 100Ã higher potency (1-10 nmol/L) than vemurafenib, whereas wild-type cells were not affected at 1,000 nmol/L.  BI 882370 administered orally was efficacious in multiple mouse models of BRAF-mutant melanomas and colorectal carcinomas, and at 25 mg/kg twice daily showed superior efficacy compared with vemurafenib, dabrafenib, or trametinib (dosed to provide exposures reached in patients).  To model drug resistance, A375 melanoma-bearing mice were initially treated with vemurafenib; all tumors responded with regression, but the majority subsequently resumed growth.  Trametinib did not show any efficacy in this progressing population.  BI 882370 induced tumor regression; however, resistance developed within 3 wk.  BI 882370 in combination with trametinib resulted in more pronounced regressions, and resistance was not obsd. during 5 wk of second-line therapy.  Importantly, mice treated with BI 882370 did not show any body wt. loss or clin. signs of intolerability, and no pathol. changes were obsd. in several major organs investigated, including skin.  Furthermore, a pilot study in rats (up to 60 mg/kg daily for 2 wk) indicated lack of toxicity in terms of clin. chem., hematol., pathol., and toxicogenomics.  Our results indicate the feasibility of developing novel compds. that provide an improved therapeutic window compared with first-generation BRAF inhibitors, resulting in more pronounced and long-lasting pathway suppression and thus improved efficacy.  Mol Cancer Ther; 15(3); 354-65. Â©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmtRl_zbyDibVg90H21EOLACvtfcHk0lhP7_roIbekcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslCms7Y%253D&md5=e35140e31364622de51538b99618001a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0617%26sid%3Dliteratum%253Aachs%26aulast%3DWaizenegger%26aufirst%3DI.%2BC.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DSteurer%26aufirst%3DS.%26aulast%3DStadtmuller%26aufirst%3DH.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DSchaaf%26aufirst%3DO.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DSchlattl%26aufirst%3DA.%26aulast%3DSchweifer%26aufirst%3DN.%26aulast%3DHaslinger%26aufirst%3DC.%26aulast%3DColbatzky%26aufirst%3DF.%26aulast%3DMousa%26aufirst%3DS.%26aulast%3DKalkuhl%26aufirst%3DA.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26atitle%3DA%2520Novel%2520RAF%2520kinase%2520inhibitor%2520with%2520DFG-out-binding%2520mode%253A%2520high%2520efficacy%2520in%2520BRAF-mutant%2520tumor%2520xenograft%2520models%2520in%2520the%2520absence%2520of%2520normal%2520tissue%2520hyperproliferation%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D354%26epage%3D365%26doi%3D10.1158%2F1535-7163.MCT-15-0617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grasso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ventocilla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samanta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maksimoska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmorstein, R.</span></span> <span> </span><span class="NLM_article-title">Chemically linked vemurafenib inhibitors promote an inactive BRAF<sup>V600E</sup> Conformation</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2876</span>â <span class="NLM_lpage">2888</span>, <span class="refDoi">Â DOI: 10.1021/acschembio.6b00529</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00529" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWltrrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2876-2888&author=M.+Grassoauthor=M.+A.+Estradaauthor=C.+Ventocillaauthor=M.+Samantaauthor=J.+Maksimoskaauthor=J.+Villanuevaauthor=J.+D.+Winklerauthor=R.+Marmorstein&title=Chemically+linked+vemurafenib+inhibitors+promote+an+inactive+BRAFV600E+Conformation&doi=10.1021%2Facschembio.6b00529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation</span></div><div class="casAuthors">Grasso, Michael; Estrada, Michelle A.; Ventocilla, Christian; Samanta, Minu; Maksimoska, Jasna; Villanueva, Jessie; Winkler, Jeffrey D.; Marmorstein, Ronen</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2876-2888</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The BRAF kinase, within the mitogen activated protein kinase (MAPK) signaling pathway, harbors activating mutations in about half of melanomas and to a significant extent in many other cancers.  A single valine to glutamic acid substitution at residue 600 (BRAFV600E) accounts for about 90% of these activating mutations.  While BRAFV600E-selective small mol. inhibitors, such as debrafenib and vemurafenib, have shown therapeutic benefit, almost all patients develop resistance.  Resistance often arises through reactivation of the MAPK pathway, typically through mutation of upstream RAS, downstream MEK or splicing variants.  RAF kinases signal as homo- and hetero-dimers, and another complication assocd. with small mol. BRAFV600E inhibition is drug-induced allosteric activation of a wild-type RAF subunit (BRAF or CRAF) of the kinase dimer, a process called 'transactivation' or 'paradoxical activation.'.  Here the authors used BRAFV600E and vemurafenib as a model system to develop chem. linked kinase inhibitors to lock RAF dimers in an inactive conformation that cannot undergo transactivation.  This structure-based design effort resulted in the development of Vem-BisAmide-2, a compd. contg. two vemurafenib mols. connected by a bis amide linker.  The authors show that Vem-BisAmide-2 has comparable inhibitory potency as vemurafenib to BRAFV600E both in vitro and in cells, but promotes an inactive dimeric BRAFV600E conformation unable to undergo transactivation.  The crystal structure of a BRAFV600E/Vem-BisAmide-2 complex and assocd. biochem. studies reveal the mol. basis for how Vem-BisAmide-2 mediates selectivity for an inactive over active dimeric BRAFV600E conformation.  These studies have implications for targeting BRAFV600E/RAF heterodimers and other kinase dimers for therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZNAGDkAWOH7Vg90H21EOLACvtfcHk0lhP7_roIbekcA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWltrrI&md5=6cecaff8b365aa21bce67243a1654241</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00529%26sid%3Dliteratum%253Aachs%26aulast%3DGrasso%26aufirst%3DM.%26aulast%3DEstrada%26aufirst%3DM.%2BA.%26aulast%3DVentocilla%26aufirst%3DC.%26aulast%3DSamanta%26aufirst%3DM.%26aulast%3DMaksimoska%26aufirst%3DJ.%26aulast%3DVillanueva%26aufirst%3DJ.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DMarmorstein%26aufirst%3DR.%26atitle%3DChemically%2520linked%2520vemurafenib%2520inhibitors%2520promote%2520an%2520inactive%2520BRAFV600E%2520Conformation%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D2876%26epage%3D2888%26doi%3D10.1021%2Facschembio.6b00529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haass, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sproesser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settachatgul, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantwell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">3041</span>â <span class="NLM_lpage">3046</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0711741105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1073%2Fpnas.0711741105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=18287029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=3041-3046&author=J.+Tsaiauthor=J.+T.+Leeauthor=W.+Wangauthor=J.+Zhangauthor=H.+Choauthor=S.+Mamoauthor=R.+Bremerauthor=S.+Gilletteauthor=J.+Kongauthor=N.+K.+Haassauthor=K.+Sproesserauthor=L.+Liauthor=K.+S.+Smalleyauthor=D.+Fongauthor=Y.+L.+Zhuauthor=A.+Marimuthuauthor=H.+Nguyenauthor=B.+Lamauthor=J.+Liuauthor=I.+Cheungauthor=J.+Riceauthor=Y.+Suzukiauthor=C.+Luuauthor=C.+Settachatgulauthor=R.+Shellooeauthor=J.+Cantwellauthor=S.+H.+Kimauthor=J.+Schlessingerauthor=K.+Y.+Zhangauthor=B.+L.+Westauthor=B.+Powellauthor=G.+Habetsauthor=C.+Zhangauthor=P.+N.+Ibrahimauthor=P.+Hirthauthor=D.+R.+Artisauthor=M.+Herlynauthor=G.+Bollag&title=Discovery+of+a+selective+inhibitor+of+oncogenic+B-Raf+kinase+with+potent+antimelanoma+activity&doi=10.1073%2Fpnas.0711741105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span></div><div class="casAuthors">Tsai, James; Lee, John T.; Wang, Weiru; Zhang, Jiazhong; Cho, Hanna; Mamo, Shumeye; Bremer, Ryan; Gillette, Sam; Kong, Jun; Haass, Nikolas K.; Sproesser, Katrin; Li, Ling; Smalley, Keiran S. M.; Fong, Daniel; Zhu, Yong-Liang; Marimuthu, Adhirai; Nguyen, Hoa; Lam, Billy; Liu, Jennifer; Cheung, Ivana; Rice, Julie; Suzuki, Yoshihisa; Luu, Catherine; Settachatgul, Calvin; Shellooe, Rafe; Cantwell, John; Kim, Sung-Hou; Schlessinger, Joseph; Zhang, Kam Y. J.; West, Brian L.; Powell, Ben; Habets, Gaston; Zhang, Chao; Ibrahim, Prabha N.; Hirth, Peter; Artis, Dean R.; Herlyn, Meenhard; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3041-3046</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">BRAFV600E is the most frequent oncogenic protein kinase mutation known.  Furthermore, inhibitors targeting "active" protein kinases have demonstrated significant utility in the therapeutic repertoire against cancer.  Therefore, the authors pursued the development of specific kinase inhibitors targeting B-Raf, and the V600E allele in particular.  By using a structure-guided discovery approach, a potent and selective inhibitor of active B-Raf has been discovered.  PLX4720, a 7-azaindole deriv. that inhibits B-RafV600E with an IC50 of 13 nM, defines a class of kinase inhibitor with marked selectivity in both biochem. and cellular assays.  PLX4720 preferentially inhibits the active B-RafV600E kinase compared with a broad spectrum of other kinases, and potent cytotoxic effects are also exclusive to cells bearing the V600E allele.  Consistent with the high degree of selectivity, ERK phosphorylation is potently inhibited by PLX4720 in B-RafV600E-bearing tumor cell lines but not in cells lacking oncogenic B-Raf.  In melanoma models, PLX4720 induces cell cycle arrest and apoptosis exclusively in B-RafV600E-pos. cells.  In B-RafV600E-dependent tumor xenograft models, orally dosed PLX4720 causes significant tumor growth delays, including tumor regressions, without evidence of toxicity.  The work described here represents the entire discovery process, from initial identification through structural and biol. studies in animal models to a promising therapeutic for testing in cancer patients bearing B-RafV600E-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPX53IQCbDJ7Vg90H21EOLACvtfcHk0lgsymE2bC9NiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D&md5=273b94202f99984e6eb24723d0c6141f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0711741105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0711741105%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DMamo%26aufirst%3DS.%26aulast%3DBremer%26aufirst%3DR.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DHaass%26aufirst%3DN.%2BK.%26aulast%3DSproesser%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DY.%2BL.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCheung%26aufirst%3DI.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DSettachatgul%26aufirst%3DC.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DCantwell%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520selective%2520inhibitor%2520of%2520oncogenic%2520B-Raf%2520kinase%2520with%2520potent%2520antimelanoma%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D3041%26epage%3D3046%26doi%3D10.1073%2Fpnas.0711741105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karoulia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">New perspectives for targeting RAF kinase in human cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">676</span>â <span class="NLM_lpage">691</span>, <span class="refDoi">Â DOI: 10.1038/nrc.2017.79</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1038%2Fnrc.2017.79" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=28984291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Sqt7fN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=676-691&author=Z.+Karouliaauthor=E.+Gavathiotisauthor=P.+I.+Poulikakos&title=New+perspectives+for+targeting+RAF+kinase+in+human+cancer&doi=10.1038%2Fnrc.2017.79"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">New perspectives for targeting RAF kinase in human cancer</span></div><div class="casAuthors">Karoulia, Zoi; Gavathiotis, Evripidis; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">676-691</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The discovery that a subset of human tumors is dependent on mutationally deregulated BRAF kinase intensified the development of RAF inhibitors to be used as potential therapeutics.  The US Food and Drug Administration (FDA)-approved second-generation RAF inhibitors vemurafenib and dabrafenib have elicited remarkable responses and improved survival of patients with BRAF-V600E/K melanoma, but their effectiveness is limited by resistance.  Beyond melanoma, current clin. RAF inhibitors show modest efficacy when used for colorectal and thyroid BRAF-V600E tumors or for tumors harboring BRAF alterations other than the V600 mutation.  Accumulated exptl. and clin. evidence indicates that the complex biochem. mechanisms of RAF kinase signalling account both for the effectiveness of RAF inhibitors and for the various mechanisms of tumor resistance to them.  Recently, a no. of next-generation RAF inhibitors, with diverse structural and biochem. properties, have entered preclin. and clin. development.  In this Review, we discuss the current understanding of RAF kinase regulation, mechanisms of inhibitor action and related clin. resistance to these drugs.  The recent elucidation of crit. structural and biochem. aspects of RAF inhibitor action, combined with the availability of a no. of structurally diverse RAF inhibitors currently in preclin. and clin. development, will enable the design of more effective RAF inhibitors and RAF-inhibitor-based therapeutic strategies, tailored to different clin. contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEUrKAljS7SrVg90H21EOLACvtfcHk0lgsymE2bC9NiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Sqt7fN&md5=7e8ee4222467a2d5c12b23ccce99fc62</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2017.79&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2017.79%26sid%3Dliteratum%253Aachs%26aulast%3DKaroulia%26aufirst%3DZ.%26aulast%3DGavathiotis%26aufirst%3DE.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DNew%2520perspectives%2520for%2520targeting%2520RAF%2520kinase%2520in%2520human%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D676%26epage%3D691%26doi%3D10.1038%2Fnrc.2017.79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dankner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, A. A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajkumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, I. R.</span></span> <span> </span><span class="NLM_article-title">Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">3183</span>â <span class="NLM_lpage">3199</span>, <span class="refDoi">Â DOI: 10.1038/s41388-018-0171-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1038%2Fs41388-018-0171-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=29540830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlt1Wit74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=3183-3199&author=M.+Danknerauthor=A.+A.+N.+Roseauthor=S.+Rajkumarauthor=P.+M.+Siegelauthor=I.+R.+Watson&title=Classifying+BRAF+alterations+in+cancer%3A+new+rational+therapeutic+strategies+for+actionable+mutations&doi=10.1038%2Fs41388-018-0171-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations</span></div><div class="casAuthors">Dankner, Matthew; Rose, April A. N.; Rajkumar, Shivshankari; Siegel, Peter M.; Watson, Ian R.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3183-3199</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The RAS-RAF-MEK-ERK signaling cascade is among the most frequently mutated pathways in human cancer.  Approx. 50% of melanoma patients possess a druggable hotspot V600E/K mutation in the BRAF protein kinase.  FDA-approved combination therapies of BRAF and MEK inhibitors are available that provide survival benefits to patients with a BRAF V600 mutation.  Non-V600 BRAF mutants are found in many cancers, and are more prevalent than V600 mutations in certain tumor types.  For example, between 50-80% of BRAF mutations in non-small cell lung cancer and 22-30% in colorectal cancer encode for non-V600 mutants.  As next generation sequencing becomes increasingly used in clin. practice, oncologists are frequently identifying non-V600 BRAF mutations in their patient's tumors, but are uncertain of viable therapeutic options that could be employed for optimal treatment.  From recent studies, a new classification system is emerging for BRAF mutations based on biochem. and signaling mechanisms assocd. with these mutants.  Class I BRAF mutations affect amino acid V600 and signal as RAS-independent active monomers, class II mutations function as RAS-independent activated dimers, and class III mutations are kinase impaired but increase signaling through the MAPK pathway due to enhanced RAS binding and subsequent CRAF activation.  These distinct classes of BRAF mutations predict response to targeted therapies and have important implications for future drug development.  Herein, we discuss pre-clin. and clin. findings that may lead to improved treatments for all classes of BRAF mutant cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXl1dLNrtnkbVg90H21EOLACvtfcHk0liwq14KfnOrRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlt1Wit74%253D&md5=2519c19c80ce42b421e3c40269df24e3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0171-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0171-x%26sid%3Dliteratum%253Aachs%26aulast%3DDankner%26aufirst%3DM.%26aulast%3DRose%26aufirst%3DA.%2BA.%2BN.%26aulast%3DRajkumar%26aufirst%3DS.%26aulast%3DSiegel%26aufirst%3DP.%2BM.%26aulast%3DWatson%26aufirst%3DI.%2BR.%26atitle%3DClassifying%2520BRAF%2520alterations%2520in%2520cancer%253A%2520new%2520rational%2520therapeutic%2520strategies%2520for%2520actionable%2520mutations%26jtitle%3DOncogene%26date%3D2018%26volume%3D37%26spage%3D3183%26epage%3D3199%26doi%3D10.1038%2Fs41388-018-0171-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bondeson, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhimschi, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishchenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">78</span>â <span class="NLM_lpage">87</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2017.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2Fj.chembiol.2017.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=29129718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=78-87&author=D.+P.+Bondesonauthor=B.+E.+Smithauthor=G.+M.+Burslemauthor=A.+D.+Buhimschiauthor=J.+Hinesauthor=S.+Jaime-Figueroaauthor=J.+Wangauthor=B.+D.+Hammanauthor=A.+Ishchenkoauthor=C.+M.+Crews&title=Lessons+in+PROTAC+Design+from+Selective+Degradation+with+a+Promiscuous+Warhead&doi=10.1016%2Fj.chembiol.2017.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead</span></div><div class="casAuthors">Bondeson, Daniel P.; Smith, Blake E.; Burslem, George M.; Buhimschi, Alexandru D.; Hines, John; Jaime-Figueroa, Saul; Wang, Jing; Hamman, Brian D.; Ishchenko, Alexey; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-87.e5</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibiting protein function selectively is a major goal of modern drug discovery.  Here, we report a previously understudied benefit of small mol. proteolysis-targeting chimeras (PROTACs) that recruit E3 ubiquitin ligases to target proteins for their ubiquitination and subsequent proteasome-mediated degrdn.  Using promiscuous CRBN- and VHL-recruiting PROTACs that bind >50 kinases, we show that only a subset of bound targets is degraded.  The basis of this selectivity relies on protein-protein interactions between the E3 ubiquitin ligase and the target protein, as illustrated by engaged proteins that are not degraded as a result of unstable ternary complexes with PROTAC-recruited E3 ligases.  In contrast, weak PROTAC:target protein affinity can be stabilized by high-affinity target:PROTAC:ligase trimer interactions, leading to efficient degrdn.  This study highlights design guidelines for generating potent PROTACs as well as possibilities for degrading undruggable proteins immune to traditional small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoISOBudOLyFrVg90H21EOLACvtfcHk0liwq14KfnOrRQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjN&md5=30fac502705a2344c4261cf531e6bf9d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DBondeson%26aufirst%3DD.%2BP.%26aulast%3DSmith%26aufirst%3DB.%2BE.%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DBuhimschi%26aufirst%3DA.%2BD.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHamman%26aufirst%3DB.%2BD.%26aulast%3DIshchenko%26aufirst%3DA.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DLessons%2520in%2520PROTAC%2520Design%2520from%2520Selective%2520Degradation%2520with%2520a%2520Promiscuous%2520Warhead%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D78%26epage%3D87%26doi%3D10.1016%2Fj.chembiol.2017.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrovolsky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doctor, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">88</span>â <span class="NLM_lpage">99</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2017.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2Fj.chembiol.2017.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=29129717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=88-99&author=H.+T.+Huangauthor=D.+Dobrovolskyauthor=J.+Paulkauthor=G.+Yangauthor=E.+L.+Weisbergauthor=Z.+M.+Doctorauthor=D.+L.+Buckleyauthor=J.+H.+Choauthor=E.+Koauthor=J.+Jangauthor=K.+Shiauthor=H.+G.+Choiauthor=J.+D.+Griffinauthor=Y.+Liauthor=S.+P.+Treonauthor=E.+S.+Fischerauthor=J.+E.+Bradnerauthor=L.+Tanauthor=N.+S.+Gray&title=A+chemoproteomic+approach+to+query+the+degradable+kinome+using+a+multi-kinase+degrader&doi=10.1016%2Fj.chembiol.2017.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader</span></div><div class="casAuthors">Huang, Hai-Tsang; Dobrovolsky, Dennis; Paulk, Joshiawa; Yang, Guang; Weisberg, Ellen L.; Doctor, Zainab M.; Buckley, Dennis L.; Cho, Joong-Heui; Ko, Eunhwa; Jang, Jaebong; Shi, Kun; Choi, Hwan Geun; Griffin, James D.; Li, Ying; Treon, Steven P.; Fischer, Eric S.; Bradner, James E.; Tan, Li; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-99.e6</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Heterobifunctional mols. that recruit E3 ubiquitin ligases, such as cereblon, for targeted protein degrdn. represent an emerging pharmacol. strategy.  A major unanswered question is how generally applicable this strategy is to all protein targets.  In this study, we designed a multi-kinase degrader by conjugating a highly promiscuous kinase inhibitor with a cereblon-binding ligand, and used quant. proteomics to discover 28 kinases, including BTK, PTK2, PTK2B, FLT3, AURKA, AURKB, TEC, ULK1, ITK, and nine members of the CDK family, as degradable.  This set of kinases is only a fraction of the intracellular targets bound by the degrader, demonstrating that successful degrdn. requires more than target engagement.  The results guided us to develop selective degraders for FLT3 and BTK, with potentials to improve disease treatment.  Together, this study demonstrates an efficient approach to triage a gene family of interest to identify readily degradable targets for further studies and pre-clin. developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYNxhoPV3127Vg90H21EOLACvtfcHk0lgMKd1NaUPyug"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjO&md5=703cfbaca3edd24176472158563f895f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%2BT.%26aulast%3DDobrovolsky%26aufirst%3DD.%26aulast%3DPaulk%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DDoctor%26aufirst%3DZ.%2BM.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DCho%26aufirst%3DJ.%2BH.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520chemoproteomic%2520approach%2520to%2520query%2520the%2520degradable%2520kinome%2520using%2520a%2520multi-kinase%2520degrader%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D88%26epage%3D99%26doi%3D10.1016%2Fj.chembiol.2017.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">131</span>, <span class="refDoi">Â DOI: 10.1038/s41467-018-08027-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1038%2Fs41467-018-08027-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=30631068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A280%3ADC%252BB3cjgt1Sksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=131&author=B.+E.+Smithauthor=S.+L.+Wangauthor=S.+Jaime-Figueroaauthor=A.+Harbinauthor=J.+Wangauthor=B.+D.+Hammanauthor=C.+M.+Crews&title=Differential+PROTAC+substrate+specificity+dictated+by+orientation+of+recruited+E3+ligase&doi=10.1038%2Fs41467-018-08027-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase</span></div><div class="casAuthors">Smith Blake E; Wang Stephen L; Jaime-Figueroa Saul; Crews Craig M; Harbin Alicia; Wang Jing; Hamman Brian D; Crews Craig M; Crews Craig M</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">131</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PROteolysis-TArgeting Chimeras (PROTACs) are hetero-bifunctional molecules that recruit an E3 ubiquitin ligase to a given substrate protein resulting in its targeted degradation.  Many potent PROTACs with specificity for dissimilar targets have been developed; however, the factors governing degradation selectivity within closely-related protein families remain elusive.  Here, we generate isoform-selective PROTACs for the p38 MAPK family using a single warhead (foretinib) and recruited E3 ligase (von Hippel-Lindau).  Based on their distinct linker attachments and lengths, these two PROTACs differentially recruit VHL, resulting in degradation of p38Î± or p38Î´.  We characterize the role of ternary complex formation in driving selectivity, showing that it is necessary, but insufficient, for PROTAC-induced substrate ubiquitination.  Lastly, we explore the p38Î´:PROTAC:VHL complex to explain the different selectivity profiles of these PROTACs.  Our work attributes the selective degradation of two closely-related proteins using the same warhead and E3 ligase to heretofore underappreciated aspects of the ternary complex model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYPr3dBOGbeuR_TJajKxJDfW6udTcc2eYij_Ef3S6Zbrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjgt1Sksg%253D%253D&md5=bd56c51f5966709ca5d1ff3dadb7cc79</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-08027-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-08027-7%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BE.%26aulast%3DWang%26aufirst%3DS.%2BL.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DHarbin%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHamman%26aufirst%3DB.%2BD.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DDifferential%2520PROTAC%2520substrate%2520specificity%2520dictated%2520by%2520orientation%2520of%2520recruited%2520E3%2520ligase%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D131%26doi%3D10.1038%2Fs41467-018-08027-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G. E.</span></span> <span> </span><span class="NLM_article-title">Homolog-selective degradation as a strategy to probe the function of CDK6 in AML</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">300</span>â <span class="NLM_lpage">306</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2018.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2Fj.chembiol.2018.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=30595531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsVSj" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=300-306&author=M.+Brandauthor=B.+Jiangauthor=S.+Bauerauthor=K.+A.+Donovanauthor=Y.+Liangauthor=E.+S.+Wangauthor=R.+P.+Nowakauthor=J.+C.+Yuanauthor=T.+Zhangauthor=N.+Kwiatkowskiauthor=A.+C.+Mullerauthor=E.+S.+Fischerauthor=N.+S.+Grayauthor=G.+E.+Winter&title=Homolog-selective+degradation+as+a+strategy+to+probe+the+function+of+CDK6+in+AML&doi=10.1016%2Fj.chembiol.2018.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML</span></div><div class="casAuthors">Brand, Matthias; Jiang, Baishan; Bauer, Sophie; Donovan, Katherine A.; Liang, Yanke; Wang, Eric S.; Nowak, Radoslaw P.; Yuan, Jingting C.; Zhang, Tinghu; Kwiatkowski, Nicholas; Mueller, Andre C.; Fischer, Eric S.; Gray, Nathanael S.; Winter, Georg E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">300-306.e9</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The design of selective small mols. is often stymied by similar ligand binding pockets.  Here, we report BSJ-03-123, a phthalimide-based degrader that exploits protein-interface determinants to achieve proteome-wide selectivity for the degrdn. of cyclin-dependent kinase 6 (CDK6).  Pharmacol. CDK6 degrdn. targets a selective dependency of acute myeloid leukemia cells, and transcriptomics and phosphoproteomics profiling of acute degrdn. of CDK6 enabled dynamic mapping of its immediate role in coordinating signaling and transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGognoz8FFoR9LVg90H21EOLACvtfcHk0limps1o4Bo1og"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsVSj&md5=f8c1c3520c6c0218763d8769c59b4342</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2018.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2018.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DBrand%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DDonovan%26aufirst%3DK.%2BA.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DE.%2BS.%26aulast%3DNowak%26aufirst%3DR.%2BP.%26aulast%3DYuan%26aufirst%3DJ.%2BC.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DMuller%26aufirst%3DA.%2BC.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWinter%26aufirst%3DG.%2BE.%26atitle%3DHomolog-selective%2520degradation%2520as%2520a%2520strategy%2520to%2520probe%2520the%2520function%2520of%2520CDK6%2520in%2520AML%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26spage%3D300%26epage%3D306%26doi%3D10.1016%2Fj.chembiol.2018.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">963</span>â <span class="NLM_lpage">969</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2005.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2Fj.molcel.2005.10.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=16364920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVOiuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=963-969&author=M.+J.+Garnettauthor=S.+Ranaauthor=H.+Patersonauthor=D.+Barfordauthor=R.+Marais&title=Wild-type+and+mutant+B-RAF+activate+C-RAF+through+distinct+mechanisms+involving+heterodimerization&doi=10.1016%2Fj.molcel.2005.10.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization</span></div><div class="casAuthors">Garnett, Mathew J.; Rana, Sareena; Paterson, Hugh; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">963-969</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The protein kinase B-Raf is mutated in approx. 7% of human cancers.  Most mutations are activating, but, surprisingly, a small no. have reduced kinase activity.  However, the latter can still stimulate cellular signaling through the MEK-ERK pathway because they activate the related family member C-Raf.  We examd. the mechanism underlying C-Raf activation by B-Raf.  We show that C-Raf is activated in the cytosol in a Ras-independent manner that requires activation segment phosphorylation and binding of 14-3-3 to C-Raf.  We show that wild-type B-Raf forms a complex with C-Raf in a Ras-dependent manner, whereas the mutants bind independently of Ras.  Importantly, we show that wild-type B-Raf can also activate C-Raf.  Our data suggest that B-Raf activates C-Raf through a mechanism involving 14-3-3 mediated heterooligomerization and C-Raf transphosphorylation.  Thus, we have identified a B-Raf-C-Raf-MEK-ERK cascade that signals not only in cancer but also in normal cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcr3ut9vW0NrVg90H21EOLACvtfcHk0limps1o4Bo1og"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVOiuw%253D%253D&md5=5db9fcc0a36f7670fcd3e92b399ed0de</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DWild-type%2520and%2520mutant%2520B-RAF%2520activate%2520C-RAF%2520through%2520distinct%2520mechanisms%2520involving%2520heterodimerization%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D20%26spage%3D963%26epage%3D969%26doi%3D10.1016%2Fj.molcel.2005.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haling, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudhamsu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandoval, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phung, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masselot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span> <span> </span><span class="NLM_article-title">Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">402</span>â <span class="NLM_lpage">413</span>, <span class="refDoi">Â DOI: 10.1016/j.ccr.2014.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2Fj.ccr.2014.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=25155755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVKntrnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=402-413&author=J.+R.+Halingauthor=J.+Sudhamsuauthor=I.+Yenauthor=S.+Siderisauthor=W.+Sandovalauthor=W.+Phungauthor=B.+J.+Bravoauthor=A.+M.+Giannettiauthor=A.+Peckauthor=A.+Masselotauthor=T.+Moralesauthor=D.+Smithauthor=B.+J.+Brandhuberauthor=S.+G.+Hymowitzauthor=S.+Malek&title=Structure+of+the+BRAF-MEK+complex+reveals+a+kinase+activity+independent+role+for+BRAF+in+MAPK+signaling&doi=10.1016%2Fj.ccr.2014.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling</span></div><div class="casAuthors">Haling, Jacob R.; Sudhamsu, Jawahar; Yen, Ivana; Sideris, Steve; Sandoval, Wendy; Phung, Wilson; Bravo, Brandon J.; Giannetti, Anthony M.; Peck, Ariana; Masselot, Alexandre; Morales, Tony; Smith, Darin; Brandhuber, Barbara J.; Hymowitz, Sarah G.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">402-413</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Numerous oncogenic mutations occur within the BRAF kinase domain (BRAFKD).  Here we show that stable BRAF-MEK1 complexes are enriched in BRAFWT and KRAS mutant (MT) cells but not in BRAFMT cells.  The crystal structure of the BRAFKD in a complex with MEK1 reveals a face-to-face dimer sensitive to MEK1 phosphorylation but insensitive to BRAF dimerization.  Structure-guided studies reveal that oncogenic BRAF mutations function by bypassing the requirement for BRAF dimerization for activity or weakening the interaction with MEK1.  Finally, we show that conformation-specific BRAF inhibitors can sequester a dormant BRAF-MEK1 complex resulting in pathway inhibition.  Taken together, these findings reveal a regulatory role for BRAF in the MAPK pathway independent of its kinase activity but dependent on interaction with MEK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXE20AD1ZxrLVg90H21EOLACvtfcHk0lgZeeNerh8ZiA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVKntrnJ&md5=a4a931aa158afbac09b972fc2a0142b8</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2014.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2014.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DSudhamsu%26aufirst%3DJ.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DSandoval%26aufirst%3DW.%26aulast%3DPhung%26aufirst%3DW.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DPeck%26aufirst%3DA.%26aulast%3DMasselot%26aufirst%3DA.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DStructure%2520of%2520the%2520BRAF-MEK%2520complex%2520reveals%2520a%2520kinase%2520activity%2520independent%2520role%2520for%2520BRAF%2520in%2520MAPK%2520signaling%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D26%26spage%3D402%26epage%3D413%26doi%3D10.1016%2Fj.ccr.2014.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jura, N.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for the non-catalytic functions of protein kinases</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">7</span>â <span class="NLM_lpage">24</span>, <span class="refDoi">Â DOI: 10.1016/j.str.2015.10.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2Fj.str.2015.10.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=26745528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC28XjvFOqsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=7-24&author=J.+E.+Kungauthor=N.+Jura&title=Structural+Basis+for+the+non-catalytic+functions+of+protein+kinases&doi=10.1016%2Fj.str.2015.10.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the non-catalytic functions of protein kinases</span></div><div class="casAuthors">Kung, Jennifer E.; Jura, Natalia</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-24</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are known primarily for their ability to phosphorylate protein substrates, which constitutes an essential biol. process.  Recently, compelling evidence has accumulated that the functions of many protein kinases extend beyond phosphorylation, and include an impressive spectrum of non-catalytic roles, such as scaffolding, allosteric regulation, or even protein-DNA interactions.  How the conserved kinase fold shared by all metazoan protein kinases can accomplish these diverse tasks in a specific and regulated manner is poorly understood.  Here, the authors analyze the mol. mechanisms supporting phosphorylation-independent signaling by kinases and attempt to identify common and unique structural characteristics that enable kinases to perform non-catalytic functions.  The authors also discuss how post-translational modifications, protein-protein interactions, and small mols. modulate these non-canonical kinase functions.  Finally, the authors highlight current efforts in the targeted design of small-mol. modulators of non-catalytic kinase functions, a new pharmacol. challenge for which structural considerations are more important than ever.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriZFnmAkj5Q7Vg90H21EOLACvtfcHk0lgZeeNerh8ZiA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjvFOqsw%253D%253D&md5=feed13f34909080e4b95a6186000da8d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2015.10.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2015.10.020%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DJ.%2BE.%26aulast%3DJura%26aufirst%3DN.%26atitle%3DStructural%2520Basis%2520for%2520the%2520non-catalytic%2520functions%2520of%2520protein%2520kinases%26jtitle%3DStructure%26date%3D2016%26volume%3D24%26spage%3D7%26epage%3D24%26doi%3D10.1016%2Fj.str.2015.10.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornev, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. S.</span></span> <span> </span><span class="NLM_article-title">Kinases and pseudokinases: lessons from RAF</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1538</span>â <span class="NLM_lpage">1546</span>, <span class="refDoi">Â DOI: 10.1128/MCB.00057-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1128%2FMCB.00057-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=24567368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVCku7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=1538-1546&author=A.+S.+Shawauthor=A.+P.+Kornevauthor=J.+Huauthor=L.+G.+Ahujaauthor=S.+S.+Taylor&title=Kinases+and+pseudokinases%3A+lessons+from+RAF&doi=10.1128%2FMCB.00057-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Kinases and pseudokinases: lessons from RAF</span></div><div class="casAuthors">Shaw, Andrey S.; Kornev, Alexandr P.; Hu, Jiancheng; Ahuja, Lalima G.; Taylor, Susan S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1538-1546, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  Protein kinases are thought to mediate their biol. effects through their catalytic activity.  The large no. of pseudokinases in the kinome and an increasing appreciation that they have crit. roles in signaling pathways, however, suggest that catalyzing protein phosphorylation may not be the only function of protein kinases.  Using the principle of hydrophobic spine assembly, we interpret how kinases are capable of performing a dual function in signaling.  Its first role is that of a signaling enzyme (classical kinases; canonical), while its second role is that of an allosteric activator of other kinases or as a scaffold protein for signaling in a manner that is independent of phosphoryl transfer (classical pseudokinases; noncanonical).  As the hydrophobic spines are a conserved feature of the kinase domain itself, all kinases carry an inherent potential to play both roles in signaling.  This review focuses on the recent lessons from the RAF kinases that effectively toggle between these roles and can be "frozen" by introducing mutations at their hydrophobic spines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMtbrpjoo1xrVg90H21EOLACvtfcHk0lin1Q8WAgvN8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVCku7c%253D&md5=9f883042d2619f33087c7605ac7f22e9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1128%2FMCB.00057-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00057-14%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BS.%26aulast%3DKornev%26aufirst%3DA.%2BP.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DAhuja%26aufirst%3DL.%2BG.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26atitle%3DKinases%2520and%2520pseudokinases%253A%2520lessons%2520from%2520RAF%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2014%26volume%3D34%26spage%3D1538%26epage%3D1546%26doi%3D10.1128%2FMCB.00057-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">855</span>â <span class="NLM_lpage">867</span>, <span class="refDoi">Â DOI: 10.1016/S0092-8674(04)00215-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2FS0092-8674%2804%2900215-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=15035987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=855-867&author=P.+T.+Wanauthor=M.+J.+Garnettauthor=S.+M.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=C.+M.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Marais&title=Mechanism+of+activation+of+the+RAF-ERK+signaling+pathway+by+oncogenic+mutations+of+B-RAF&doi=10.1016%2FS0092-8674%2804%2900215-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span></div><div class="casAuthors">Wan, Paul T. C.; Garnett, Mathew J.; Roe, S. Mark; Lee, Sharlene; Niculescu-Duvaz, Dan; Good, Valerie M.; Project, Cancer Genome; Jones, C. Michael; Marshall, Christopher J.; Springer, Caroline J.; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Over 30 mutations of the B-RAF gene assocd. with human cancers have been identified, the majority of which are located within the kinase domain.  Here the authors show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo.  Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells.  The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by assocn. with the P loop.  The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation.  The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYiQicwc1xVLVg90H21EOLACvtfcHk0lin1Q8WAgvN8w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D&md5=4cc020056c64e514286c000666da1972</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900215-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900215-6%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMechanism%2520of%2520activation%2520of%2520the%2520RAF-ERK%2520signaling%2520pathway%2520by%2520oncogenic%2520mutations%2520of%2520B-RAF%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D855%26epage%3D867%26doi%3D10.1016%2FS0092-8674%2804%2900215-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 13 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Jianping Hu, Jieli Wei, Hyerin Yim, Li Wang, Ling Xie, Margaret S. Jin, Md Kabir, Lihuai Qin, Xian Chen, Jing Liu, <span class="NLM_string-name hlFld-ContribAuthor">Jian Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15883-15905. <a href="https://doi.org/10.1021/acs.jmedchem.0c01609" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01609</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01609%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPotent%252Band%252BSelective%252BMitogen-Activated%252BProtein%252BKinase%252BKinase%252B1%25252F2%252B%252528MEK1%25252F2%252529%252BHeterobifunctional%252BSmall-molecule%252BDegraders%26aulast%3DHu%26aufirst%3DJianping%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D14092020%26date%3D07122020%26volume%3D63%26issue%3D24%26spage%3D15883%26epage%3D15905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Liqun Chen, Yanke Chen, Chunyan Zhang, Bingyang Jiao, Sheng Liang, Qiong Tan, Hongyu Chai, Weihua Yu, Yongzheng Qian, Hui Yang, Wuyi Yao, Jianguo Yu, Ying Luo, Michael Plewe, Jialiang Wang, Xiao-Ran Han, <span class="NLM_string-name hlFld-ContribAuthor">Jing Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 14562-14575. <a href="https://doi.org/10.1021/acs.jmedchem.0c01342" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01342</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01342%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BFirst-In-Class%252BPotent%252Band%252BSelective%252BTropomyosin%252BReceptor%252BKinase%252BDegraders%26aulast%3DChen%26aufirst%3DLiqun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D07082020%26date%3D15102020%26volume%3D63%26issue%3D23%26spage%3D14562%26epage%3D14575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shanique  Alabi</span>, <span class="hlFld-ContribAuthor ">Saul  Jaime-Figueroa</span>, <span class="hlFld-ContribAuthor ">Zhan  Yao</span>, <span class="hlFld-ContribAuthor ">Yijun  Gao</span>, <span class="hlFld-ContribAuthor ">John  Hines</span>, <span class="hlFld-ContribAuthor ">Kusal T. G.  Samarasinghe</span>, <span class="hlFld-ContribAuthor ">Lea  Vogt</span>, <span class="hlFld-ContribAuthor ">Neal  Rosen</span>, <span class="hlFld-ContribAuthor ">Craig M.  Crews</span>. </span><span class="cited-content_cbyCitation_article-title">Mutant-selective degradation by BRAF-targeting PROTACs. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-021-21159-7" title="DOI URL">https://doi.org/10.1038/s41467-021-21159-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-021-21159-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-021-21159-7%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DMutant-selective%252Bdegradation%252Bby%252BBRAF-targeting%252BPROTACs%26aulast%3DAlabi%26aufirst%3DShanique%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Yunhua  Peng</span>, <span class="hlFld-ContribAuthor ">Wenyi  Wei</span>. </span><span class="cited-content_cbyCitation_article-title">Light-Controllable PROTACs for Temporospatial Control of Protein Degradation. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.678077" title="DOI URL">https://doi.org/10.3389/fcell.2021.678077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.678077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.678077%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DLight-Controllable%252BPROTACs%252Bfor%252BTemporospatial%252BControl%252Bof%252BProtein%252BDegradation%26aulast%3DLiu%26aufirst%3DJing%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming  He</span>, <span class="hlFld-ContribAuthor ">Wenxing  Lv</span>, <span class="hlFld-ContribAuthor ">Yu  Rao</span>. </span><span class="cited-content_cbyCitation_article-title">Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.685106" title="DOI URL">https://doi.org/10.3389/fcell.2021.685106</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.685106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.685106%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DOpportunities%252Band%252BChallenges%252Bof%252BSmall%252BMolecule%252BInduced%252BTargeted%252BProtein%252BDegradation%26aulast%3DHe%26aufirst%3DMing%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brandon  Dale</span>, <span class="hlFld-ContribAuthor ">Meng  Cheng</span>, <span class="hlFld-ContribAuthor ">Kwang-Su  Park</span>, <span class="hlFld-ContribAuthor ">H. Ãmit  Kaniskan</span>, <span class="hlFld-ContribAuthor ">Yue  Xiong</span>, <span class="hlFld-ContribAuthor ">Jian  Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Advancing targeted protein degradation for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Cancer</span><span> <strong>2021,</strong> <em>170 </em><a href="https://doi.org/10.1038/s41568-021-00365-x" title="DOI URL">https://doi.org/10.1038/s41568-021-00365-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41568-021-00365-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41568-021-00365-x%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Cancer%26atitle%3DAdvancing%252Btargeted%252Bprotein%252Bdegradation%252Bfor%252Bcancer%252Btherapy%26aulast%3DDale%26aufirst%3DBrandon%26date%3D2021%26date%3D2021%26volume%3D170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">William  Farnaby</span>, <span class="hlFld-ContribAuthor ">Manfred  Koegl</span>, <span class="hlFld-ContribAuthor ">Darryl B.  McConnell</span>, <span class="hlFld-ContribAuthor ">Alessio  Ciulli</span>. </span><span class="cited-content_cbyCitation_article-title">Transforming targeted cancer therapy with PROTACs: A forward-looking perspective. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Pharmacology</span><span> <strong>2021,</strong> <em>57 </em>, 175-183. <a href="https://doi.org/10.1016/j.coph.2021.02.009" title="DOI URL">https://doi.org/10.1016/j.coph.2021.02.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.coph.2021.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.coph.2021.02.009%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Pharmacology%26atitle%3DTransforming%252Btargeted%252Bcancer%252Btherapy%252Bwith%252BPROTACs%25253A%252BA%252Bforward-looking%252Bperspective%26aulast%3DFarnaby%26aufirst%3DWilliam%26date%3D2021%26volume%3D57%26spage%3D175%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinrui  Yang</span>, <span class="hlFld-ContribAuthor ">He  Yin</span>, <span class="hlFld-ContribAuthor ">Richard D.  Kim</span>, <span class="hlFld-ContribAuthor ">Jason B.  Fleming</span>, <span class="hlFld-ContribAuthor ">Hao  Xie</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective. </span><span class="cited-content_cbyCitation_journal-name">Targeted Oncology</span><span> <strong>2021,</strong> <em>16 </em>
                                    (1)
                                     , 1-12. <a href="https://doi.org/10.1007/s11523-020-00782-2" title="DOI URL">https://doi.org/10.1007/s11523-020-00782-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11523-020-00782-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11523-020-00782-2%26sid%3Dliteratum%253Aachs%26jtitle%3DTargeted%2520Oncology%26atitle%3DPreclinical%252Band%252BClinical%252BAdvances%252Bof%252BTargeted%252BProtein%252BDegradation%252Bas%252Ba%252BNovel%252BCancer%252BTherapeutic%252BStrategy%25253A%252BAn%252BOncologist%252BPerspective%26aulast%3DYang%26aufirst%3DXinrui%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D1%26spage%3D1%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthew D  Ringel</span>. </span><span class="cited-content_cbyCitation_article-title">New Horizons: Emerging Therapies and Targets in Thyroid Cancer. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Clinical Endocrinology & Metabolism</span><span> <strong>2021,</strong> <em>106 </em>
                                    (1)
                                     , e382-e388. <a href="https://doi.org/10.1210/clinem/dgaa687" title="DOI URL">https://doi.org/10.1210/clinem/dgaa687</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1210/clinem/dgaa687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1210%2Fclinem%2Fdgaa687%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Clinical%2520Endocrinology%2520%2526%2520Metabolism%26atitle%3DNew%252BHorizons%25253A%252BEmerging%252BTherapies%252Band%252BTargets%252Bin%252BThyroid%252BCancer%26aulast%3DRingel%26aufirst%3DMatthew%2BD%26date%3D2021%26date%3D2020%26volume%3D106%26issue%3D1%26spage%3De382%26epage%3De388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M.  Maneiro</span>, <span class="hlFld-ContribAuthor ">E.  De Vita</span>, <span class="hlFld-ContribAuthor ">D.  Conole</span>, <span class="hlFld-ContribAuthor ">C.S.  Kounde</span>, <span class="hlFld-ContribAuthor ">Q.  Zhang</span>, <span class="hlFld-ContribAuthor ">E.W.  Tate</span>. </span><span class="cited-content_cbyCitation_article-title">PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/bs.pmch.2021.01.002" title="DOI URL">https://doi.org/10.1016/bs.pmch.2021.01.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.pmch.2021.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.pmch.2021.01.002%26sid%3Dliteratum%253Aachs%26atitle%3DPROTACs%25252C%252Bmolecular%252Bglues%252Band%252Bbifunctionals%252Bfrom%252Bbench%252Bto%252Bbedside%25253A%252BUnlocking%252Bthe%252Bclinical%252Bpotential%252Bof%252Bcatalytic%252Bdrugs%26aulast%3DManeiro%26aufirst%3DM.%26date%3D2021%26pub%3DElsevier%26date%3D2021%26volume%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anthony  Feral</span>, <span class="hlFld-ContribAuthor ">Guillaume  Laconde</span>, <span class="hlFld-ContribAuthor ">Muriel  Amblard</span>, <span class="hlFld-ContribAuthor ">Nicolas  Masurier</span>. </span><span class="cited-content_cbyCitation_article-title">PROteolysis TArgetting Chimeras (PROTACs) Strategy Applied to Kinases: Recent Advances. </span><span class="cited-content_cbyCitation_journal-name">Advanced Therapeutics</span><span> <strong>2020,</strong> <em>3 </em>
                                    (11)
                                     , 2000148. <a href="https://doi.org/10.1002/adtp.202000148" title="DOI URL">https://doi.org/10.1002/adtp.202000148</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adtp.202000148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadtp.202000148%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Therapeutics%26atitle%3DPROteolysis%252BTArgetting%252BChimeras%252B%252528PROTACs%252529%252BStrategy%252BApplied%252Bto%252BKinases%25253A%252BRecent%252BAdvances%26aulast%3DFeral%26aufirst%3DAnthony%26date%3D2020%26date%3D2020%26volume%3D3%26issue%3D11%26spage%3D2000148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joshua J.  Feng</span>, <span class="hlFld-ContribAuthor ">Chao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">A two-pronged attack. </span><span class="cited-content_cbyCitation_journal-name">Nature Chemical Biology</span><span> <strong>2020,</strong> <em>16 </em>
                                    (11)
                                     , 1154-1155. <a href="https://doi.org/10.1038/s41589-020-0647-1" title="DOI URL">https://doi.org/10.1038/s41589-020-0647-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41589-020-0647-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41589-020-0647-1%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Chemical%2520Biology%26atitle%3DA%252Btwo-pronged%252Battack%26aulast%3DFeng%26aufirst%3DJoshua%2BJ.%26date%3D2020%26date%3D2020%26volume%3D16%26issue%3D11%26spage%3D1154%26epage%3D1155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  GÃ¼tschow</span>, <span class="hlFld-ContribAuthor ">Jean Jacques  Vanden Eynde</span>, <span class="hlFld-ContribAuthor ">Josef  Jampilek</span>, <span class="hlFld-ContribAuthor ">CongBao  Kang</span>, <span class="hlFld-ContribAuthor ">Arduino A.  Mangoni</span>, <span class="hlFld-ContribAuthor ">Paola  Fossa</span>, <span class="hlFld-ContribAuthor ">Rafik  Karaman</span>, <span class="hlFld-ContribAuthor ">Andrea  Trabocchi</span>, <span class="hlFld-ContribAuthor ">Peter J. H.  Scott</span>, <span class="hlFld-ContribAuthor ">JÃ³hannes  Reynisson</span>, <span class="hlFld-ContribAuthor ">Simona  Rapposelli</span>, <span class="hlFld-ContribAuthor ">Stefania  Galdiero</span>, <span class="hlFld-ContribAuthor ">Jean-Yves  Winum</span>, <span class="hlFld-ContribAuthor ">Chiara  Brullo</span>, <span class="hlFld-ContribAuthor ">Katalin  Prokai-Tatrai</span>, <span class="hlFld-ContribAuthor ">Arun K.  Sharma</span>, <span class="hlFld-ContribAuthor ">Matthieu  Schapira</span>, <span class="hlFld-ContribAuthor ">Yasu-Taka  Azuma</span>, <span class="hlFld-ContribAuthor ">Laura  Cerchia</span>, <span class="hlFld-ContribAuthor ">Mariana  Spetea</span>, <span class="hlFld-ContribAuthor ">Giangiacomo  Torri</span>, <span class="hlFld-ContribAuthor ">Simona  Collina</span>, <span class="hlFld-ContribAuthor ">Athina  Geronikaki</span>, <span class="hlFld-ContribAuthor ">Alfonso T.  GarcÃ­a-Sosa</span>, <span class="hlFld-ContribAuthor ">M. Helena  Vasconcelos</span>, <span class="hlFld-ContribAuthor ">Maria EmÃ­lia  Sousa</span>, <span class="hlFld-ContribAuthor ">Ivan  Kosalec</span>, <span class="hlFld-ContribAuthor ">Tiziano  Tuccinardi</span>, <span class="hlFld-ContribAuthor ">Iola F.  Duarte</span>, <span class="hlFld-ContribAuthor ">Jorge A. R.  Salvador</span>, <span class="hlFld-ContribAuthor ">Massimo  Bertinaria</span>, <span class="hlFld-ContribAuthor ">Maurizio  Pellecchia</span>, <span class="hlFld-ContribAuthor ">Jussara  Amato</span>, <span class="hlFld-ContribAuthor ">Giulio  Rastelli</span>, <span class="hlFld-ContribAuthor ">Paula A. C.  Gomes</span>, <span class="hlFld-ContribAuthor ">Rita C.  Guedes</span>, <span class="hlFld-ContribAuthor ">Jean-Marc  Sabatier</span>, <span class="hlFld-ContribAuthor ">Ana  EstÃ©vez-Braun</span>, <span class="hlFld-ContribAuthor ">Bruno  Pagano</span>, <span class="hlFld-ContribAuthor ">Stefano  Mangani</span>, <span class="hlFld-ContribAuthor ">Rino  Ragno</span>, <span class="hlFld-ContribAuthor ">George  Kokotos</span>, <span class="hlFld-ContribAuthor ">Margherita  Brindisi</span>, <span class="hlFld-ContribAuthor ">Florenci V.  GonzÃ¡lez</span>, <span class="hlFld-ContribAuthor ">Fernanda  Borges</span>, <span class="hlFld-ContribAuthor ">Mariarosaria  Miloso</span>, <span class="hlFld-ContribAuthor ">Jarkko  Rautio</span>, <span class="hlFld-ContribAuthor ">Diego  MuÃ±oz-Torrero</span>. </span><span class="cited-content_cbyCitation_article-title">Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopesâ7. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (13)
                                     , 2968. <a href="https://doi.org/10.3390/molecules25132968" title="DOI URL">https://doi.org/10.3390/molecules25132968</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25132968&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25132968%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBreakthroughs%252Bin%252BMedicinal%252BChemistry%25253A%252BNew%252BTargets%252Band%252BMechanisms%25252C%252BNew%252BDrugs%25252C%252BNew%252BHopes%2525E2%252580%2525937%26aulast%3DG%25C3%25BCtschow%26aufirst%3DMichael%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D13%26spage%3D2968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/medium/jm9b02083_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02083&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/medium/jm9b02083_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of <b>1</b> (vemurafenib), <b>2</b> (dabrafenib), <b>3</b> (encorafenib), <b>4</b> (BI882370), and <b>5</b> (Vem-bisamide-2).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02083&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/medium/jm9b02083_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>12</b> and <b>23</b> and Their Cereblon Binding-Deficient Derivatives<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02083&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd(dppf)Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 80 Â°C, 6 h; (b) HCl/EtOAc, rt, overnight; (c) DIEA, NMP, microwave, 85 Â°C, 30 min; (d) TFA, rt, 2 h; (e) EDCI, HOAt, NMM, DMSO, rt, overnight; (f) CuI, (<i>R</i>,<i>R</i>)-<i>N</i>,<i>N</i>â²-dimethyl-1,2-diaminocyclohexane, Cs<sub>2</sub>CO<sub>3</sub>, toluene, 120 Â°C, 48 h; (g) NIS, DMF/THF, rt, 1 h; and (h) Pd(dppf)Cl<sub>2</sub>, LiCl, Na<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 100 Â°C, 1 h.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/medium/jm9b02083_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding affinities of vemurafenib, BI882370, degraders (<b>12</b>, <b>23</b>), and negative controls (<b>13</b>, <b>24</b>) to BRAF or BRAF-V600E. Binding affinities of individual compounds were determined using the KINOMEscan assay (DiscoveryX). The lowest concentration points represent data for the DMSO samples. Data are shown as mean Â± SEM derived from duplicated independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02083&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/medium/jm9b02083_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. <b>12</b> and <b>23</b> induce degradation of BRAF-V600E. (A, B) A375 cells were treated with DMSO or serial dilutions of indicated compounds for 16 h. (C) A375 cells were treated with DMSO, 500 nM BI882370 or <b>23</b> for the indicated length of time.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02083&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/medium/jm9b02083_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <b>12</b> and <b>23</b> do not degrade wild-type BRAF. (A, B) A549 cells were treated with DMSO or indicated compounds following a 3-fold serial dilution for 16 h. (C, D) A375 cells stably expressing the kinase domain of BRAF or BRAF-V600E were treated with DMSO or indicated compounds for 16 h following a 3-fold serial dilution. Levels of indicated proteins were shown using immunoblotting.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02083&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/medium/jm9b02083_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Degradation of BRAF-V600E is mediated by the UPS. (A, B) A375 cells were treated with serial dilutions of compound <b>12</b>, <b>23</b>, or their respective negative controls <b>13</b> or <b>24</b> for 16 h prior to immunoblotting. (C, D) A375 cells were pretreated for 1 h with DMSO, pomalidomide (POM, 10 Î¼M), MG-132 (20 Î¼M), bortezomib (200 nM), or MLN4924 (1 Î¼M) and subsequently incubated with 500 nM <b>12</b> or <b>23</b> for 6 h prior to immunoblotting.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02083&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/medium/jm9b02083_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Degradation of BRAF-V600E impairs cell viability and colony formation. (AâD) Compounds <b>12</b> and <b>23</b> reduced viability of A375 and HT-29 cells in a dose-dependent manner. (E, F) Compounds <b>12</b> and <b>23</b> inhibited colony formation of A375 cells. Data are shown as mean Â± SD *: <i>p</i> < 0.05 by Studentâs <i>t</i> test compared with the corresponding control groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-8/acs.jmedchem.9b02083/20200416/images/large/jm9b02083_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b02083&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55402" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55402" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 36 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durrant, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. K.</span></span> <span> </span><span class="NLM_article-title">Targeting the Raf kinases in human cancer: the Raf dimer dilemma</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">3</span>â <span class="NLM_lpage">8</span>, <span class="refDoi">Â DOI: 10.1038/bjc.2017.399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1038%2Fbjc.2017.399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=29235562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFKhu7vL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=3-8&author=D.+E.+Durrantauthor=D.+K.+Morrison&title=Targeting+the+Raf+kinases+in+human+cancer%3A+the+Raf+dimer+dilemma&doi=10.1038%2Fbjc.2017.399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Raf kinases in human cancer: the Raf dimer dilemma</span></div><div class="casAuthors">Durrant, David E.; Morrison, Deborah K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-8</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The Raf protein kinases are key intermediates in cellular signal transduction, functioning as direct effectors of the Ras GTPases and as the initiating kinases in the ERK cascade.  In human cancer, Raf activity is frequently dysregulated due to mutations in the Raf family member B-Raf or to alterations in upstream Raf regulators, including Ras and receptor tyrosine kinases.  First-generation Raf inhibitors, such as vemurafenib and dabrafenib, have yielded dramatic responses in malignant melanomas contg. B-Raf mutations; however, their overall usefulness has been limited by both intrinsic and acquired drug resistance.  In particular, issues related to the dimerization of the Raf kinases can impact the efficacy of these compds. and are a primary cause of drug resistance.  Here, we will review the importance of Raf dimerization in cell signalling as well as its effects on Raf inhibitor therapy, and we will present the new strategies that are being pursued to overcome the 'Raf Dimer Dilemma'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHTShTLpMLiLVg90H21EOLACvtfcHk0lh92jK7eZGv9Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFKhu7vL&md5=186dbe3ee9006a384d9b50831000e144</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2017.399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2017.399%26sid%3Dliteratum%253Aachs%26aulast%3DDurrant%26aufirst%3DD.%2BE.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DTargeting%2520the%2520Raf%2520kinases%2520in%2520human%2520cancer%253A%2520the%2520Raf%2520dimer%2520dilemma%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2018%26volume%3D118%26spage%3D3%26epage%3D8%26doi%3D10.1038%2Fbjc.2017.399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignell, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clegg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teague, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woffendin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottomley, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicks, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewing, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosmidou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mould, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayatilake, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gusterson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shipley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrave, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard-Jones, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitland, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chenevix-Trench, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggins, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigner, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cossu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flanagan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seigler, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wooster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futreal, P. A.</span></span> <span> </span><span class="NLM_article-title">Mutations of the BRAF gene in human cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>417</i></span>,  <span class="NLM_fpage">949</span>â <span class="NLM_lpage">954</span>, <span class="refDoi">Â DOI: 10.1038/nature00766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1038%2Fnature00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=12068308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=949-954&author=H.+Daviesauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S.+Edkinsauthor=S.+Cleggauthor=J.+Teagueauthor=H.+Woffendinauthor=M.+J.+Garnettauthor=W.+Bottomleyauthor=N.+Davisauthor=E.+Dicksauthor=R.+Ewingauthor=Y.+Floydauthor=K.+Grayauthor=S.+Hallauthor=R.+Hawesauthor=J.+Hughesauthor=V.+Kosmidouauthor=A.+Menziesauthor=C.+Mouldauthor=A.+Parkerauthor=C.+Stevensauthor=S.+Wattauthor=S.+Hooperauthor=R.+Wilsonauthor=H.+Jayatilakeauthor=B.+A.+Gustersonauthor=C.+Cooperauthor=J.+Shipleyauthor=D.+Hargraveauthor=K.+Pritchard-Jonesauthor=N.+Maitlandauthor=G.+Chenevix-Trenchauthor=G.+J.+Rigginsauthor=D.+D.+Bignerauthor=G.+Palmieriauthor=A.+Cossuauthor=A.+Flanaganauthor=A.+Nicholsonauthor=J.+W.+Hoauthor=S.+Y.+Leungauthor=S.+T.+Yuenauthor=B.+L.+Weberauthor=H.+F.+Seiglerauthor=T.+L.+Darrowauthor=H.+Patersonauthor=R.+Maraisauthor=C.+J.+Marshallauthor=R.+Woosterauthor=M.+R.+Strattonauthor=P.+A.+Futreal&title=Mutations+of+the+BRAF+gene+in+human+cancer&doi=10.1038%2Fnature00766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the BRAF gene in human cancer</span></div><div class="casAuthors">Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian; Hall, Sarah; Hawes, Rachel; Hughes, Jaime; Kosmidou, Vivian; Menzies, Andrew; Mould, Catherine; Parker, Adrian; Stevens, Claire; Watt, Stephen; Hooper, Steven; Wilson, Rebecca; Jayatilake, Hiran; Gusterson, Barry A.; Cooper, Colin; Shipley, Janet; Hargrave, Darren; Pritchard-Jones, Katherine; Maitland, Norman; Chenevix-Trench, Georgia; Riggins, Gregory J.; Bigner, Darell D.; Palmieri, Giuseppe; Cossu, Antonio; Flanagan, Adrienne; Nicholson, Andrew; Ho, Judy W. C.; Leung, Suet Y.; Yuen, Siu T.; Weber, Barbara L.; Seigler, Hilliard F.; Darrow, Timothy L.; Paterson, Hugh; Marais, Richard; Marshall, Christopher J.; Wooster, Richard; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6892</span>),
    <span class="NLM_cas:pages">949-954</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancers arise owing to the accumulation of mutations in crit. genes that alter normal programs of cell proliferation, differentiation and death.  As the first stage of a systematic genome-wide screen for these genes, we have prioritized for anal. signalling pathways in which at least one gene is mutated in human cancer.  The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular responses to growth signals.  RAS is mutated to an oncogenic form in about 15% of human cancer.  The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS.  Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers.  All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%.  Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.  Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.  As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBmhJC0GAjrVg90H21EOLACvtfcHk0lhlSb2SRHnLow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D&md5=4625be53ad9a382d51b6ee753d0c17e8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnature00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature00766%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS.%26aulast%3DClegg%26aufirst%3DS.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWoffendin%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DBottomley%26aufirst%3DW.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DDicks%26aufirst%3DE.%26aulast%3DEwing%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DHawes%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DKosmidou%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DA.%26aulast%3DMould%26aufirst%3DC.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DJayatilake%26aufirst%3DH.%26aulast%3DGusterson%26aufirst%3DB.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DPritchard-Jones%26aufirst%3DK.%26aulast%3DMaitland%26aufirst%3DN.%26aulast%3DChenevix-Trench%26aufirst%3DG.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DJ.%2BW.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSeigler%26aufirst%3DH.%2BF.%26aulast%3DDarrow%26aufirst%3DT.%2BL.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520of%2520the%2520BRAF%2520gene%2520in%2520human%2520cancer%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D949%26epage%3D954%26doi%3D10.1038%2Fnature00766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lavoie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, M.</span></span> <span> </span><span class="NLM_article-title">Regulation of RAF protein kinases in ERK signalling</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">281</span>â <span class="NLM_lpage">298</span>, <span class="refDoi">Â DOI: 10.1038/nrm3979</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1038%2Fnrm3979" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=25907612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFCitbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=281-298&author=H.+Lavoieauthor=M.+Therrien&title=Regulation+of+RAF+protein+kinases+in+ERK+signalling&doi=10.1038%2Fnrm3979"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of RAF protein kinases in ERK signalling</span></div><div class="casAuthors">Lavoie, Hugo; Therrien, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">281-298</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">RAF family kinases were among the first oncoproteins to be described more than 30 years ago.  They primarily act as signalling relays downstream of RAS, and their close ties to cancer have fuelled a large no. of studies.  However, we still lack a systems-level understanding of their regulation and mode of action.  The recent discovery that the catalytic activity of RAF depends on an allosteric mechanism driven by kinase domain dimerization is providing a vital new piece of information towards a comprehensive model of RAF function.  The fact that current RAF inhibitors unexpectedly induce ERK signalling by stimulating RAF dimerization also calls for a deeper structural characterization of this family of kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwzK227mPD3rVg90H21EOLACvtfcHk0lhorRT3dBsCzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFCitbk%253D&md5=1f4c4fbbacb1e3d790b81dbb027520b9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrm3979&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3979%26sid%3Dliteratum%253Aachs%26aulast%3DLavoie%26aufirst%3DH.%26aulast%3DTherrien%26aufirst%3DM.%26atitle%3DRegulation%2520of%2520RAF%2520protein%2520kinases%2520in%2520ERK%2520signalling%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2015%26volume%3D16%26spage%3D281%26epage%3D298%26doi%3D10.1038%2Fnrm3979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAndrea, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grippo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathanson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span> <span> </span><span class="NLM_article-title">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>467</i></span>,  <span class="NLM_fpage">596</span>â <span class="NLM_lpage">599</span>, <span class="refDoi">Â DOI: 10.1038/nature09454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1038%2Fnature09454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=20823850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=596-599&author=G.+Bollagauthor=P.+Hirthauthor=J.+Tsaiauthor=J.+Zhangauthor=P.+N.+Ibrahimauthor=H.+Choauthor=W.+Spevakauthor=C.+Zhangauthor=Y.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=G.+Tsangauthor=B.+L.+Westauthor=B.+Powellauthor=R.+Shellooeauthor=A.+Marimuthuauthor=H.+Nguyenauthor=K.+Y.+Zhangauthor=D.+R.+Artisauthor=J.+Schlessingerauthor=F.+Suauthor=B.+Higginsauthor=R.+Iyerauthor=K.+D%E2%80%99Andreaauthor=A.+Koehlerauthor=M.+Stummauthor=P.+S.+Linauthor=R.+J.+Leeauthor=J.+Grippoauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+B.+Chapmanauthor=K.+T.+Flahertyauthor=X.+Xuauthor=K.+L.+Nathansonauthor=K.+Nolop&title=Clinical+efficacy+of+a+RAF+inhibitor+needs+broad+target+blockade+in+BRAF-mutant+melanoma&doi=10.1038%2Fnature09454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span></div><div class="casAuthors">Bollag, Gideon; Hirth, Peter; Tsai, James; Zhang, Jiazhong; Ibrahim, Prabha N.; Cho, Hanna; Spevak, Wayne; Zhang, Chao; Zhang, Ying; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Tsang, Garson; West, Brian L.; Powell, Ben; Shellooe, Rafe; Marimuthu, Adhirai; Nguyen, Hoa; Zhang, Kam Y. J.; Artis, Dean R.; Schlessinger, Joseph; Su, Fei; Higgins, Brian; Iyer, Raman; D'Andrea, Kurt; Koehler, Astrid; Stumm, Michael; Lin, Paul S.; Lee, Richard J.; Grippo, Joseph; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; Chapman, Paul B.; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.; Nolop, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">596-599</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B-RAF is the most frequently mutated protein kinase in human cancers.  The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway, offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients.  Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity.  Preclin. expts. demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts.  Toxicol. studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clin. trials using a cryst. formulation of PLX4032 (ref. 5).  In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following 2 wk of treatment.  This anal. revealed substantial inhibition of ERK phosphorylation, yet clin. evaluation did not show tumor regressions.  At higher drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK phosphorylation in the tumors of patients correlated with clin. response.  Indeed, the Phase 1 clin. data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily.  These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYwlns1EfcLVg90H21EOLACvtfcHk0li6vgpsinRFQQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK&md5=8a26d0ab41970f39a109ddafff2f17b4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnature09454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09454%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DKoehler%26aufirst%3DA.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DNolop%26aufirst%3DK.%26atitle%3DClinical%2520efficacy%2520of%2520a%2520RAF%2520inhibitor%2520needs%2520broad%2520target%2520blockade%2520in%2520BRAF-mutant%2520melanoma%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D596%26epage%3D599%26doi%3D10.1038%2Fnature09454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouary, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutzmer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, W. H.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaempgen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Algarra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaszewska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haney, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirakhur, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guckert, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span> <span> </span><span class="NLM_article-title">Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>380</i></span>,  <span class="NLM_fpage">358</span>â <span class="NLM_lpage">365</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(12)60868-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2FS0140-6736%2812%2960868-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=22735384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt1SgtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2012&pages=358-365&author=A.+Hauschildauthor=J.+J.+Grobauthor=L.+V.+Demidovauthor=T.+Jouaryauthor=R.+Gutzmerauthor=M.+Millwardauthor=P.+Rutkowskiauthor=C.+U.+Blankauthor=W.+H.+Millerauthor=E.+Kaempgenauthor=S.+Martin-Algarraauthor=B.+Karaszewskaauthor=C.+Mauchauthor=V.+Chiarion-Sileniauthor=A.+M.+Martinauthor=S.+Swannauthor=P.+Haneyauthor=B.+Mirakhurauthor=M.+E.+Guckertauthor=V.+Goodmanauthor=P.+B.+Chapman&title=Dabrafenib+in+BRAF-mutated+metastatic+melanoma%3A+a+multicentre%2C+open-label%2C+phase+3+randomised+controlled+trial&doi=10.1016%2FS0140-6736%2812%2960868-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</span></div><div class="casAuthors">Hauschild, Axel; Grob, Jean-Jacques; Demidov, Lev V.; Jouary, Thomas; Gutzmer, Ralf; Millward, Michael; Rutkowski, Piotr; Blank, Christian U.; Miller, Wilson H.; Kaempgen, Eckhart; Martin-Algarra, Salvador; Karaszewska, Boguslawa; Mauch, Cornelia; Chiarion-Sileni, Vanna; Martin, Anne-Marie; Swann, Suzanne; Haney, Patricia; Mirakhur, Beloo; Guckert, Mary E.; Goodman, Vicki; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">9839</span>),
    <span class="NLM_cas:pages">358-365</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dabrafenib, an inhibitor of mutated BRAF, has clin. activity with a manageable safety profile in studies of phase 1 and 2 in patients with BRAFV600-mutated metastatic melanoma.  We studied the efficacy of dabrafenib in patients with BRAFV600E-mutated metastatic melanoma.We enrolled patients in this open-label phase 3 trial between Dec 23, 2010, and Sept 1, 2011.  This report is based on a data cutoff date of Dec 19, 2011.  Patients aged 18 years or older with previously untreated, stage IV or unresectable stage III BRAFV600E mutation-pos. melanoma were randomly assigned (3:1) to receive dabrafenib (150 mg twice daily, orally) or dacarbazine (1000 mg/m2 i.v. every 3 wk).  Patients were stratified according to American Joint Committee on Cancer stage (unresectable III+IVM1a+IVM1b vs IVM1c).  The primary endpoint was investigator-assessed progression-free survival and was analyzed by intention to treat; safety was assessed per protocol.  This study is registered with ClinicalTrials.gov, no. NCT01227889.Of the 733 patients screened, 250 were randomly assigned to receive either dabrafenib (187 patients) or dacarbazine (63 patients).  Median progression-free survival was 5Â·1 mo for dabrafenib and 2Â·7 mo for dacarbazine, with a hazard ratio (HR) of 0Â·30 (95% CI 0Â·18-0Â·51; p<0Â·0001).  At data cutoff, 107 (57%) patients in the dabrafenib group and 14 (22%) in the dacarbazine group remained on randomized treatment.  Treatment-related adverse events (grade 2 or higher) occurred in 100 (53%) of the 187 patients who received dabrafenib and in 26 (44%) of the 59 patients who received dacarbazine.  The most common adverse events with dabrafenib were skin-related toxic effects, fever, fatigue, arthralgia, and headache.  The most common adverse events with dacarbazine were nausea, vomiting, neutropenia, fatigue, and asthenia.  Grade 3-4 adverse events were uncommon in both groups.Dabrafenib significantly improved progression-free survival compared with dacarbazine.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEDYPJULE5c7Vg90H21EOLACvtfcHk0li6vgpsinRFQQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt1SgtLg%253D&md5=5e8699780f47bd37e075d39636e0d809</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2960868-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252960868-X%26sid%3Dliteratum%253Aachs%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DDemidov%26aufirst%3DL.%2BV.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DGutzmer%26aufirst%3DR.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DBlank%26aufirst%3DC.%2BU.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DKaempgen%26aufirst%3DE.%26aulast%3DMartin-Algarra%26aufirst%3DS.%26aulast%3DKaraszewska%26aufirst%3DB.%26aulast%3DMauch%26aufirst%3DC.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DSwann%26aufirst%3DS.%26aulast%3DHaney%26aufirst%3DP.%26aulast%3DMirakhur%26aufirst%3DB.%26aulast%3DGuckert%26aufirst%3DM.%2BE.%26aulast%3DGoodman%26aufirst%3DV.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DDabrafenib%2520in%2520BRAF-mutated%2520metastatic%2520melanoma%253A%2520a%2520multicentre%252C%2520open-label%252C%2520phase%25203%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D380%26spage%3D358%26epage%3D365%26doi%3D10.1016%2FS0140-6736%2812%2960868-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koelblinger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuerigen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span> <span> </span><span class="NLM_article-title">Development of encorafenib for BRAF-mutated advanced melanoma</span>. <i>Curr. Opin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">125</span>â <span class="NLM_lpage">133</span>, <span class="refDoi">Â DOI: 10.1097/CCO.0000000000000426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1097%2FCCO.0000000000000426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=29356698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ymtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2018&pages=125-133&author=P.+Koelblingerauthor=O.+Thuerigenauthor=R.+Dummer&title=Development+of+encorafenib+for+BRAF-mutated+advanced+melanoma&doi=10.1097%2FCCO.0000000000000426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Development of encorafenib for BRAF-mutated advanced melanoma</span></div><div class="casAuthors">Koelblinger, Peter; Thuerigen, Olaf; Dummer, Reinhard</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-133</span>CODEN:
                <span class="NLM_cas:coden">CUOOE8</span>;
        ISSN:<span class="NLM_cas:issn">1040-8746</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: To describe the pharmacol. properties, preclin. and clin. data of the novel V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF)-inhibitor encorafenib (LGX818) and to compare these with established BRAF-inhibitors in the treatment of locally advanced or metastatic melanoma.  Recent findings: Encorafenib has shown improved efficacy in the treatment of metastatic melanoma in comparison with vemurafenib.  Combination with the MEK inhibitor (MEKi) binimetinib allows for higher dose intensities of encorafenib further improving response rates (RRs).  Summary: Combination therapy with BRAF and MEKi has evolved as a std. of care in the treatment of locally advanced or metastatic BRAF-mutated melanoma.  Despite compelling initial RRs, development of treatment resistance eventually leads to tumor progression in the majority of BRAF/MEK-inhibitor treated patients.  Moreover, treatment-related adverse events are frequent, resulting in a substantial proportion of dose modifications and/or treatment discontinuations.  The second-generation BRAF inhibitor encorafenib has been developed aiming at improved efficacy and tolerability through modifications in pharmacol. properties.  Clin. phase 3 data show improved progression-free survival both for encorafenib monotherapy and combination therapy with binimetinib compared with vemurafenib.  Overall survival data and regulatory approval of this novel substance are eagerly awaited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomkirq-JaxiLVg90H21EOLACvtfcHk0liiqlZIaKfYBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ymtLg%253D&md5=1c1a53766823737b3039bbd96bb8910f</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1097%2FCCO.0000000000000426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCCO.0000000000000426%26sid%3Dliteratum%253Aachs%26aulast%3DKoelblinger%26aufirst%3DP.%26aulast%3DThuerigen%26aufirst%3DO.%26aulast%3DDummer%26aufirst%3DR.%26atitle%3DDevelopment%2520of%2520encorafenib%2520for%2520BRAF-mutated%2520advanced%2520melanoma%26jtitle%3DCurr.%2520Opin.%2520Oncol.%26date%3D2018%26volume%3D30%26spage%3D125%26epage%3D133%26doi%3D10.1097%2FCCO.0000000000000426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span>,  <span class="NLM_fpage">427</span>â <span class="NLM_lpage">430</span>, <span class="refDoi">Â DOI: 10.1038/nature08902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1038%2Fnature08902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=20179705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFWjsrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=427-430&author=P.+I.+Poulikakosauthor=C.+Zhangauthor=G.+Bollagauthor=K.+M.+Shokatauthor=N.+Rosen&title=RAF+inhibitors+transactivate+RAF+dimers+and+ERK+signalling+in+cells+with+wild-type+BRAF&doi=10.1038%2Fnature08902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</span></div><div class="casAuthors">Poulikakos, Poulikos I.; Zhang, Chao; Bollag, Gideon; Shokat, Kevan M.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">427-430</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tumors with mutant BRAF are dependent on the RAF-MEK-ERK signaling pathway for their growth.  We found that ATP-competitive RAF inhibitors inhibit ERK signaling in cells with mutant BRAF, but unexpectedly enhance signaling in cells with wild-type BRAF.  Here we demonstrate the mechanistic basis for these findings.  We used chem. genetic methods to show that drug-mediated transactivation of RAF dimers is responsible for paradoxical activation of the enzyme by inhibitors.  Induction of ERK signaling requires direct binding of the drug to the ATP-binding site of one kinase of the dimer and is dependent on RAS activity.  Drug binding to one member of RAF homodimers (CRAF-CRAF) or heterodimers (CRAF-BRAF) inhibits one protomer, but results in transactivation of the drug-free protomer.  In BRAF(V600E) tumors, RAS is not activated, thus transactivation is minimal and ERK signaling is inhibited in cells exposed to RAF inhibitors.  These results indicate that RAF inhibitors will be effective in tumors in which BRAF is mutated.  Furthermore, because RAF inhibitors do not inhibit ERK signaling in other cells, the model predicts that they would have a higher therapeutic index and greater antitumor activity than mitogen-activated protein kinase (MEK) inhibitors, but could also cause toxicity due to MEK/ERK activation.  These predictions have been borne out in a recent clin. trial of the RAF inhibitor PLX4032 (refs 4, 5).  The model indicates that promotion of RAF dimerization by elevation of wild-type RAF expression or RAS activity could lead to drug resistance in mutant BRAF tumors.  In agreement with this prediction, RAF inhibitors do not inhibit ERK signaling in cells that coexpress BRAF(V600E) and mutant RAS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMlm9feupyNrVg90H21EOLACvtfcHk0liiqlZIaKfYBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFWjsrs%253D&md5=8323a558886ccbb8f7d85b22b9bfbc15</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature08902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08902%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DRAF%2520inhibitors%2520transactivate%2520RAF%2520dimers%2520and%2520ERK%2520signalling%2520in%2520cells%2520with%2520wild-type%2520BRAF%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D427%26epage%3D430%26doi%3D10.1038%2Fnature08902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fedorenko, I. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paraiso, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S.</span></span> <span> </span><span class="NLM_article-title">Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">201</span>â <span class="NLM_lpage">209</span>, <span class="refDoi">Â DOI: 10.1016/j.bcp.2011.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2Fj.bcp.2011.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=21635872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVegsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2011&pages=201-209&author=I.+V.+Fedorenkoauthor=K.+H.+Paraisoauthor=K.+S.+Smalley&title=Acquired+and+intrinsic+BRAF+inhibitor+resistance+in+BRAF+V600E+mutant+melanoma&doi=10.1016%2Fj.bcp.2011.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma</span></div><div class="casAuthors">Fedorenko, Inna V.; Paraiso, Kim H. T.; Smalley, Keiran S. M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">201-209</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The discovery of activating BRAF V600E mutations in 50% of all cutaneous melanomas has revolutionized the understanding of melanoma biol. and provided new strategies for the therapeutic management of this deadly disease.  Highly potent small mol. inhibitors of BRAF are now showing great promise as a novel therapeutic strategy for melanomas harboring activating BRAF V600E mutations and are assocd. with high levels of response.  This commentary article discusses the latest data on the role of mutated BRAF in the development and progression of melanoma as the basis for understanding the mechanism of action of BRAF inhibitors in the preclin. and clin. settings.  We further address the issue of BRAF inhibitor resistance and outline the latest insights into the mechanisms of therapeutic escape as well as describing approaches to prevent and abrogate the onset of both intrinsic and acquired drug resistance.  It is likely that our evolving understanding of melanoma genetics and signaling will allow for the further personalization of melanoma therapy with the goal of improving clin. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqup86oCotLPrVg90H21EOLACvtfcHk0ljenScuyyJV2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVegsro%253D&md5=2afe517b5af24ff622263777057b4ef1</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2011.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2011.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DFedorenko%26aufirst%3DI.%2BV.%26aulast%3DParaiso%26aufirst%3DK.%2BH.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%26atitle%3DAcquired%2520and%2520intrinsic%2520BRAF%2520inhibitor%2520resistance%2520in%2520BRAF%2520V600E%2520mutant%2520melanoma%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2011%26volume%3D82%26spage%3D201%26epage%3D209%26doi%3D10.1016%2Fj.bcp.2011.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milagre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trunzer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spleiss, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koya, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilton, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhomen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preece, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otte, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kee, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kockx, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andries, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lestini, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joe, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">207</span>â <span class="NLM_lpage">215</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1105358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1056%2FNEJMoa1105358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=22256804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yltr8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=207-215&author=F.+Suauthor=A.+Virosauthor=C.+Milagreauthor=K.+Trunzerauthor=G.+Bollagauthor=O.+Spleissauthor=J.+S.+Reis-Filhoauthor=X.+Kongauthor=R.+C.+Koyaauthor=K.+T.+Flahertyauthor=P.+B.+Chapmanauthor=M.+J.+Kimauthor=R.+Haywardauthor=M.+Martinauthor=H.+Yangauthor=Q.+Wangauthor=H.+Hiltonauthor=J.+S.+Hangauthor=J.+Noeauthor=M.+Lambrosauthor=F.+Geyerauthor=N.+Dhomenauthor=I.+Niculescu-Duvazauthor=A.+Zambonauthor=D.+Niculescu-Duvazauthor=N.+Preeceauthor=L.+Robertauthor=N.+J.+Otteauthor=S.+Mokauthor=D.+Keeauthor=Y.+Maauthor=C.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=H.+Nguyenauthor=M.+Kockxauthor=L.+Andriesauthor=B.+Lestiniauthor=K.+B.+Nolopauthor=R.+J.+Leeauthor=A.+K.+Joeauthor=J.+L.+Troyauthor=R.+Gonzalezauthor=T.+E.+Hutsonauthor=I.+Puzanovauthor=B.+Chmielowskiauthor=C.+J.+Springerauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=R.+S.+Loauthor=A.+Ribasauthor=R.+Marais&title=RAS+mutations+in+cutaneous+squamous-cell+carcinomas+in+patients+treated+with+BRAF+inhibitors&doi=10.1056%2FNEJMoa1105358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors</span></div><div class="casAuthors">Su, Fei; Viros, Amaya; Milagre, Carla; Trunzer, Kerstin; Bollag, Gideon; Spleiss, Olivia; Reis-Filho, Jorge S.; Kong, Xiangju; Koya, Richard C.; Flaherty, Keith T.; Chapman, Paul B.; Kim, Min Jung; Hayward, Robert; Martin, Matthew; Yang, Hong; Wang, Qiongqing; Hilton, Holly; Hang, Julie S.; Noe, Johannes; Lambros, Maryou; Geyer, Felipe; Dhomen, Nathalie; Niculescu-Duvaz, Ion; Zambon, Alfonso; Niculescu-Duvaz, Dan; Preece, Natasha; Robert, Lidia; Otte, Nicholas J.; Mok, Stephen; Kee, Damien; Ma, Yan; Zhang, Chao; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Nguyen, Hoa; Kockx, Mark; Andries, Luc; Lestini, Brian; Nolop, Keith B.; Lee, Richard J.; Joe, Andrew K.; Troy, James L.; Gonzalez, Rene; Hutson, Thomas E.; Puzanov, Igor; Chmielowski, Bartosz; Springer, Caroline J.; McArthur, Grant A.; Sosman, Jeffrey A.; Lo, Roger S.; Ribas, Antoni; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">207-215</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Cutaneous squamous-cell carcinomas and keratoacanthomas are common findings in patients treated with BRAF inhibitors.  METHODS: We performed a mol. anal. to identify oncogenic mutations (HRAS, KRAS, NRAS, CDKN2A, and TP53) in the lesions from patients treated with the BRAF inhibitor vemurafenib.  An anal. of an independent validation set and functional studies with BRAF inhibitors in the presence of the prevalent RAS mutation was also performed.  RESULTS: Among 21 tumor samples, 13 had RAS mutations (12 in HRAS).  In a validation set of 14 samples, 8 had RAS mutations (4 in HRAS).  Thus, 60% (21 of 35) of the specimens harbored RAS mutations, the most prevalent being HRAS Q61L.  Increased proliferation of HRAS Q61L-mutant cell lines exposed to vemurafenib was assocd. with mitogen-activated protein kinase (MAPK)-pathway signaling and activation of ERK-mediated transcription.  In a mouse model of HRAS Q61L-mediated skin carcinogenesis, the vemurafenib analog PLX4720 was not an initiator or a.promoter of carcinogenesis but accelerated growth of the lesions harboring HRAS mutations, and this growth was blocked by concomitant treatment with a MEK inhibitor.  CONCLUSIONS: Mutations in RAS, particularly HRAS, are frequent in cutaneous squamous-cell carcinomas and keratoacanthomas that develop in patients treated with vemurafenib.  The mol. mechanism is consistent with the paradoxical activation of MAPK signaling and leads to accelerated growth of these lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplrkvSEAdDG7Vg90H21EOLACvtfcHk0lhQNu8HOAs9eQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yltr8%253D&md5=6c813dc23344a8eedcc7a289d2326f4f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1105358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1105358%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DF.%26aulast%3DViros%26aufirst%3DA.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DTrunzer%26aufirst%3DK.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DSpleiss%26aufirst%3DO.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DKoya%26aufirst%3DR.%2BC.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DKim%26aufirst%3DM.%2BJ.%26aulast%3DHayward%26aufirst%3DR.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHilton%26aufirst%3DH.%26aulast%3DHang%26aufirst%3DJ.%2BS.%26aulast%3DNoe%26aufirst%3DJ.%26aulast%3DLambros%26aufirst%3DM.%26aulast%3DGeyer%26aufirst%3DF.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DNiculescu-Duvaz%26aufirst%3DI.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DPreece%26aufirst%3DN.%26aulast%3DRobert%26aufirst%3DL.%26aulast%3DOtte%26aufirst%3DN.%2BJ.%26aulast%3DMok%26aufirst%3DS.%26aulast%3DKee%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DKockx%26aufirst%3DM.%26aulast%3DAndries%26aufirst%3DL.%26aulast%3DLestini%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%2BB.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DJoe%26aufirst%3DA.%2BK.%26aulast%3DTroy%26aufirst%3DJ.%2BL.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DRAS%2520mutations%2520in%2520cutaneous%2520squamous-cell%2520carcinomas%2520in%2520patients%2520treated%2520with%2520BRAF%2520inhibitors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D207%26epage%3D215%26doi%3D10.1056%2FNEJMoa1105358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouary, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâDay, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkwood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggermont, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Group, B.-S.</span></span> <span> </span><span class="NLM_article-title">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">2507</span>â <span class="NLM_lpage">2516</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1103782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-2516&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthurauthor=B.-S.+Group&title=Improved+survival+with+vemurafenib+in+melanoma+with+BRAF+V600E+mutation&doi=10.1056%2FNEJMoa1103782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0lhQNu8HOAs9eQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DGroup%26aufirst%3DB.-S.%26atitle%3DImproved%2520survival%2520with%2520vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2507%26epage%3D2516%26doi%3D10.1056%2FNEJMoa1103782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroyakovskiy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levchenko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Braud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouary, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millward, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondarenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utikal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraresi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovalenko, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Probachai, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMarini, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irani, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K.</span></span> <span> </span><span class="NLM_article-title">Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">1877</span>â <span class="NLM_lpage">1888</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1406037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1056%2FNEJMoa1406037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=25265492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslGnuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=1877-1888&author=G.+V.+Longauthor=D.+Stroyakovskiyauthor=H.+Gogasauthor=E.+Levchenkoauthor=F.+de+Braudauthor=J.+Larkinauthor=C.+Garbeauthor=T.+Jouaryauthor=A.+Hauschildauthor=J.+J.+Grobauthor=V.+Chiarion+Sileniauthor=C.+Lebbeauthor=M.+Mandalaauthor=M.+Millwardauthor=A.+Aranceauthor=I.+Bondarenkoauthor=J.+B.+Haanenauthor=J.+Hanssonauthor=J.+Utikalauthor=V.+Ferraresiauthor=N.+Kovalenkoauthor=P.+Mohrauthor=V.+Probachaiauthor=D.+Schadendorfauthor=P.+Nathanauthor=C.+Robertauthor=A.+Ribasauthor=D.+J.+DeMariniauthor=J.+G.+Iraniauthor=M.+Caseyauthor=D.+Ouelletauthor=A.+M.+Martinauthor=N.+Leauthor=K.+Patelauthor=K.+Flaherty&title=Combined+BRAF+and+MEK+inhibition+versus+BRAF+inhibition+alone+in+melanoma&doi=10.1056%2FNEJMoa1406037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma</span></div><div class="casAuthors">Long, G. V.; Stroyakovskiy, D.; Gogas, H.; Levchenko, E.; de Braud, F.; Larkin, J.; Garbe, C.; Jouary, T.; Hauschild, A.; Grob, J. J.; Sileni, V. Chiarion; Lebbe, C.; Mandala, M.; Millward, M.; Arance, A.; Bondarenko, I.; Haanen, J. B. A. G.; Hansson, J.; Utikal, J.; Ferraresi, V.; Kovalenko, N.; Mohr, P.; Probachai, V.; Schadendorf, D.; Nathan, P.; Robert, C.; Ribas, A.; De Marini, D. J.; Irani, J. G.; Casey, M.; Ouellet, D.; Martin, A.-M.; Le, N.; Patel, K.; Flaherty, K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1877-1888, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone, delays the emergence of resistance and reduces toxic effects in patients who have melanoma with BRAF V600E or V600K mutations.  Methods: In this phase 3 trial, we randomly assigned 423 previously untreated patients who had unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K mutation to receive a combination of dabrafenib (150 mg orally twice daily) and trametinib (2 mg orally once daily) or dabrafenib and placebo.  The primary end point was progression-free survival.  Secondary end points included overall survival, response rate, response duration, and safety.  A preplanned interim overall survival anal. was conducted. Results: The median progression-free survival was 9.3 mo in the dabrafenib-trametinib group and 8.8 mo in the dabrafenib-only group (hazard ratio for progression or death in the dabrafenib-trametinib group, 0.75; 95% confidence interval [CI], 0.57 to 0.99; P = 0.03).  The overall response rate was 67% in the dabrafenib-trametinib group and 51% in the dabrafenib-only group (P = 0.002).  At 6 mo, the interim overall survival rate was 93% with dabrafenib-trametinib and 85% with dabrafenib alone (hazard ratio for death, 0.63; 95% CI, 0.42 to 0.94; P = 0.02).  However, a specified efficacy-stopping boundary (two-sided P = 0.00028) was not crossed.  Rates of adverse events were similar in the two groups, although more dose modifications occurred in the dabrafenib-trametinib group.  The rate of cutaneous squamous-cell carcinoma was lower in the dabrafenib-trametinib group than in the dabrafenib-only group (2% vs. 9%), whereas pyrexia occurred in more patients (51% vs. 28%) and was more often severe (grade 3, 6% vs. 2%) in the dabrafenib-trametinib group. Conclusions: A combination of dabrafenib and trametinib, as compared with dabrafenib alone, improved the rate of progression-free survival in previously untreated patients who had metastatic melanoma with BRAF V600E or V600K mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrV_cVsKKBhY7Vg90H21EOLACvtfcHk0lif-ldrblgopg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslGnuw%253D%253D&md5=65dbfbb0d9d16017ac58729326835724</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1406037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1406037%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DStroyakovskiy%26aufirst%3DD.%26aulast%3DGogas%26aufirst%3DH.%26aulast%3DLevchenko%26aufirst%3DE.%26aulast%3Dde%2BBraud%26aufirst%3DF.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DChiarion%2BSileni%26aufirst%3DV.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DMandala%26aufirst%3DM.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DHansson%26aufirst%3DJ.%26aulast%3DUtikal%26aufirst%3DJ.%26aulast%3DFerraresi%26aufirst%3DV.%26aulast%3DKovalenko%26aufirst%3DN.%26aulast%3DMohr%26aufirst%3DP.%26aulast%3DProbachai%26aufirst%3DV.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DDeMarini%26aufirst%3DD.%2BJ.%26aulast%3DIrani%26aufirst%3DJ.%2BG.%26aulast%3DCasey%26aufirst%3DM.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DLe%26aufirst%3DN.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DFlaherty%26aufirst%3DK.%26atitle%3DCombined%2520BRAF%2520and%2520MEK%2520inhibition%2520versus%2520BRAF%2520inhibition%2520alone%2520in%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D1877%26epage%3D1888%26doi%3D10.1056%2FNEJMoa1406037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Induced protein degradation: an emerging drug discovery paradigm</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">101</span>â <span class="NLM_lpage">114</span>, <span class="refDoi">Â DOI: 10.1038/nrd.2016.211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1038%2Fnrd.2016.211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=27885283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=101-114&author=A.+C.+Laiauthor=C.+M.+Crews&title=Induced+protein+degradation%3A+an+emerging+drug+discovery+paradigm&doi=10.1038%2Fnrd.2016.211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation: an emerging drug discovery paradigm</span></div><div class="casAuthors">Lai, Ashton C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-114</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function, and this approach typically precludes targeting proteins that lack such amenable sites.  Furthermore, high systemic drug exposures may be needed to maintain sufficient target inhibition in vivo, increasing the risk of undesirable off-target effects.  Induced protein degrdn. is an alternative approach that is event-driven: upon drug binding, the target protein is tagged for elimination.  Emerging technologies based on proteolysis-targeting chimaeras (PROTACs) that exploit cellular quality control machinery to selectively degrade target proteins are attracting considerable attention in the pharmaceutical industry owing to the advantages they could offer over traditional small-mol. strategies.  These advantages include the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj-O7zXGOpXLVg90H21EOLACvtfcHk0lhRvMjMSz-z7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP&md5=a01ff43e9b696fe4dc03f0815158a98f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.211%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DInduced%2520protein%2520degradation%253A%2520an%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D101%26epage%3D114%26doi%3D10.1038%2Fnrd.2016.211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Development of dual and selective degraders of cyclin-dependent kinases 4 and 6</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6321</span>â <span class="NLM_lpage">6326</span>, <span class="refDoi">Â DOI: 10.1002/anie.201901336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1002%2Fanie.201901336" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtlKqsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=6321-6326&author=B.+Jiangauthor=E.+S.+Wangauthor=K.+A.+Donovanauthor=Y.+Liangauthor=E.+S.+Fischerauthor=T.+Zhangauthor=N.+S.+Gray&title=Development+of+dual+and+selective+degraders+of+cyclin-dependent+kinases+4+and+6&doi=10.1002%2Fanie.201901336"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6</span></div><div class="casAuthors">Jiang, Baishan; Wang, Eric S.; Donovan, Katherine A.; Liang, Yanke; Fischer, Eric S.; Zhang, Tinghu; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6321-6326</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases 4 and 6 (CDK4/6) are key regulators of the cell cycle, and there are FDA-approved CDK4/6 inhibitors for treating patients with metastatic breast cancer.  However, due to conservation of their ATP-binding sites, development of selective agents has remained elusive.  Here, we report imide-based degrader mols. capable of degrading both CDK4/6, or selectively degrading either CDK4 or CDK6.  We were also able to tune the activity of these mols. against Ikaros (IKZF1) and Aiolos (IKZF3), which are well-established targets of imide-based degraders.  We found that in mantle cell lymphoma cell lines, combined IKZF1/3 degrdn. with dual CDK4/6 degrdn. produced enhanced anti-proliferative effects compared to CDK4/6 inhibition, CDK4/6 degrdn., or IKZF1/3 degrdn.  In summary, we report here the first compds. capable of inducing selective degrdn. of CDK4 and CDK6 as tools to pharmacol. dissect their distinct biol. functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_Vsqs-SM6hrVg90H21EOLACvtfcHk0lhRvMjMSz-z7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtlKqsrw%253D&md5=39a6937b24abad0940d359020e2b2f74</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fanie.201901336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201901336%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DE.%2BS.%26aulast%3DDonovan%26aufirst%3DK.%2BA.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520dual%2520and%2520selective%2520degraders%2520of%2520cyclin-dependent%2520kinases%25204%2520and%25206%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2019%26volume%3D58%26spage%3D6321%26epage%3D6326%26doi%3D10.1002%2Fanie.201901336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellerschmied, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salami, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Modular PROTAC design for the degradation of oncogenic BCR-ABL</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">807</span>â <span class="NLM_lpage">810</span>, <span class="refDoi">Â DOI: 10.1002/anie.201507634</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1002%2Fanie.201507634" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOlt7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=807-810&author=A.+C.+Laiauthor=M.+Toureauthor=D.+Hellerschmiedauthor=J.+Salamiauthor=S.+Jaime-Figueroaauthor=E.+Koauthor=J.+Hinesauthor=C.+M.+Crews&title=Modular+PROTAC+design+for+the+degradation+of+oncogenic+BCR-ABL&doi=10.1002%2Fanie.201507634"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL</span></div><div class="casAuthors">Lai, Ashton C.; Toure, Momar; Hellerschmied, Doris; Salami, Jemilat; Jaime-Figueroa, Saul; Ko, Eunhwa; Hines, John; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">807-810</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Proteolysis Targeting Chimera (PROTAC) technol. is a rapidly emerging alternative therapeutic strategy with the potential to address many of the challenges currently faced in modern drug development programs.  PROTAC technol. employs small mols. that recruit target proteins for ubiquitination and removal by the proteasome.  The synthesis of PROTAC compds. that mediate the degrdn. of c-ABL and BCR-ABL by recruiting either Cereblon or Von Hippel Lindau E3 ligases is reported.  During the course of their development, the authors discovered that the capacity of a PROTAC to induce degrdn. involves more than just target binding: the identity of the inhibitor warhead and the recruited E3 ligase largely det. the degrdn. profiles of the compds.; thus, as a starting point for PROTAC development, both the target ligand and the recruited E3 ligase should be varied to rapidly generate a PROTAC with the desired degrdn. profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdcSTHt5WfILVg90H21EOLACvtfcHk0lii6eFLI8Sftw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOlt7rN&md5=58a5d78f32bc8a21fd1a6e0c38b8979c</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fanie.201507634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201507634%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DToure%26aufirst%3DM.%26aulast%3DHellerschmied%26aufirst%3DD.%26aulast%3DSalami%26aufirst%3DJ.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DModular%2520PROTAC%2520design%2520for%2520the%2520degradation%2520of%2520oncogenic%2520BCR-ABL%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D807%26epage%3D810%26doi%3D10.1002%2Fanie.201507634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altieri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crew, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">755</span>â <span class="NLM_lpage">763</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2015.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2Fj.chembiol.2015.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=26051217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWrtbrM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=755-763&author=J.+Luauthor=Y.+Qianauthor=M.+Altieriauthor=H.+Dongauthor=J.+Wangauthor=K.+Rainaauthor=J.+Hinesauthor=J.+D.+Winklerauthor=A.+P.+Crewauthor=K.+Colemanauthor=C.+M.+Crews&title=Hijacking+the+E3+ubiquitin+ligase+cereblon+to+efficiently+target+BRD4&doi=10.1016%2Fj.chembiol.2015.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4</span></div><div class="casAuthors">Lu, Jing; Qian, Yimin; Altieri, Martha; Dong, Hanqing; Wang, Jing; Raina, Kanak; Hines, John; Winkler, James D.; Crew, Andrew P.; Coleman, Kevin; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">755-763</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">BRD4, a bromodomain and extraterminal domain (BET) family member, is an attractive target in multiple pathol. settings, particularly cancer.  While BRD4 inhibitors have shown some promise in MYC-driven malignancies such as Burkitt's lymphoma (BL), we show that BRD4 inhibitors lead to robust BRD4 protein accumulation, which may account for their limited suppression of MYC expression, modest antiproliferative activity, and lack of apoptotic induction.  To address these limitations we designed ARV-825, a hetero-bifunctional PROTAC (Proteolysis Targeting Chimera) that recruits BRD4 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degrdn. of BRD4 in all BL cell lines tested.  Consequently, ARV-825 more effectively suppresses c-MYC levels and downstream signaling than small-mol. BRD4 inhibitors, resulting in more effective cell proliferation inhibition and apoptosis induction in BL.  Our findings provide strong evidence that cereblon-based PROTACs provide a better and more efficient strategy in targeting BRD4 than traditional small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6Ol4grCG2RbVg90H21EOLACvtfcHk0lii6eFLI8Sftw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWrtbrM&md5=a64675e7a0cd006a8737be9730f447e3</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2015.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2015.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DAltieri%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DRaina%26aufirst%3DK.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrew%26aufirst%3DA.%2BP.%26aulast%3DColeman%26aufirst%3DK.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DHijacking%2520the%2520E3%2520ubiquitin%2520ligase%2520cereblon%2520to%2520efficiently%2520target%2520BRD4%26jtitle%3DChem.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D755%26epage%3D763%26doi%3D10.1016%2Fj.chembiol.2015.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Salas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McEachern, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przybranowski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuckey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meagher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziazadeh, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of QCA570 as an exceptionally potent and efficacious proteolysis targeting chimera (PROTAC) degrader of the bromodomain and extra-Terminal (BET) proteins capable of inducing complete and durable tumor regression</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6685</span>â <span class="NLM_lpage">6704</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00506</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00506" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlaqsLrE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6685-6704&author=C.+Qinauthor=Y.+Huauthor=B.+Zhouauthor=E.+Fernandez-Salasauthor=C.+Y.+Yangauthor=L.+Liuauthor=D.+McEachernauthor=S.+Przybranowskiauthor=M.+Wangauthor=J.+Stuckeyauthor=J.+Meagherauthor=L.+Baiauthor=Z.+Chenauthor=M.+Linauthor=J.+Yangauthor=D.+N.+Ziazadehauthor=F.+Xuauthor=J.+Huauthor=W.+Xiangauthor=L.+Huangauthor=S.+Liauthor=B.+Wenauthor=D.+Sunauthor=S.+Wang&title=Discovery+of+QCA570+as+an+exceptionally+potent+and+efficacious+proteolysis+targeting+chimera+%28PROTAC%29+degrader+of+the+bromodomain+and+extra-Terminal+%28BET%29+proteins+capable+of+inducing+complete+and+durable+tumor+regression&doi=10.1021%2Facs.jmedchem.8b00506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression</span></div><div class="casAuthors">Qin, Chong; Hu, Yang; Zhou, Bing; Fernandez-Salas, Ester; Yang, Chao-Yie; Liu, Liu; McEachern, Donna; Przybranowski, Sally; Wang, Mi; Stuckey, Jeanne; Meagher, Jennifer; Bai, Longchuan; Chen, Zhuo; Lin, Mei; Yang, Jiuling; Ziazadeh, Danya N.; Xu, Fuming; Hu, Jiantao; Xing, Weiguo; Huang, Liyue; Li, Siwei; Wen, Bo; Sun, Duxin; Wang, Shaomeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6685-6704</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Proteins of the bromodomain and extra-terminal (BET) family are epigenetics "readers" and promising therapeutic targets for cancer and other human diseases.  We describe herein a structure-guided design of [1,4]oxazepines as a new class of BET inhibitors and our subsequent design, synthesis, and evaluation of proteolysis-targeting chimeric (PROTAC) small-mol. BET degraders.  Our efforts have led to the discovery of extremely potent BET degraders, exemplified by QCA570, which effectively induces degrdn. of BET proteins and inhibits cell growth in human acute leukemia cell lines even at low picomolar concns.  QCA570 achieves complete and durable tumor regression in leukemia xenograft models in mice at well-tolerated dose-schedules.  QCA570 is the most potent and efficacious BET degrader reported to date.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6ZUIsfX3p6LVg90H21EOLACvtfcHk0liOUKR4vpF9dQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlaqsLrE&md5=2a731730641372f4526543e03d9ac76f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00506%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DFernandez-Salas%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DC.%2BY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMcEachern%26aufirst%3DD.%26aulast%3DPrzybranowski%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DStuckey%26aufirst%3DJ.%26aulast%3DMeagher%26aufirst%3DJ.%26aulast%3DBai%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DZiazadeh%26aufirst%3DD.%2BN.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DXiang%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520QCA570%2520as%2520an%2520exceptionally%2520potent%2520and%2520efficacious%2520proteolysis%2520targeting%2520chimera%2520%2528PROTAC%2529%2520degrader%2520of%2520the%2520bromodomain%2520and%2520extra-Terminal%2520%2528BET%2529%2520proteins%2520capable%2520of%2520inducing%2520complete%2520and%2520durable%2520tumor%2520regression%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6685%26epage%3D6704%26doi%3D10.1021%2Facs.jmedchem.8b00506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Remillard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brien, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonnett, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dastjerdi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuhr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span> <span> </span><span class="NLM_article-title">Degradation of the BAF complex factor BRD9 by heterobifunctional ligands</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5738</span>â <span class="NLM_lpage">5743</span>, <span class="refDoi">Â DOI: 10.1002/anie.201611281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1002%2Fanie.201611281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtFGrurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=5738-5743&author=D.+Remillardauthor=D.+L.+Buckleyauthor=J.+Paulkauthor=G.+L.+Brienauthor=M.+Sonnettauthor=H.+S.+Seoauthor=S.+Dastjerdiauthor=M.+Wuhrauthor=S.+Dhe-Paganonauthor=S.+A.+Armstrongauthor=J.+E.+Bradner&title=Degradation+of+the+BAF+complex+factor+BRD9+by+heterobifunctional+ligands&doi=10.1002%2Fanie.201611281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands</span></div><div class="casAuthors">Remillard, David; Buckley, Dennis L.; Paulk, Joshiawa; Brien, Gerard L.; Sonnett, Matthew; Seo, Hyuk-Soo; Dastierdi, Shiva; Wuehr, Martin; Dhe-Paganon, Sirano; Armstrong, Scott A.; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5738-5743</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The bromodomain-contg. protein BRD9, a subunit of the human BAF (SWI/SNF) nucleosome remodeling complex, has emerged as an attractive therapeutic target in cancer.  Despite the development of chem. probes targeting the BRD9 bromodomain, there is a limited understanding of BRD9 function beyond acetyl-lysine recognition.  We have therefore created the first BRD9-directed chem. degraders, through iterative design and testing of heterobifunctional ligands that bridge the BRD9 bromodomain and the cereblon E3 ubiquitin ligase complex.  Degraders of BRD9 exhibit markedly enhanced potency compared to parental ligands (10- to 100-fold).  Parallel study of degraders with divergent BRD9-binding chemotypes in models of acute myeloid leukemia resolves bromodomain polypharmacol. in this emerging drug class.  Together, these findings reveal the tractability of non-BET bromodomain contg. proteins to chem. degrdn., and highlight lead compd. dBRD9 as a tool for the study of BRD9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ9FU2Ipaq27Vg90H21EOLACvtfcHk0liOUKR4vpF9dQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtFGrurk%253D&md5=2eb6562cc9d976c7ae6070c9a419e9ea</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fanie.201611281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201611281%26sid%3Dliteratum%253Aachs%26aulast%3DRemillard%26aufirst%3DD.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DPaulk%26aufirst%3DJ.%26aulast%3DBrien%26aufirst%3DG.%2BL.%26aulast%3DSonnett%26aufirst%3DM.%26aulast%3DSeo%26aufirst%3DH.%2BS.%26aulast%3DDastjerdi%26aufirst%3DS.%26aulast%3DWuhr%26aufirst%3DM.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26aulast%3DArmstrong%26aufirst%3DS.%2BA.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DDegradation%2520of%2520the%2520BAF%2520complex%2520factor%2520BRD9%2520by%2520heterobifunctional%2520ligands%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D5738%26epage%3D5743%26doi%3D10.1002%2Fanie.201611281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Proteolysis targeting chimeras (PROTACs) of naplastic Lymphoma Kinase (ALK)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">304</span>â <span class="NLM_lpage">314</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2018.03.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2Fj.ejmech.2018.03.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=29627725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ejs7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=304-314&author=C.+Zhangauthor=X.+R.+Hanauthor=X.+Yangauthor=B.+Jiangauthor=J.+Liuauthor=Y.+Xiongauthor=J.+Jin&title=Proteolysis+targeting+chimeras+%28PROTACs%29+of+naplastic+Lymphoma+Kinase+%28ALK%29&doi=10.1016%2Fj.ejmech.2018.03.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Zhang, Chengwei; Han, Xiao-Ran; Yang, Xiaobao; Jiang, Biao; Liu, Jing; Xiong, Yue; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">304-314</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) activation has been assocd. with many types of human cancer.  Significant efforts have been devoted to the development of ALK inhibitors to antagonize the kinase activity of ALK.  Four ALK inhibitors have been approved by the FDA to date for treating patients with ALK-pos. nonsmall cell lung cancers (NSCLC).  However, drug resistance has been obsd. in the majority of patients treated with these inhibitors.  New therapeutic strategies (e.g., compds. with novel mechanisms of action) are needed to overcome the drug resistance issue.  The emerging PROTAC (Proteolysis Targeting Chimera) technol. has been successfully applied to selective degrdn. of multiple protein targets, but not ALK.  Since ALK protein levels are not important for viability in mammals, ALK PROTACs could lead to novel therapeutics with minimal toxicity.  Here the authors report the design, synthesis and biol. evaluation of novel PROTACs (degraders) of ALK.  MS4077 (I) and MS4078 (II) potently decreased cellular levels of oncogenic active ALK fusion proteins in a concn.- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells.  The ALK protein degrdn. induced by compds. I and II was cereblon and proteasome dependent.  In addn., compds. I and II potently inhibited proliferation of SU-DHL-1 cells.  Furthermore, compd. II displayed good plasma exposure in a mouse pharmacokinetic study, thus is suitable for in vivo efficacy studies.  The authors also developed MS4748 and MS4740 , very close analogs of I and II resp., which are incapable to degrade the ALK fusion proteins, as neg. controls.  All 4 compds. are valuable chem. tools for investigating effects of ALK pharmacol. degrdn.  The study paved the way for developing the next generation of ALK PROTACs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPGM3aAZZ6h7Vg90H21EOLACvtfcHk0liqQxCzhZf3TQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ejs7Y%253D&md5=804324b95034f38b46e45f89e18e55be</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.071%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DX.%2BR.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DProteolysis%2520targeting%2520chimeras%2520%2528PROTACs%2529%2520of%2520naplastic%2520Lymphoma%2520Kinase%2520%2528ALK%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D304%26epage%3D314%26doi%3D10.1016%2Fj.ejmech.2018.03.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, K.</span></span> <span> </span><span class="NLM_article-title">PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer</span>. <i>Chem. Commun. (Cambridge, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2704</span>â <span class="NLM_lpage">2707</span>, <span class="refDoi">Â DOI: 10.1039/C9CC00163H</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1039%2FC9CC00163H" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=30758029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtFGht7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2019&pages=2704-2707&author=B.+Zhaoauthor=K.+Burgess&title=PROTACs+suppression+of+CDK4%2F6%2C+crucial+kinases+for+cell+cycle+regulation+in+cancer&doi=10.1039%2FC9CC00163H"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer</span></div><div class="casAuthors">Zhao, Bosheng; Burgess, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2704-2707</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">PROTACs based on two selective, FDA approved, CDK4/6 inhibitors were formed.  One of them, based on palbociclib, potently initiates degrdn. of these CDK proteins, and suppresses phosphorylation of retinoblastoma protein (Rb) leading to cell cycle arrest.  These PROTACs are active at nanomolar concns., and appear to be the first for CDK4/6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBWDRf65Fl6bVg90H21EOLACvtfcHk0liqQxCzhZf3TQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtFGht7c%253D&md5=8798e9aa7ecc0e6504c2717e815b04fc</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1039%2FC9CC00163H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9CC00163H%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DB.%26aulast%3DBurgess%26aufirst%3DK.%26atitle%3DPROTACs%2520suppression%2520of%2520CDK4%252F6%252C%2520crucial%2520kinases%2520for%2520cell%2520cycle%2520regulation%2520in%2520cancer%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2019%26volume%3D55%26spage%3D2704%26epage%3D2707%26doi%3D10.1039%2FC9CC00163H" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zoppi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maniaci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmaschitz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieshofer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koegl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riching, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spallarossa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciulli, A.</span></span> <span> </span><span class="NLM_article-title">Iterative design and optimization of initially inactive proteolysis targeting chimeras (PROTACs) identify VZ185 as a potent, fast, and selective von Hippel-Lindau (VHL) based dual degrader probe of BRD9 and BRD7</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">699</span>â <span class="NLM_lpage">726</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b01413</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01413" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVyhsLjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=699-726&author=V.+Zoppiauthor=S.+J.+Hughesauthor=C.+Maniaciauthor=A.+Testaauthor=T.+Gmaschitzauthor=C.+Wieshoferauthor=M.+Koeglauthor=K.+M.+Richingauthor=D.+L.+Danielsauthor=A.+Spallarossaauthor=A.+Ciulli&title=Iterative+design+and+optimization+of+initially+inactive+proteolysis+targeting+chimeras+%28PROTACs%29+identify+VZ185+as+a+potent%2C+fast%2C+and+selective+von+Hippel-Lindau+%28VHL%29+based+dual+degrader+probe+of+BRD9+and+BRD7&doi=10.1021%2Facs.jmedchem.8b01413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7</span></div><div class="casAuthors">Zoppi, Vittoria; Hughes, Scott J.; Maniaci, Chiara; Testa, Andrea; Gmaschitz, Teresa; Wieshofer, Corinna; Koegl, Manfred; Riching, Kristin M.; Daniels, Danette L.; Spallarossa, Andrea; Ciulli, Alessio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">699-726</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Developing PROTACs to redirect the ubiquitination activity of E3 ligases and potently degrade a target protein within cells can be a lengthy and unpredictable process, and it remains unclear whether any combination of E3 and target might be productive for degrdn.  The authors describe a probe-quality degrader for a ligase-target pair deemed unsuitable: the von Hippel-Lindau (VHL) and BRD9, a bromodomain-contg. subunit of the SWI/SNF chromatin remodeling complex BAF.  VHL-based degraders could be optimized from suboptimal compds. in two rounds by systematically varying conjugation patterns and linkers and monitoring cellular degrdn. activities, kinetic profiles, and ubiquitination, as well as ternary complex formation thermodn.  The emerged structure-activity relations guided the discovery of VZ185, a potent, fast, and selective degrader of BRD9 and of its close homolog BRD7.  The authors' findings qualify a new chem. tool for BRD7/9 knockdown and provide a roadmap for PROTAC development against seemingly incompatible target-ligase combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiPnajotKvqLVg90H21EOLACvtfcHk0li7LEcxkkabrw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVyhsLjN&md5=be7938c26807a2535b7f9b7de8ebfbb0</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01413%26sid%3Dliteratum%253Aachs%26aulast%3DZoppi%26aufirst%3DV.%26aulast%3DHughes%26aufirst%3DS.%2BJ.%26aulast%3DManiaci%26aufirst%3DC.%26aulast%3DTesta%26aufirst%3DA.%26aulast%3DGmaschitz%26aufirst%3DT.%26aulast%3DWieshofer%26aufirst%3DC.%26aulast%3DKoegl%26aufirst%3DM.%26aulast%3DRiching%26aufirst%3DK.%2BM.%26aulast%3DDaniels%26aufirst%3DD.%2BL.%26aulast%3DSpallarossa%26aufirst%3DA.%26aulast%3DCiulli%26aufirst%3DA.%26atitle%3DIterative%2520design%2520and%2520optimization%2520of%2520initially%2520inactive%2520proteolysis%2520targeting%2520chimeras%2520%2528PROTACs%2529%2520identify%2520VZ185%2520as%2520a%2520potent%252C%2520fast%252C%2520and%2520selective%2520von%2520Hippel-Lindau%2520%2528VHL%2529%2520based%2520dual%2520degrader%2520probe%2520of%2520BRD9%2520and%2520BRD7%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D699%26epage%3D726%26doi%3D10.1021%2Facs.jmedchem.8b01413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agianian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span> <span> </span><span class="NLM_article-title">Current insights of BRAF inhibitors in cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5775</span>â <span class="NLM_lpage">5793</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b01306</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01306" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFChu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5775-5793&author=B.+Agianianauthor=E.+Gavathiotis&title=Current+insights+of+BRAF+inhibitors+in+cancer&doi=10.1021%2Facs.jmedchem.7b01306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Current Insights of BRAF Inhibitors in Cancer</span></div><div class="casAuthors">Agianian, Bogos; Gavathiotis, Evripidis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5775-5793</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oncogenic BRAF kinase deregulates the ERK signaling pathway in a large no. of human tumors.  FDA-approved BRAF inhibitors for BRAFV600E/K tumors have provided impressive clin. responses extending survival of melanoma patients.  However, these drugs display paradoxical activation in normal tissue with BRAFWT due to RAF transactivation and priming, acquired drug resistance, and limited clin. effectiveness in non-V600 BRAF-dependent tumors, underscoring the urgent need to develop improved BRAF inhibitors.  This review provides an overview of recent structural and biochem. insights into the mechanisms of BRAF regulation by BRAF inhibitors that are linked to their clin. activity, clin. liabilities, and medicinal chem. properties.  The effectiveness and challenges of structurally diverse next generation RAF inhibitors currently in preclin. and clin. development are discussed, along with mechanistic insights for developing more effective RAF inhibitors targeting different oncogenic BRAF conformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFSsceLmTALVg90H21EOLACvtfcHk0li7LEcxkkabrw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFChu70%253D&md5=7dcd6ce731bb591ecfac244b3b2b9b32</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01306%26sid%3Dliteratum%253Aachs%26aulast%3DAgianian%26aufirst%3DB.%26aulast%3DGavathiotis%26aufirst%3DE.%26atitle%3DCurrent%2520insights%2520of%2520BRAF%2520inhibitors%2520in%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5775%26epage%3D5793%26doi%3D10.1021%2Facs.jmedchem.7b01306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spevak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAndrea, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grippo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathanson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span> <span> </span><span class="NLM_article-title">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>467</i></span>,  <span class="NLM_fpage">596</span>â <span class="NLM_lpage">599</span>, <span class="refDoi">Â DOI: 10.1038/nature09454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1038%2Fnature09454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=20823850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=596-599&author=G+H.+P.+Bollagauthor=P.+Hirthauthor=J.+Tsaiauthor=J.+Zhangauthor=P.+N.+Ibrahimauthor=H.+Choauthor=W.+Spevakauthor=C.+Zhangauthor=Y.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=G.+Tsangauthor=B.+L.+Westauthor=B.+Powellauthor=R.+Shellooeauthor=A.+Marimuthuauthor=H.+Nguyenauthor=K.+Y.+Zhangauthor=D.+R.+Artisauthor=J.+Schlessingerauthor=F.+Suauthor=B.+Higginsauthor=R.+Iyerauthor=K.+D%E2%80%99Andreaauthor=A.+Koehlerauthor=M.+Stummauthor=P.+S.+Linauthor=R.+J.+Leeauthor=J.+Grippoauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+B.+Chapmanauthor=K.+T.+Flahertyauthor=X.+Xuauthor=K.+L.+Nathansonauthor=K.+Nolop&title=Clinical+efficacy+of+a+RAF+inhibitor+needs+broad+target+blockade+in+BRAF-mutant+melanoma&doi=10.1038%2Fnature09454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span></div><div class="casAuthors">Bollag, Gideon; Hirth, Peter; Tsai, James; Zhang, Jiazhong; Ibrahim, Prabha N.; Cho, Hanna; Spevak, Wayne; Zhang, Chao; Zhang, Ying; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Tsang, Garson; West, Brian L.; Powell, Ben; Shellooe, Rafe; Marimuthu, Adhirai; Nguyen, Hoa; Zhang, Kam Y. J.; Artis, Dean R.; Schlessinger, Joseph; Su, Fei; Higgins, Brian; Iyer, Raman; D'Andrea, Kurt; Koehler, Astrid; Stumm, Michael; Lin, Paul S.; Lee, Richard J.; Grippo, Joseph; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; Chapman, Paul B.; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.; Nolop, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">596-599</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B-RAF is the most frequently mutated protein kinase in human cancers.  The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway, offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients.  Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity.  Preclin. expts. demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts.  Toxicol. studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clin. trials using a cryst. formulation of PLX4032 (ref. 5).  In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following 2 wk of treatment.  This anal. revealed substantial inhibition of ERK phosphorylation, yet clin. evaluation did not show tumor regressions.  At higher drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK phosphorylation in the tumors of patients correlated with clin. response.  Indeed, the Phase 1 clin. data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily.  These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYwlns1EfcLVg90H21EOLACvtfcHk0ljDGz9Gy9dKFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK&md5=8a26d0ab41970f39a109ddafff2f17b4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnature09454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09454%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG%2BH.%2BP.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DKoehler%26aufirst%3DA.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DNolop%26aufirst%3DK.%26atitle%3DClinical%2520efficacy%2520of%2520a%2520RAF%2520inhibitor%2520needs%2520broad%2520target%2520blockade%2520in%2520BRAF-mutant%2520melanoma%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D596%26epage%3D599%26doi%3D10.1038%2Fnature09454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waizenegger, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steurer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmuller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaaf, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garin-Chesa, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlattl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweifer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haslinger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colbatzky, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mousa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalkuhl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraut, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adolf, G. R.</span></span> <span> </span><span class="NLM_article-title">A Novel RAF kinase inhibitor with DFG-out-binding mode: high efficacy in BRAF-mutant tumor xenograft models in the absence of normal tissue hyperproliferation</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">354</span>â <span class="NLM_lpage">365</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-15-0617</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1158%2F1535-7163.MCT-15-0617" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=26916115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslCms7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=354-365&author=I.+C.+Waizeneggerauthor=A.+Baumauthor=S.+Steurerauthor=H.+Stadtmullerauthor=G.+Baderauthor=O.+Schaafauthor=P.+Garin-Chesaauthor=A.+Schlattlauthor=N.+Schweiferauthor=C.+Haslingerauthor=F.+Colbatzkyauthor=S.+Mousaauthor=A.+Kalkuhlauthor=N.+Krautauthor=G.+R.+Adolf&title=A+Novel+RAF+kinase+inhibitor+with+DFG-out-binding+mode%3A+high+efficacy+in+BRAF-mutant+tumor+xenograft+models+in+the+absence+of+normal+tissue+hyperproliferation&doi=10.1158%2F1535-7163.MCT-15-0617"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation</span></div><div class="casAuthors">Waizenegger, Irene C.; Baum, Anke; Steurer, Steffen; Stadtmuller, Heinz; Bader, Gerd; Schaaf, Otmar; Garin-Chesa, Pilar; Schlattl, Andreas; Schweifer, Norbert; Haslinger, Christian; Colbatzky, Florian; Mousa, Sien; Kalkuhl, Arno; Kraut, Norbert; Adolf, Gunther R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">354-365</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">BI 882370 is a highly potent and selective RAF inhibitor that binds to the DFG-out (inactive) conformation of the BRAF kinase.  The compd. inhibited proliferation of human BRAF-mutant melanoma cells with 100Ã higher potency (1-10 nmol/L) than vemurafenib, whereas wild-type cells were not affected at 1,000 nmol/L.  BI 882370 administered orally was efficacious in multiple mouse models of BRAF-mutant melanomas and colorectal carcinomas, and at 25 mg/kg twice daily showed superior efficacy compared with vemurafenib, dabrafenib, or trametinib (dosed to provide exposures reached in patients).  To model drug resistance, A375 melanoma-bearing mice were initially treated with vemurafenib; all tumors responded with regression, but the majority subsequently resumed growth.  Trametinib did not show any efficacy in this progressing population.  BI 882370 induced tumor regression; however, resistance developed within 3 wk.  BI 882370 in combination with trametinib resulted in more pronounced regressions, and resistance was not obsd. during 5 wk of second-line therapy.  Importantly, mice treated with BI 882370 did not show any body wt. loss or clin. signs of intolerability, and no pathol. changes were obsd. in several major organs investigated, including skin.  Furthermore, a pilot study in rats (up to 60 mg/kg daily for 2 wk) indicated lack of toxicity in terms of clin. chem., hematol., pathol., and toxicogenomics.  Our results indicate the feasibility of developing novel compds. that provide an improved therapeutic window compared with first-generation BRAF inhibitors, resulting in more pronounced and long-lasting pathway suppression and thus improved efficacy.  Mol Cancer Ther; 15(3); 354-65. Â©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmtRl_zbyDibVg90H21EOLACvtfcHk0ljK71KiVFrdMg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslCms7Y%253D&md5=e35140e31364622de51538b99618001a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-0617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-0617%26sid%3Dliteratum%253Aachs%26aulast%3DWaizenegger%26aufirst%3DI.%2BC.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DSteurer%26aufirst%3DS.%26aulast%3DStadtmuller%26aufirst%3DH.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DSchaaf%26aufirst%3DO.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DSchlattl%26aufirst%3DA.%26aulast%3DSchweifer%26aufirst%3DN.%26aulast%3DHaslinger%26aufirst%3DC.%26aulast%3DColbatzky%26aufirst%3DF.%26aulast%3DMousa%26aufirst%3DS.%26aulast%3DKalkuhl%26aufirst%3DA.%26aulast%3DKraut%26aufirst%3DN.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26atitle%3DA%2520Novel%2520RAF%2520kinase%2520inhibitor%2520with%2520DFG-out-binding%2520mode%253A%2520high%2520efficacy%2520in%2520BRAF-mutant%2520tumor%2520xenograft%2520models%2520in%2520the%2520absence%2520of%2520normal%2520tissue%2520hyperproliferation%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D354%26epage%3D365%26doi%3D10.1158%2F1535-7163.MCT-15-0617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grasso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ventocilla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samanta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maksimoska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villanueva, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmorstein, R.</span></span> <span> </span><span class="NLM_article-title">Chemically linked vemurafenib inhibitors promote an inactive BRAF<sup>V600E</sup> Conformation</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2876</span>â <span class="NLM_lpage">2888</span>, <span class="refDoi">Â DOI: 10.1021/acschembio.6b00529</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00529" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWltrrI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2876-2888&author=M.+Grassoauthor=M.+A.+Estradaauthor=C.+Ventocillaauthor=M.+Samantaauthor=J.+Maksimoskaauthor=J.+Villanuevaauthor=J.+D.+Winklerauthor=R.+Marmorstein&title=Chemically+linked+vemurafenib+inhibitors+promote+an+inactive+BRAFV600E+Conformation&doi=10.1021%2Facschembio.6b00529"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation</span></div><div class="casAuthors">Grasso, Michael; Estrada, Michelle A.; Ventocilla, Christian; Samanta, Minu; Maksimoska, Jasna; Villanueva, Jessie; Winkler, Jeffrey D.; Marmorstein, Ronen</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2876-2888</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The BRAF kinase, within the mitogen activated protein kinase (MAPK) signaling pathway, harbors activating mutations in about half of melanomas and to a significant extent in many other cancers.  A single valine to glutamic acid substitution at residue 600 (BRAFV600E) accounts for about 90% of these activating mutations.  While BRAFV600E-selective small mol. inhibitors, such as debrafenib and vemurafenib, have shown therapeutic benefit, almost all patients develop resistance.  Resistance often arises through reactivation of the MAPK pathway, typically through mutation of upstream RAS, downstream MEK or splicing variants.  RAF kinases signal as homo- and hetero-dimers, and another complication assocd. with small mol. BRAFV600E inhibition is drug-induced allosteric activation of a wild-type RAF subunit (BRAF or CRAF) of the kinase dimer, a process called 'transactivation' or 'paradoxical activation.'.  Here the authors used BRAFV600E and vemurafenib as a model system to develop chem. linked kinase inhibitors to lock RAF dimers in an inactive conformation that cannot undergo transactivation.  This structure-based design effort resulted in the development of Vem-BisAmide-2, a compd. contg. two vemurafenib mols. connected by a bis amide linker.  The authors show that Vem-BisAmide-2 has comparable inhibitory potency as vemurafenib to BRAFV600E both in vitro and in cells, but promotes an inactive dimeric BRAFV600E conformation unable to undergo transactivation.  The crystal structure of a BRAFV600E/Vem-BisAmide-2 complex and assocd. biochem. studies reveal the mol. basis for how Vem-BisAmide-2 mediates selectivity for an inactive over active dimeric BRAFV600E conformation.  These studies have implications for targeting BRAFV600E/RAF heterodimers and other kinase dimers for therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZNAGDkAWOH7Vg90H21EOLACvtfcHk0ljK71KiVFrdMg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWltrrI&md5=6cecaff8b365aa21bce67243a1654241</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00529%26sid%3Dliteratum%253Aachs%26aulast%3DGrasso%26aufirst%3DM.%26aulast%3DEstrada%26aufirst%3DM.%2BA.%26aulast%3DVentocilla%26aufirst%3DC.%26aulast%3DSamanta%26aufirst%3DM.%26aulast%3DMaksimoska%26aufirst%3DJ.%26aulast%3DVillanueva%26aufirst%3DJ.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DMarmorstein%26aufirst%3DR.%26atitle%3DChemically%2520linked%2520vemurafenib%2520inhibitors%2520promote%2520an%2520inactive%2520BRAFV600E%2520Conformation%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D2876%26epage%3D2888%26doi%3D10.1021%2Facschembio.6b00529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haass, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sproesser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settachatgul, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantwell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">3041</span>â <span class="NLM_lpage">3046</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0711741105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1073%2Fpnas.0711741105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=18287029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=3041-3046&author=J.+Tsaiauthor=J.+T.+Leeauthor=W.+Wangauthor=J.+Zhangauthor=H.+Choauthor=S.+Mamoauthor=R.+Bremerauthor=S.+Gilletteauthor=J.+Kongauthor=N.+K.+Haassauthor=K.+Sproesserauthor=L.+Liauthor=K.+S.+Smalleyauthor=D.+Fongauthor=Y.+L.+Zhuauthor=A.+Marimuthuauthor=H.+Nguyenauthor=B.+Lamauthor=J.+Liuauthor=I.+Cheungauthor=J.+Riceauthor=Y.+Suzukiauthor=C.+Luuauthor=C.+Settachatgulauthor=R.+Shellooeauthor=J.+Cantwellauthor=S.+H.+Kimauthor=J.+Schlessingerauthor=K.+Y.+Zhangauthor=B.+L.+Westauthor=B.+Powellauthor=G.+Habetsauthor=C.+Zhangauthor=P.+N.+Ibrahimauthor=P.+Hirthauthor=D.+R.+Artisauthor=M.+Herlynauthor=G.+Bollag&title=Discovery+of+a+selective+inhibitor+of+oncogenic+B-Raf+kinase+with+potent+antimelanoma+activity&doi=10.1073%2Fpnas.0711741105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span></div><div class="casAuthors">Tsai, James; Lee, John T.; Wang, Weiru; Zhang, Jiazhong; Cho, Hanna; Mamo, Shumeye; Bremer, Ryan; Gillette, Sam; Kong, Jun; Haass, Nikolas K.; Sproesser, Katrin; Li, Ling; Smalley, Keiran S. M.; Fong, Daniel; Zhu, Yong-Liang; Marimuthu, Adhirai; Nguyen, Hoa; Lam, Billy; Liu, Jennifer; Cheung, Ivana; Rice, Julie; Suzuki, Yoshihisa; Luu, Catherine; Settachatgul, Calvin; Shellooe, Rafe; Cantwell, John; Kim, Sung-Hou; Schlessinger, Joseph; Zhang, Kam Y. J.; West, Brian L.; Powell, Ben; Habets, Gaston; Zhang, Chao; Ibrahim, Prabha N.; Hirth, Peter; Artis, Dean R.; Herlyn, Meenhard; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3041-3046</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">BRAFV600E is the most frequent oncogenic protein kinase mutation known.  Furthermore, inhibitors targeting "active" protein kinases have demonstrated significant utility in the therapeutic repertoire against cancer.  Therefore, the authors pursued the development of specific kinase inhibitors targeting B-Raf, and the V600E allele in particular.  By using a structure-guided discovery approach, a potent and selective inhibitor of active B-Raf has been discovered.  PLX4720, a 7-azaindole deriv. that inhibits B-RafV600E with an IC50 of 13 nM, defines a class of kinase inhibitor with marked selectivity in both biochem. and cellular assays.  PLX4720 preferentially inhibits the active B-RafV600E kinase compared with a broad spectrum of other kinases, and potent cytotoxic effects are also exclusive to cells bearing the V600E allele.  Consistent with the high degree of selectivity, ERK phosphorylation is potently inhibited by PLX4720 in B-RafV600E-bearing tumor cell lines but not in cells lacking oncogenic B-Raf.  In melanoma models, PLX4720 induces cell cycle arrest and apoptosis exclusively in B-RafV600E-pos. cells.  In B-RafV600E-dependent tumor xenograft models, orally dosed PLX4720 causes significant tumor growth delays, including tumor regressions, without evidence of toxicity.  The work described here represents the entire discovery process, from initial identification through structural and biol. studies in animal models to a promising therapeutic for testing in cancer patients bearing B-RafV600E-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPX53IQCbDJ7Vg90H21EOLACvtfcHk0li1Wkluz1NNmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D&md5=273b94202f99984e6eb24723d0c6141f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0711741105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0711741105%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DMamo%26aufirst%3DS.%26aulast%3DBremer%26aufirst%3DR.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DHaass%26aufirst%3DN.%2BK.%26aulast%3DSproesser%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DY.%2BL.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCheung%26aufirst%3DI.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DSettachatgul%26aufirst%3DC.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DCantwell%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520selective%2520inhibitor%2520of%2520oncogenic%2520B-Raf%2520kinase%2520with%2520potent%2520antimelanoma%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D3041%26epage%3D3046%26doi%3D10.1073%2Fpnas.0711741105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karoulia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">New perspectives for targeting RAF kinase in human cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">676</span>â <span class="NLM_lpage">691</span>, <span class="refDoi">Â DOI: 10.1038/nrc.2017.79</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1038%2Fnrc.2017.79" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=28984291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Sqt7fN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=676-691&author=Z.+Karouliaauthor=E.+Gavathiotisauthor=P.+I.+Poulikakos&title=New+perspectives+for+targeting+RAF+kinase+in+human+cancer&doi=10.1038%2Fnrc.2017.79"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">New perspectives for targeting RAF kinase in human cancer</span></div><div class="casAuthors">Karoulia, Zoi; Gavathiotis, Evripidis; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">676-691</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The discovery that a subset of human tumors is dependent on mutationally deregulated BRAF kinase intensified the development of RAF inhibitors to be used as potential therapeutics.  The US Food and Drug Administration (FDA)-approved second-generation RAF inhibitors vemurafenib and dabrafenib have elicited remarkable responses and improved survival of patients with BRAF-V600E/K melanoma, but their effectiveness is limited by resistance.  Beyond melanoma, current clin. RAF inhibitors show modest efficacy when used for colorectal and thyroid BRAF-V600E tumors or for tumors harboring BRAF alterations other than the V600 mutation.  Accumulated exptl. and clin. evidence indicates that the complex biochem. mechanisms of RAF kinase signalling account both for the effectiveness of RAF inhibitors and for the various mechanisms of tumor resistance to them.  Recently, a no. of next-generation RAF inhibitors, with diverse structural and biochem. properties, have entered preclin. and clin. development.  In this Review, we discuss the current understanding of RAF kinase regulation, mechanisms of inhibitor action and related clin. resistance to these drugs.  The recent elucidation of crit. structural and biochem. aspects of RAF inhibitor action, combined with the availability of a no. of structurally diverse RAF inhibitors currently in preclin. and clin. development, will enable the design of more effective RAF inhibitors and RAF-inhibitor-based therapeutic strategies, tailored to different clin. contexts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEUrKAljS7SrVg90H21EOLACvtfcHk0liFuSM6ognDPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Sqt7fN&md5=7e8ee4222467a2d5c12b23ccce99fc62</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2017.79&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2017.79%26sid%3Dliteratum%253Aachs%26aulast%3DKaroulia%26aufirst%3DZ.%26aulast%3DGavathiotis%26aufirst%3DE.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DNew%2520perspectives%2520for%2520targeting%2520RAF%2520kinase%2520in%2520human%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D676%26epage%3D691%26doi%3D10.1038%2Fnrc.2017.79" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dankner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, A. A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajkumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, I. R.</span></span> <span> </span><span class="NLM_article-title">Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">3183</span>â <span class="NLM_lpage">3199</span>, <span class="refDoi">Â DOI: 10.1038/s41388-018-0171-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1038%2Fs41388-018-0171-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=29540830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlt1Wit74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=3183-3199&author=M.+Danknerauthor=A.+A.+N.+Roseauthor=S.+Rajkumarauthor=P.+M.+Siegelauthor=I.+R.+Watson&title=Classifying+BRAF+alterations+in+cancer%3A+new+rational+therapeutic+strategies+for+actionable+mutations&doi=10.1038%2Fs41388-018-0171-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations</span></div><div class="casAuthors">Dankner, Matthew; Rose, April A. N.; Rajkumar, Shivshankari; Siegel, Peter M.; Watson, Ian R.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">3183-3199</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  The RAS-RAF-MEK-ERK signaling cascade is among the most frequently mutated pathways in human cancer.  Approx. 50% of melanoma patients possess a druggable hotspot V600E/K mutation in the BRAF protein kinase.  FDA-approved combination therapies of BRAF and MEK inhibitors are available that provide survival benefits to patients with a BRAF V600 mutation.  Non-V600 BRAF mutants are found in many cancers, and are more prevalent than V600 mutations in certain tumor types.  For example, between 50-80% of BRAF mutations in non-small cell lung cancer and 22-30% in colorectal cancer encode for non-V600 mutants.  As next generation sequencing becomes increasingly used in clin. practice, oncologists are frequently identifying non-V600 BRAF mutations in their patient's tumors, but are uncertain of viable therapeutic options that could be employed for optimal treatment.  From recent studies, a new classification system is emerging for BRAF mutations based on biochem. and signaling mechanisms assocd. with these mutants.  Class I BRAF mutations affect amino acid V600 and signal as RAS-independent active monomers, class II mutations function as RAS-independent activated dimers, and class III mutations are kinase impaired but increase signaling through the MAPK pathway due to enhanced RAS binding and subsequent CRAF activation.  These distinct classes of BRAF mutations predict response to targeted therapies and have important implications for future drug development.  Herein, we discuss pre-clin. and clin. findings that may lead to improved treatments for all classes of BRAF mutant cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXl1dLNrtnkbVg90H21EOLACvtfcHk0liFuSM6ognDPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlt1Wit74%253D&md5=2519c19c80ce42b421e3c40269df24e3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0171-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0171-x%26sid%3Dliteratum%253Aachs%26aulast%3DDankner%26aufirst%3DM.%26aulast%3DRose%26aufirst%3DA.%2BA.%2BN.%26aulast%3DRajkumar%26aufirst%3DS.%26aulast%3DSiegel%26aufirst%3DP.%2BM.%26aulast%3DWatson%26aufirst%3DI.%2BR.%26atitle%3DClassifying%2520BRAF%2520alterations%2520in%2520cancer%253A%2520new%2520rational%2520therapeutic%2520strategies%2520for%2520actionable%2520mutations%26jtitle%3DOncogene%26date%3D2018%26volume%3D37%26spage%3D3183%26epage%3D3199%26doi%3D10.1038%2Fs41388-018-0171-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bondeson, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burslem, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhimschi, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hines, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishchenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">78</span>â <span class="NLM_lpage">87</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2017.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2Fj.chembiol.2017.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=29129718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=78-87&author=D.+P.+Bondesonauthor=B.+E.+Smithauthor=G.+M.+Burslemauthor=A.+D.+Buhimschiauthor=J.+Hinesauthor=S.+Jaime-Figueroaauthor=J.+Wangauthor=B.+D.+Hammanauthor=A.+Ishchenkoauthor=C.+M.+Crews&title=Lessons+in+PROTAC+Design+from+Selective+Degradation+with+a+Promiscuous+Warhead&doi=10.1016%2Fj.chembiol.2017.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead</span></div><div class="casAuthors">Bondeson, Daniel P.; Smith, Blake E.; Burslem, George M.; Buhimschi, Alexandru D.; Hines, John; Jaime-Figueroa, Saul; Wang, Jing; Hamman, Brian D.; Ishchenko, Alexey; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">78-87.e5</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Inhibiting protein function selectively is a major goal of modern drug discovery.  Here, we report a previously understudied benefit of small mol. proteolysis-targeting chimeras (PROTACs) that recruit E3 ubiquitin ligases to target proteins for their ubiquitination and subsequent proteasome-mediated degrdn.  Using promiscuous CRBN- and VHL-recruiting PROTACs that bind >50 kinases, we show that only a subset of bound targets is degraded.  The basis of this selectivity relies on protein-protein interactions between the E3 ubiquitin ligase and the target protein, as illustrated by engaged proteins that are not degraded as a result of unstable ternary complexes with PROTAC-recruited E3 ligases.  In contrast, weak PROTAC:target protein affinity can be stabilized by high-affinity target:PROTAC:ligase trimer interactions, leading to efficient degrdn.  This study highlights design guidelines for generating potent PROTACs as well as possibilities for degrading undruggable proteins immune to traditional small-mol. inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoISOBudOLyFrVg90H21EOLACvtfcHk0liC4xzriT-kWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjN&md5=30fac502705a2344c4261cf531e6bf9d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DBondeson%26aufirst%3DD.%2BP.%26aulast%3DSmith%26aufirst%3DB.%2BE.%26aulast%3DBurslem%26aufirst%3DG.%2BM.%26aulast%3DBuhimschi%26aufirst%3DA.%2BD.%26aulast%3DHines%26aufirst%3DJ.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHamman%26aufirst%3DB.%2BD.%26aulast%3DIshchenko%26aufirst%3DA.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DLessons%2520in%2520PROTAC%2520Design%2520from%2520Selective%2520Degradation%2520with%2520a%2520Promiscuous%2520Warhead%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D78%26epage%3D87%26doi%3D10.1016%2Fj.chembiol.2017.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrovolsky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paulk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doctor, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">88</span>â <span class="NLM_lpage">99</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2017.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2Fj.chembiol.2017.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=29129717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=88-99&author=H.+T.+Huangauthor=D.+Dobrovolskyauthor=J.+Paulkauthor=G.+Yangauthor=E.+L.+Weisbergauthor=Z.+M.+Doctorauthor=D.+L.+Buckleyauthor=J.+H.+Choauthor=E.+Koauthor=J.+Jangauthor=K.+Shiauthor=H.+G.+Choiauthor=J.+D.+Griffinauthor=Y.+Liauthor=S.+P.+Treonauthor=E.+S.+Fischerauthor=J.+E.+Bradnerauthor=L.+Tanauthor=N.+S.+Gray&title=A+chemoproteomic+approach+to+query+the+degradable+kinome+using+a+multi-kinase+degrader&doi=10.1016%2Fj.chembiol.2017.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader</span></div><div class="casAuthors">Huang, Hai-Tsang; Dobrovolsky, Dennis; Paulk, Joshiawa; Yang, Guang; Weisberg, Ellen L.; Doctor, Zainab M.; Buckley, Dennis L.; Cho, Joong-Heui; Ko, Eunhwa; Jang, Jaebong; Shi, Kun; Choi, Hwan Geun; Griffin, James D.; Li, Ying; Treon, Steven P.; Fischer, Eric S.; Bradner, James E.; Tan, Li; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-99.e6</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Heterobifunctional mols. that recruit E3 ubiquitin ligases, such as cereblon, for targeted protein degrdn. represent an emerging pharmacol. strategy.  A major unanswered question is how generally applicable this strategy is to all protein targets.  In this study, we designed a multi-kinase degrader by conjugating a highly promiscuous kinase inhibitor with a cereblon-binding ligand, and used quant. proteomics to discover 28 kinases, including BTK, PTK2, PTK2B, FLT3, AURKA, AURKB, TEC, ULK1, ITK, and nine members of the CDK family, as degradable.  This set of kinases is only a fraction of the intracellular targets bound by the degrader, demonstrating that successful degrdn. requires more than target engagement.  The results guided us to develop selective degraders for FLT3 and BTK, with potentials to improve disease treatment.  Together, this study demonstrates an efficient approach to triage a gene family of interest to identify readily degradable targets for further studies and pre-clin. developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYNxhoPV3127Vg90H21EOLACvtfcHk0liC4xzriT-kWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2lsrjO&md5=703cfbaca3edd24176472158563f895f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DH.%2BT.%26aulast%3DDobrovolsky%26aufirst%3DD.%26aulast%3DPaulk%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DWeisberg%26aufirst%3DE.%2BL.%26aulast%3DDoctor%26aufirst%3DZ.%2BM.%26aulast%3DBuckley%26aufirst%3DD.%2BL.%26aulast%3DCho%26aufirst%3DJ.%2BH.%26aulast%3DKo%26aufirst%3DE.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DK.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520chemoproteomic%2520approach%2520to%2520query%2520the%2520degradable%2520kinome%2520using%2520a%2520multi-kinase%2520degrader%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D88%26epage%3D99%26doi%3D10.1016%2Fj.chembiol.2017.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaime-Figueroa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">131</span>, <span class="refDoi">Â DOI: 10.1038/s41467-018-08027-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1038%2Fs41467-018-08027-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=30631068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A280%3ADC%252BB3cjgt1Sksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=131&author=B.+E.+Smithauthor=S.+L.+Wangauthor=S.+Jaime-Figueroaauthor=A.+Harbinauthor=J.+Wangauthor=B.+D.+Hammanauthor=C.+M.+Crews&title=Differential+PROTAC+substrate+specificity+dictated+by+orientation+of+recruited+E3+ligase&doi=10.1038%2Fs41467-018-08027-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase</span></div><div class="casAuthors">Smith Blake E; Wang Stephen L; Jaime-Figueroa Saul; Crews Craig M; Harbin Alicia; Wang Jing; Hamman Brian D; Crews Craig M; Crews Craig M</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">131</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PROteolysis-TArgeting Chimeras (PROTACs) are hetero-bifunctional molecules that recruit an E3 ubiquitin ligase to a given substrate protein resulting in its targeted degradation.  Many potent PROTACs with specificity for dissimilar targets have been developed; however, the factors governing degradation selectivity within closely-related protein families remain elusive.  Here, we generate isoform-selective PROTACs for the p38 MAPK family using a single warhead (foretinib) and recruited E3 ligase (von Hippel-Lindau).  Based on their distinct linker attachments and lengths, these two PROTACs differentially recruit VHL, resulting in degradation of p38Î± or p38Î´.  We characterize the role of ternary complex formation in driving selectivity, showing that it is necessary, but insufficient, for PROTAC-induced substrate ubiquitination.  Lastly, we explore the p38Î´:PROTAC:VHL complex to explain the different selectivity profiles of these PROTACs.  Our work attributes the selective degradation of two closely-related proteins using the same warhead and E3 ligase to heretofore underappreciated aspects of the ternary complex model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYPr3dBOGbeuR_TJajKxJDfW6udTcc2eazWD9gBfyTBrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjgt1Sksg%253D%253D&md5=bd56c51f5966709ca5d1ff3dadb7cc79</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-08027-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-08027-7%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BE.%26aulast%3DWang%26aufirst%3DS.%2BL.%26aulast%3DJaime-Figueroa%26aufirst%3DS.%26aulast%3DHarbin%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHamman%26aufirst%3DB.%2BD.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DDifferential%2520PROTAC%2520substrate%2520specificity%2520dictated%2520by%2520orientation%2520of%2520recruited%2520E3%2520ligase%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D131%26doi%3D10.1038%2Fs41467-018-08027-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donovan, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, G. E.</span></span> <span> </span><span class="NLM_article-title">Homolog-selective degradation as a strategy to probe the function of CDK6 in AML</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">300</span>â <span class="NLM_lpage">306</span>, <span class="refDoi">Â DOI: 10.1016/j.chembiol.2018.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2Fj.chembiol.2018.11.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=30595531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsVSj" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=300-306&author=M.+Brandauthor=B.+Jiangauthor=S.+Bauerauthor=K.+A.+Donovanauthor=Y.+Liangauthor=E.+S.+Wangauthor=R.+P.+Nowakauthor=J.+C.+Yuanauthor=T.+Zhangauthor=N.+Kwiatkowskiauthor=A.+C.+Mullerauthor=E.+S.+Fischerauthor=N.+S.+Grayauthor=G.+E.+Winter&title=Homolog-selective+degradation+as+a+strategy+to+probe+the+function+of+CDK6+in+AML&doi=10.1016%2Fj.chembiol.2018.11.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML</span></div><div class="casAuthors">Brand, Matthias; Jiang, Baishan; Bauer, Sophie; Donovan, Katherine A.; Liang, Yanke; Wang, Eric S.; Nowak, Radoslaw P.; Yuan, Jingting C.; Zhang, Tinghu; Kwiatkowski, Nicholas; Mueller, Andre C.; Fischer, Eric S.; Gray, Nathanael S.; Winter, Georg E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">300-306.e9</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The design of selective small mols. is often stymied by similar ligand binding pockets.  Here, we report BSJ-03-123, a phthalimide-based degrader that exploits protein-interface determinants to achieve proteome-wide selectivity for the degrdn. of cyclin-dependent kinase 6 (CDK6).  Pharmacol. CDK6 degrdn. targets a selective dependency of acute myeloid leukemia cells, and transcriptomics and phosphoproteomics profiling of acute degrdn. of CDK6 enabled dynamic mapping of its immediate role in coordinating signaling and transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGognoz8FFoR9LVg90H21EOLACvtfcHk0lg7fc_RW9I3DA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsVSj&md5=f8c1c3520c6c0218763d8769c59b4342</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2018.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2018.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DBrand%26aufirst%3DM.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DDonovan%26aufirst%3DK.%2BA.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DE.%2BS.%26aulast%3DNowak%26aufirst%3DR.%2BP.%26aulast%3DYuan%26aufirst%3DJ.%2BC.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DMuller%26aufirst%3DA.%2BC.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWinter%26aufirst%3DG.%2BE.%26atitle%3DHomolog-selective%2520degradation%2520as%2520a%2520strategy%2520to%2520probe%2520the%2520function%2520of%2520CDK6%2520in%2520AML%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26spage%3D300%26epage%3D306%26doi%3D10.1016%2Fj.chembiol.2018.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paterson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">963</span>â <span class="NLM_lpage">969</span>, <span class="refDoi">Â DOI: 10.1016/j.molcel.2005.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2Fj.molcel.2005.10.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=16364920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVOiuw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=963-969&author=M.+J.+Garnettauthor=S.+Ranaauthor=H.+Patersonauthor=D.+Barfordauthor=R.+Marais&title=Wild-type+and+mutant+B-RAF+activate+C-RAF+through+distinct+mechanisms+involving+heterodimerization&doi=10.1016%2Fj.molcel.2005.10.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization</span></div><div class="casAuthors">Garnett, Mathew J.; Rana, Sareena; Paterson, Hugh; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">963-969</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The protein kinase B-Raf is mutated in approx. 7% of human cancers.  Most mutations are activating, but, surprisingly, a small no. have reduced kinase activity.  However, the latter can still stimulate cellular signaling through the MEK-ERK pathway because they activate the related family member C-Raf.  We examd. the mechanism underlying C-Raf activation by B-Raf.  We show that C-Raf is activated in the cytosol in a Ras-independent manner that requires activation segment phosphorylation and binding of 14-3-3 to C-Raf.  We show that wild-type B-Raf forms a complex with C-Raf in a Ras-dependent manner, whereas the mutants bind independently of Ras.  Importantly, we show that wild-type B-Raf can also activate C-Raf.  Our data suggest that B-Raf activates C-Raf through a mechanism involving 14-3-3 mediated heterooligomerization and C-Raf transphosphorylation.  Thus, we have identified a B-Raf-C-Raf-MEK-ERK cascade that signals not only in cancer but also in normal cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcr3ut9vW0NrVg90H21EOLACvtfcHk0ljITAETYwctTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVOiuw%253D%253D&md5=5db9fcc0a36f7670fcd3e92b399ed0de</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRana%26aufirst%3DS.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DWild-type%2520and%2520mutant%2520B-RAF%2520activate%2520C-RAF%2520through%2520distinct%2520mechanisms%2520involving%2520heterodimerization%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D20%26spage%3D963%26epage%3D969%26doi%3D10.1016%2Fj.molcel.2005.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haling, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudhamsu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandoval, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phung, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masselot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span> <span> </span><span class="NLM_article-title">Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">402</span>â <span class="NLM_lpage">413</span>, <span class="refDoi">Â DOI: 10.1016/j.ccr.2014.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2Fj.ccr.2014.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=25155755" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVKntrnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=402-413&author=J.+R.+Halingauthor=J.+Sudhamsuauthor=I.+Yenauthor=S.+Siderisauthor=W.+Sandovalauthor=W.+Phungauthor=B.+J.+Bravoauthor=A.+M.+Giannettiauthor=A.+Peckauthor=A.+Masselotauthor=T.+Moralesauthor=D.+Smithauthor=B.+J.+Brandhuberauthor=S.+G.+Hymowitzauthor=S.+Malek&title=Structure+of+the+BRAF-MEK+complex+reveals+a+kinase+activity+independent+role+for+BRAF+in+MAPK+signaling&doi=10.1016%2Fj.ccr.2014.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling</span></div><div class="casAuthors">Haling, Jacob R.; Sudhamsu, Jawahar; Yen, Ivana; Sideris, Steve; Sandoval, Wendy; Phung, Wilson; Bravo, Brandon J.; Giannetti, Anthony M.; Peck, Ariana; Masselot, Alexandre; Morales, Tony; Smith, Darin; Brandhuber, Barbara J.; Hymowitz, Sarah G.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">402-413</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Numerous oncogenic mutations occur within the BRAF kinase domain (BRAFKD).  Here we show that stable BRAF-MEK1 complexes are enriched in BRAFWT and KRAS mutant (MT) cells but not in BRAFMT cells.  The crystal structure of the BRAFKD in a complex with MEK1 reveals a face-to-face dimer sensitive to MEK1 phosphorylation but insensitive to BRAF dimerization.  Structure-guided studies reveal that oncogenic BRAF mutations function by bypassing the requirement for BRAF dimerization for activity or weakening the interaction with MEK1.  Finally, we show that conformation-specific BRAF inhibitors can sequester a dormant BRAF-MEK1 complex resulting in pathway inhibition.  Taken together, these findings reveal a regulatory role for BRAF in the MAPK pathway independent of its kinase activity but dependent on interaction with MEK.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXE20AD1ZxrLVg90H21EOLACvtfcHk0ljITAETYwctTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVKntrnJ&md5=a4a931aa158afbac09b972fc2a0142b8</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2014.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2014.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DSudhamsu%26aufirst%3DJ.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DSandoval%26aufirst%3DW.%26aulast%3DPhung%26aufirst%3DW.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DPeck%26aufirst%3DA.%26aulast%3DMasselot%26aufirst%3DA.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DStructure%2520of%2520the%2520BRAF-MEK%2520complex%2520reveals%2520a%2520kinase%2520activity%2520independent%2520role%2520for%2520BRAF%2520in%2520MAPK%2520signaling%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D26%26spage%3D402%26epage%3D413%26doi%3D10.1016%2Fj.ccr.2014.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kung, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jura, N.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for the non-catalytic functions of protein kinases</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">7</span>â <span class="NLM_lpage">24</span>, <span class="refDoi">Â DOI: 10.1016/j.str.2015.10.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2Fj.str.2015.10.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=26745528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC28XjvFOqsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=7-24&author=J.+E.+Kungauthor=N.+Jura&title=Structural+Basis+for+the+non-catalytic+functions+of+protein+kinases&doi=10.1016%2Fj.str.2015.10.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the non-catalytic functions of protein kinases</span></div><div class="casAuthors">Kung, Jennifer E.; Jura, Natalia</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-24</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are known primarily for their ability to phosphorylate protein substrates, which constitutes an essential biol. process.  Recently, compelling evidence has accumulated that the functions of many protein kinases extend beyond phosphorylation, and include an impressive spectrum of non-catalytic roles, such as scaffolding, allosteric regulation, or even protein-DNA interactions.  How the conserved kinase fold shared by all metazoan protein kinases can accomplish these diverse tasks in a specific and regulated manner is poorly understood.  Here, the authors analyze the mol. mechanisms supporting phosphorylation-independent signaling by kinases and attempt to identify common and unique structural characteristics that enable kinases to perform non-catalytic functions.  The authors also discuss how post-translational modifications, protein-protein interactions, and small mols. modulate these non-canonical kinase functions.  Finally, the authors highlight current efforts in the targeted design of small-mol. modulators of non-catalytic kinase functions, a new pharmacol. challenge for which structural considerations are more important than ever.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriZFnmAkj5Q7Vg90H21EOLACvtfcHk0ljhq8erUwgyfA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjvFOqsw%253D%253D&md5=feed13f34909080e4b95a6186000da8d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2015.10.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2015.10.020%26sid%3Dliteratum%253Aachs%26aulast%3DKung%26aufirst%3DJ.%2BE.%26aulast%3DJura%26aufirst%3DN.%26atitle%3DStructural%2520Basis%2520for%2520the%2520non-catalytic%2520functions%2520of%2520protein%2520kinases%26jtitle%3DStructure%26date%3D2016%26volume%3D24%26spage%3D7%26epage%3D24%26doi%3D10.1016%2Fj.str.2015.10.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kornev, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahuja, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. S.</span></span> <span> </span><span class="NLM_article-title">Kinases and pseudokinases: lessons from RAF</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1538</span>â <span class="NLM_lpage">1546</span>, <span class="refDoi">Â DOI: 10.1128/MCB.00057-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1128%2FMCB.00057-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=24567368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVCku7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=1538-1546&author=A.+S.+Shawauthor=A.+P.+Kornevauthor=J.+Huauthor=L.+G.+Ahujaauthor=S.+S.+Taylor&title=Kinases+and+pseudokinases%3A+lessons+from+RAF&doi=10.1128%2FMCB.00057-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Kinases and pseudokinases: lessons from RAF</span></div><div class="casAuthors">Shaw, Andrey S.; Kornev, Alexandr P.; Hu, Jiancheng; Ahuja, Lalima G.; Taylor, Susan S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1538-1546, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review.  Protein kinases are thought to mediate their biol. effects through their catalytic activity.  The large no. of pseudokinases in the kinome and an increasing appreciation that they have crit. roles in signaling pathways, however, suggest that catalyzing protein phosphorylation may not be the only function of protein kinases.  Using the principle of hydrophobic spine assembly, we interpret how kinases are capable of performing a dual function in signaling.  Its first role is that of a signaling enzyme (classical kinases; canonical), while its second role is that of an allosteric activator of other kinases or as a scaffold protein for signaling in a manner that is independent of phosphoryl transfer (classical pseudokinases; noncanonical).  As the hydrophobic spines are a conserved feature of the kinase domain itself, all kinases carry an inherent potential to play both roles in signaling.  This review focuses on the recent lessons from the RAF kinases that effectively toggle between these roles and can be "frozen" by introducing mutations at their hydrophobic spines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMtbrpjoo1xrVg90H21EOLACvtfcHk0ljhq8erUwgyfA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVCku7c%253D&md5=9f883042d2619f33087c7605ac7f22e9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1128%2FMCB.00057-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00057-14%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BS.%26aulast%3DKornev%26aufirst%3DA.%2BP.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DAhuja%26aufirst%3DL.%2BG.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26atitle%3DKinases%2520and%2520pseudokinases%253A%2520lessons%2520from%2520RAF%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2014%26volume%3D34%26spage%3D1538%26epage%3D1546%26doi%3D10.1128%2FMCB.00057-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wan, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roe, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barford, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">855</span>â <span class="NLM_lpage">867</span>, <span class="refDoi">Â DOI: 10.1016/S0092-8674(04)00215-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=10.1016%2FS0092-8674%2804%2900215-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=15035987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=855-867&author=P.+T.+Wanauthor=M.+J.+Garnettauthor=S.+M.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=C.+M.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Marais&title=Mechanism+of+activation+of+the+RAF-ERK+signaling+pathway+by+oncogenic+mutations+of+B-RAF&doi=10.1016%2FS0092-8674%2804%2900215-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span></div><div class="casAuthors">Wan, Paul T. C.; Garnett, Mathew J.; Roe, S. Mark; Lee, Sharlene; Niculescu-Duvaz, Dan; Good, Valerie M.; Project, Cancer Genome; Jones, C. Michael; Marshall, Christopher J.; Springer, Caroline J.; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Over 30 mutations of the B-RAF gene assocd. with human cancers have been identified, the majority of which are located within the kinase domain.  Here the authors show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo.  Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells.  The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by assocn. with the P loop.  The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation.  The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYiQicwc1xVLVg90H21EOLACvtfcHk0lgX2FewesJzhQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D&md5=4cc020056c64e514286c000666da1972</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900215-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900215-6%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DMechanism%2520of%2520activation%2520of%2520the%2520RAF-ERK%2520signaling%2520pathway%2520by%2520oncogenic%2520mutations%2520of%2520B-RAF%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D855%26epage%3D867%26doi%3D10.1016%2FS0092-8674%2804%2900215-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3OG7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3OG7','PDB','3OG7'); return false;">PDB: 3OG7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JT2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JT2','PDB','5JT2'); return false;">PDB: 5JT2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CSX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CSX','PDB','5CSX'); return false;">PDB: 5CSX</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i33"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02083">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_06135"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b02083?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b02083</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Figures S1âS6 compound information (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02083/suppl_file/jm9b02083_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular string data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b02083/suppl_file/jm9b02083_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02083/suppl_file/jm9b02083_si_001.pdf">jm9b02083_si_001.pdf (6.18 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b02083/suppl_file/jm9b02083_si_002.csv">jm9b02083_si_002.csv (4.9 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b02083&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b02083%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-8%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b02083" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679936b2ec803ddd","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
